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1.1 Introduction 
 
 
After over half a century of chemotherapy research, cancer remains one of the most difficult 
life-threatening diseases to treat, a consequence of factors that include limitations of animal 
models, tumor diversity, drug resistance and the side effects of therapy. Therefore, it is easy 
to understand that cancer therapy is in the focus of common interest. Synthetic drugs have 
always played an important role in cancer therapy. In fact, systemic chemotherapy for cancer 
began in the 1940s and 1950s with the pioneering studies by Rhoads1, Goodman et al.2, 
Gilman and Philips3 and Karnofsky4 showed that nitrogen mustard–a mustard gas (i.e., 
S(CH2CH2Cl)2) derivative–dramatically lowers white blood cell count in leukemias and 
decreases tumor masses in lymphoproliferative diseases. As a consequence of these 
observations cancer chemotherapy started to develop extensively on a large scale and with 
great optimism. The large-scale random screening programs over the next 25 years (mainly 
by the U.S. National Cancer Institute)5 had screened and tested approximately 2000000 
compounds for their possible anticancer activity. From these efforts, several anticancer 
agents were identified and classified into several groups expliciting their mechanism of 
action in a similar way. These classes are as such:  
a) Alkylating agents, cross–linking DNA and thereby blocking cell division (e.g., nitrogen 
mustards) 
b) Antimetabolites, inhibiting synthesis of precursor molecules essential for cell division 
(e.g., methotraxate)  
c) Antimitotics, as spindle poisons hindering chromosomal arrangement required for cell 
division (e.g., Taxol, vinblastin)  
d) Antibiotics, possessing any of the above mentioned functions (e.g., mitomycin, 
anthraxmycine) 
e) Drugs with hormonal activity expliciting antitumor effect (e.g., estramustine).  
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By the late 1980s, however, advances in molecular biology had begun to provide greatly 
increased understanding of regulatory and signalling networks in normal cells that control 
fundamental cellular processes such as vascularisation, growth and proliferation. 
Concequently, several new targets were identified for chemotherapy. This resulted imergence 
of a number of new anticancer drugs such as 1) estrogen antagonist (e.g., tamoxifan), 2) 
Aromataze inhibitor (e.g., anastrozole), 3) EGFR kinase inhibitor (e.g., gefitinib) and 4) 
farnesyl transferase inhibitor (e.g., tipifarnib). 
 
1.2 DNA-Alkylating Agents 
 
Compounds that alkylate DNA have long been of interest as anticancer drugs. Many different 
types of chemicals are able to alkylate DNA, and several are used as anticancer drugs, but the 
most important classes of such agents in clinical use are the nitrogen mustards. The first 
DNA alkylating agents used in the cancer therapy was mechlorethamine (1), and the related 
compounds chlorambucil (2), melphalan (3) and cyclophosphamide (4), temozolomide (5) 
and estramustine (6) remain in use today. Other DNA alkylating agents of importance are the 
bismethanesulfonates (7), the cisplatin (8) and the anthramycine (9) derivatives (Figure 1).  
The majority of the clinically employed alkylating agents behave as electrophilic traps for 
macromolecular nucleophiles. There are several nucleophilic groups in DNA such as N-1 and 
N-3 of adenine bases, N-3 of cystosine, and in particular N-7 of guanine. Drug with two 
alkylating groups can react with a guanine on each chain and cross-links the strand such that 
they disrupt the replication of transcription leading to the cell death. Thus binding of 
alkylating agents to the cellular DNA is considered to be the lethal event associated with 
anticancer activity.  
 
1.2.1 Nitrogen Mustards 
 
As noted above, the N-mustards were among the very earliest class of anticancer agents 
developed, and perhaps most extensively studied of the DNA alkylating agents.6 The 
pronounce cytotoxicity of the N-mustard derivatives is attributed to their ability to induce 
interstrand cross-links between the two strands of DNA thereby inhibiting replication. The 
 7
overall process of DNA alkylation by N-mustard is a two-step process (Figure 2). The 
nitrogen atom is able to displace a chloride ion intramolecularly to form the highly 
elctrophilic aziridinium ion. Alkylation of DNA can then take place via nucleophilic attack 
on that intermediate by DNA.7 For N-mustards, the regiospecificity of alkylation of DNA is 
largely governed by electronic and steric properties of DNA. Therefore, they target DNA at 
the most electronegative sites, with monoadducts occurring primarily at the N-7 of guanines8 
and the interstrand cross-links between the N-7 positions of guanines in each strand at 5’-
GNC sequences.9  
 
 Figure 1. Chemical structures of some DNA-alkylating agents
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Despite their clinical importance, the usefulness of many DNA-alkylating drugs is often 
limited by a number of pharmacological deficiencies resulting from the intrinsic chemical 
reactivity of the agent. For example a drawback common to all DNA alkylating agents is 
their (necessarily) high chemical reactivity. This can result in loss of drug by reaction with 
other cellular nucleophiles, particularly proteins and low molecular weight thiols. This makes 
them vulnerable to cellular resistance mechanisms such as increased levels of glutathione.9,10 
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Other limitations, particularly for mustards, are a lack of intrinsic DNA binding affinity of 
the core N,N-bis(2-chloroethyl)amine pharmacophore, and a requirement for bifunctional 
cross-linking of DNA to be fully cytotoxic. These characteristics lower their potency, and 
produce carcinogenicity due to the formation of high ratio of genotoxic monoadducts to 
cross-links (up to 20:1).10,11 There is also evidence that the major guanine N-7 adduct formed 
by mustards and other “simple” alkylators is readily repaired, which may also result in lower 
cytotoxicity. These drawbacks place severe restrictions on the potential utility of DNA-
reactive agents.12,13 
 
Figure 2. Mechanism of DNA cross-linking by N-mustard
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1.2.2 DNA-directed Nitrogen Mustards 
 
The therapeutic utility of the alkylating agents would be greatly enhanced if they could be 
more precisely targeted to defined geometric sites of DNA. One design for achieving this is 
to link “simple” mustards and other alkylators with DNA affine carrier molecules which 
possess an intrinsic reversible DNA-binding capability. The use of DNA-affinic carriers with 
their own defined binding geometry makes it possible to alter both the region and sequence 
specificity of alkylation compared with that of the “simple” mustards (or other alkylators). 
Moreover, the side reactions mentioned above would be reduced by specifically targeting the 
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drug in the vicinity of the DNA. Attachment of N-mustards to the DNA-intercalating carriers 
goes back to the work of Creech et al.14 who originally suggested that the attachment to 
acridine carriers might serve to target the reactive center to DNA. Since then, many reports 
have been found in the literature based on the DNA-directed alkylating agents described as 
follows.  
Creech et al.14-17 have synthesized several mono- and bifunctional nitrogen mustards attached 
to the heterocyclic nuclei such as acridine, benz[c]acridine and phenanthridine nuclei through 
aminoalkyl side chain or amide linkage for antitumor studies (Figure 3).  
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It demonstrated that the presence of DNA-intercalating nuclei increased the antitumor 
effectiveness of the mustard moiety against Ehrlich ascites tumors in vivo and prolonged the 
survival time (relative to a control of 16 days) by a factor of at least 2.6 at the optimal dose. 
A striking observation was that, contrary to the common nitrogen mustards which required 
bifunctionality for good antitumor activity, some of the heterocyclic nitrogen mustards were 
almost equally effective as mono-or difunctional variants. In case of amide linkage, it was 
revealed that the entire molecule functioned as a unit in its action on the ascites tumors rather 
than through the formation of glycine mustard or glycine half–mustard by hydrolysis of the 
amide linkage.  
Later work showed that N-mustards linked with DNA intercalators could also drastically 
modify the pattern of DNA alkylation by the N-mustard. The DNA-binding properties of the 
 10
para substituted aniline mustards in which the mustard is covalently linked to 9-
aminoacridines and 4-aminoquinazolines were studied (Figure 4).18-20 For N-mustards linked 
to the acridine by a short alkyl chain through a para O-or S-link group (17), 5’-GT sequences 
was the most preferred sites at which N-7-guanine alkylation occurred. For analogues with 
longer chain lengths, the preference of 5’-GT sequence diminishes in favor of N-7-adenine 
alkylation at the complementary 5’-AC sequence. The in vivo antitumor activities of these 
compounds have also been evaluated.18-19 Compounds having a (CH2)nO and (CH2)n showed 
to have higher activity (ILS values of 50-60%) and much greater potency (optimal doses of 
20-30 mg/kg) than either chlorambucil (ILS 33% at an optimal dose of 225 mg/kg) or any of 
the untargeted mustards, using a single-dose protocol. In contrast, compounds in the (CH2)nS 
and (CH2)nSO2 series showed only minimal in vivo activity.18 In the series of compounds 
bearing CO-NH, CO or NH-CO linker, CONH-linked compound was the most potent 
(optimal doses of 20-30 mg/kg) having ILS values of 58% against P388 lymphocytic 
leukemia in vivo.19 The antitumor activity of N-mustards linked to amsacrine (clinical 
antileukemic drug and DNA-intercalating agent) is also reported (e.g., 19, 20).21 The aniline 
mustards of varying reactivity attached either off the 4-carboxamide (19) or at the 1’-position 
of the 9-anilino ring (20). Interactions of 19 and 20 with calf thymus DNA showed that 19 
gave only one adduct, resulting from alkylation at guanine N-7 in the major groove. In 
contrast, the primary adduct (57%) of 20 resulted from alkylation at adenine N-3 in the minor 
groove.22  Although, the patterns of DNA alkylation were broadly similar, the comparison of 
their cytotoxicities in wild-type and DNA repair-deficient lines indicated that they were 
considerably more cytotoxic than analogous untargeted mustards. The 4-linked analogues 
(19) showed slightly higher in vivo antileukemic activity than the corresponding 1’-linked 
analogues (20).21  
However, most of the recent work has used DNA minor groove binders as carriers to 
construct DNA-directed mustards, because these offer much higher region-and sequence 
selectivity than intercalators. For examples, the prototype of distamycin A derivatives 
(tallimustine) bearing a benzoyl nitrogen mustards group (Figure 5) was synthesized for 
antitumor evaluation and found to have a broad spectrum of antitumor activity in 
experimental tumor models.23,24 Previous studies have shown that tallimustine (21) possess a 
high preference for alkylation of adenines located in the 5’-TTTTGA-3’ sequence.25 The 
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tallimustine derivatives without a reactive halogen group or difluoro mustard or the diol 
derivatives showed a very low level of cytotoxic potency while the presence of a dibromo 
mustard significantly increased cytotoxicity (83-fold higher than tallimustine).26 The isosteric 
tallimustine derivatives (e.g., 22)27 containing one or more pyrazolic ring showed on L1210 
four-fold reduced cytoxicity with respect to tallimustine but superior in vivo antileukemic 
activity. 
 
Figure 4
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The cinnamic N-mustard derivative of distamycin A (PNU-157911, 23a-e)28  a vinylogue of 
tallimustine, showed very good antileukemic activity, significantly superior to that of 
tallimustine. In the case of compound 23a, the replacement of the amidino group with basic 
or nonbasic amidino moieties of different nature led to compounds 23b-e, in which the potent 
cytotoxicity of the parent amidino derivative was fully maintained and in some cases even 
increased.29 The cinnamic acid mustard derivative of 22 (compound 24)30 appeared to be 20-
fold more cytotoxic than 22 (IC50 = 14.2±0.52 vs 306±56 nM for 24 and 22, respectively) 
and maintained an in vitro potency quivalent to that of tallimustine’s vinylogue 21.  
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a: R1 = H HCl, R2 = H             d: R1 = H, R2 = CN
b: R1 = H HCl, R2 = CH3            e: R1 = H, R2 = OH
c: R1 = CH3 HCl, R2 = CH3
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Denny et al31 have reported a series of bis(benzimidazole) analogue of Hoechst 33258 (25) 
bearing nitrogen mustard moieties linked by a variable-length polymethylene chain (Figure 
6). These agents efficiently cross-linked the cellular DNA and exhibited potent cytotoxicity 
(up to 85-fold more potent than chlorambucil), with IC50 value of 10 nM against the P388 
cell culture for the C3 analogue 26.  Studies on bisbenzimidazoles where the mustard was 
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directly attached to the phenyl ring, but the benzimidazole DNA binding chromophores were 
altered by changing the heteroatoms, showed that analogues (e.g., 27)32 retaining the 
cytotoxic effects with higher reversible DNA binding. The DNA minor groove binding 
ligands based on polybenzamide moiety bearing either one or two monofunctional mustards 
have been reported (Figure 7).33,34 The antitumor evaluation and DNA interaction study 
showed that these agents possessed significant cytotoxicity against murine p388 leukemia 
cells in culture with high degree of DNA interstrand cross-linking ability. Compounds with 
two alkylating functions were the most cytotoxic, with 28a being 1000-fold more potent 
(IC50 = 0.007 nM) than the chlorambucil in vitro.  
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In contrast, the other monofunctional compounds are more than 10-fold less cytotoxic except 
the compound 29c which showed the comparable cytotoxicity with IC50 value of 0.027µM. 
Despite the large variation in in vitro cytotoxicity, all of these compounds showed broadly 
similar potency in vivo, with optimal doses in a single dose protocol of about 5-10 mg/kg.  
Synthesis and antitumor studies of a number of amidine analogs of chlorambucil and 
melphalan have been reported (Figure 8).35-37 In case of chlorambucil analogues, the 5-[4-(N-
alkylamidino)phenyl]-2-furancarboxamide and the chlorambucil moiety were linked by a -
NH(CH2)2NH- chain (30a-e). Evaluation of the cytotoxicity of these compounds employing a 
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and inhibition of [3H]-
thymidine incorporation into DNA in both MDA-MB-231 and MCF-7 breast cancer cells 
demonstrated that these compounds were more active than chlorambucil.35,36 The degree to 
which these compounds inhibited cell growth breast cancer cells was directly correlated to 
DNA-binding affinity. Moreover, these studies showed that cyclic amidine analogs of 
chlorambucil are potent catalytic inhibitors of topoisomerase II but not topoisomerase I. The 
highest degree of DNA binding and cytotoxicity in both MDA-MB-231 and MCF-7 breast 
cancer cells was observed for the compound, which possess a 4,5-dihydro-1H-imidazol 
moiety (30e). On the other hand, among the amidine analogues of melphalan (31a-e),37 
compound 31b which possessed a N-cyclopropylamidine function was the most cytotoxic 
with IC50 value of 10 µM and showed strong binding to the minor groove AT-rich sequences.  
From these results, it was suggested that the simultaneous DNA-binding and Inhibition of 
Topo-II activity may lead to increased antiproliferative activity. 
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Recently, Su et al. reported alkyl N-mustard-9-anilinoacridine conjugates (Figure 9), in 
which the  N-mustard pharmacophore was linked linked to the anilino ring of the 9-
anilinoacridine via various length of alkyl chain (O-ethyl (O-C2) or O-butyl (O-C4)) spacer at 
C3' or C4' position (e.g 36 (BO-0742))38 or with acridine ring at 4-postion (e.g., 37, BO-
0944).39 The 9-anilinoacridines, 3-(9-acridinylamino)-5-hydroxymehtylaniline (AHMA, 
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32),40,41 AHMA-alkylcarbamates (e.g., 33),42,43 5-(9-acridinylamino)toluidines (34)43 and 5-
(9-acridinylamino) anisidines (35)44 were used as the carriers. The results showed that all 
compounds exhibited potent in vitro cytotoxicity against human lymphoblastic leukemia cells 
(CCRF-CEM) in culture. Studies on the structure-activity relationships of these N-mustards 
indicated that the antitumor activity was slightly affected by the length of the spacer and the 
location of the N-mustard pharmacophore. Among these agents, compound 36 (BO-0742) 
exhibited significant cytotoxicity against CCRF-CEM, with 107-fold higher potency than its 
parent analogue, 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA, 32).40,41  
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Additionally, it also exhibited a significant cytotoxic effect against drug-resistant sublines, 
such as those resistant to vinblastine and taxol, CCRF-CEM/VBL and CCRF-CEM/taxol, 
espectively. Remarkably, compound 36 at one-tenth of the taxol’s therapeutic dose resulted 
in complete tumor remission in nude mice bearing human breast carcinoma MX-1 
xenografts. Furthermore, 36 yielded xenograft tumor suppression of 81-96% using human T-
cell acute lymphoblastic leukemia CCRFCEM, colon carcinoma HCT-116, and ovarian 
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adenocarcinoma SK-OV-3 tumor models. BO-0742 was about 10-fold less toxic to human 
normal hematopoietic stem cells (CFU-E, BFU-E and CFU-GM) than leukemic CCRF-CEM 
indicating that this agent has low toxicity to human bone marrow. Further studies suggested 
that the main mechanism of action of compound 36 is primarily through its DNA cross-
linking activity rather than its inhibitory effect on DNA-topoisomerases. However, BO-0742 
is chemically unstable and has a short half-life in rat (<25 min.) which put restriction on its 
utility as therapeutic agent.  
 
All these studies clearly demonstrated that alkylating agents (N-mustard) ‘targeted’ to DNA 
by attachment to DNA-affinic carriers (either intercalators of minor groove binders) have 
generally shown altered sequence-selectivity of DNA alkylation,  higher cytotoxicities and 
enhanced in vivo antitumor efficacy compared with the corresponding ‘untargeted’ mustards.  
 
1.2.3 N-mustard prodrugs for ADEPT or MDEPT 
 
One of the stratergies to overcome the high reactivity and poor pharmacokinetic properties of 
N-mustards is to prepare N-mustard prodrug, which can be activated selectively at tumor site 
after enzymatic hydrolysis.  Springer et al. have synthesized a series of N-mustard prodrug 
by attaching the aniline mustards to L-glutamic acid moiety through a urea, carbamate (38, 
Figure 10)45 or carboxamide (39, CMDA)46,47 linker for antibody-directed enzyme prodrug 
therapy (ADEPT). After enzymatic cleavage by bacterial enzyme carboxypeptidase G2 
(CPG2), they can be transformed into their corresponding active metabolite phenol or aniline 
N-mustard drugs.  It has been demonstrated that these prodrugs were effective substrates of 
the enzyme and showed to have improved therapeutic efficacy in CPG2-expressing 
xenografts.48-52 The prodrugs, 4053 and 4154 were also synthesized by linking the aniline N-
mustard to the trigger unit tyramine or 3-hydroxytyramine via a urea or carbamate linker, 
respectively, for melanocyte-directed enzyme prodrug therapy (MDEPT).55  Upon exposure 
to tyrosinase, these conjugates can release the active aniline or phenol N-mustard. Since the 
trigger tyramines were found to be the substrates for tyrosinase by oximetry, the prodrug 42 
was also prepared for MDEPT.48 Simillarly, the 5-aziridinyl-2,4-dinitrobenzamides (i.e., 43, 
CB 1954),56,57 2,4-dinitrobenzamide 5-N-mustards (44)58,59 and related derivatives can be 
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used as prodrugs for gene-directed enzyme prodrug therapy (GDEPT) with the E. coli nfsB 
nitroreductase (NTR) as activator enzyme in hypoxia conditions.60,61 This suggested that the 
cytotoxic 2-hydroxyamine metabolite for forming DNA cross-linking may be generated in 
the presence of NTR.62,63 
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Figure 10. Chemical structures of some N-mustard prodrugs
 
 
From these studies one can envisage that the urea, carbamate, or carboxamide linker is 
capable of lowering the reactivity of aniline or phenol N-mustard pharmacophore resulting in 
formation of rather stable N-mustard derivatives. 
 
1.3 Bifunctional DNA-alkylating agents 
 
Apart from DNA-alkylating nitrogen mustards, the bifunctional DNA-alkyating agents have 
also played an important role in cancer chemotherapy. For example, Mitomycin C (45, 
Figure 11), a product of the mold Streptomyces caespitosis, is a bifunctional alkylating agent 
used to treat a variety of tumors.64 The polyfunctionality and presence of reactive 
electrophilic centers in the molecule contributes to the antitumor activity, cell specificity, and 
toxicity which this agent exhibit overall.65,66 Unlike the nitrogen mustards, which form cross-
 18
links with 5’-GNC-3’ sequences through the major groove of DNA, mitomycin C reacts with 
guanine residues of 5’-CG-3’ sequences through the minor groove of DNA. Mitomycin C 
itself is relatively inert and requires chemical or enzymatic reduction of its quinone ring to 
initiate alkylation.67 Extensive studies have been carried out on the biosynthesis of 
mitomycin C, and its reactions with DNA have been reviewed recently.68 When interstrand 
cross-links are formed with DNA, mitomycin C undergoes a rather complicated series of 
reactions and rearrangements whose salient features are summarized in Figure 11. Two-
electron reduction of the quinone ring of 45 facilitates the loss of the methoxy group, leading 
to the formation of the hydroquinone intermediate (46). Tautomerization followed by the 
reaction with the N2- amino group of guanine produces monoadduct 47. Elimination of the 
carbamoyl group produces the highly reactive vinylogous hydroquinone methide 
intermediate (48), which alkylates the guanine on the opposite strand of DNA to produce, 
after oxidation, an interstrand cross-link (49).   
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Figure 11. Mechanism of action of Mitomycin C
 
 
A similar mechanism of action has been established for antitumor pyrrolizidine alkaloids (50, 
retrorsine).69-71 Chemical oxidation in vitro69 or hepatic oxidation in vivo70,71 affords the 
relevant dehydro derivatives (dehydropyrolizidines) which are interstrand cross-linking 
agents. Along with mitomycin C (45) and pyrrolizidine alkaloids (50), several other naturally 
occurring or synthetic antitumor agents contains at least one, often two or three, reactive 
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electrophilic centers in the molecule through which they exerts their anticancer activity. For 
examples (Figure 12), indoloquinone EO9 (51),72 aflatoxin B1(52),73 7,8-dihydroxy-9,10-
epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE) (53),74 azinomycin B (54),75 
isochrysohermidin (55)76 and anthramycin (56).77 
Structure-activity relationship studies with many of these natural products are often limited 
by the small quantities of material available and by the relatively limited number of 
modifications which actually can be performed on these complex molecules. On the other 
hand, the simple synthetic analogues of such complex natural products can serve as better 
probes to explore their structure-biological activity with mechanistic pathways. 
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On the basis of the potent antitumor activity of mitomycin C and pyrrolizidine alkaloids (50), 
Anderson et al78,79 have designed and synthesized several “acylated vinylogous 
carbinolamine” tumor inhibitors including (Figure 13); 1) Derivatives of l-Phenyl-2,5-
dimethy1-3,4-bis(hydroxyme-thy1)-pyrrole-bis(N-methylcarbamate) (57a-j)78 and, 2) Phenyl 
substituted derivatives of 1,2-dimethyl-3,4-bis-(hydroxymethyl)-5-phenylpyrrol bis(N-
methylcarbamate) (58a-i).79 The rationale design of these agents is based on the concept that 
these agents can act as bifunctional electrophiles in which [(carbamoy1)oxyl]methyl groups 
serve as reactive electrophilic centers. The SAR studies of these agents against P338 
lymphocytic leukemia reveled that in case of C-2-substituted derivatives (57a-i) the 
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electronic and lipophilic character of the substituent X can be varied rather extensively 
without loss of significant antileukemic activity. Derivative 57c (X = C(CH)3) stand out as 
most potent of the series with the  T/C = 198 at the dose of 100 mg/kg.78 In the series of 1-
substituted derivatives,  compounds bearing  electron donating substituents 58a or 58e (X = 
OCH3, -O-CH2-O-, respectively) were more active with the lowest dose tested, 12.5 mg/kg, 
T/C = 190-132 with low toxicity.79 
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In the course of exploring the structure-biological activity relationships of pyrrole-derived 
bifunctional alkylating agents, a family of 6,7-disubstituted pyrrolizine diesters have been 
synthesized and evaluated for antitumor studies (Figure 14).80   
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All of these compounds were quite potent, a feature particularly evident for 59 which showed 
significant activity at the lowest dose tested, 0.78 mg/kg; one derivative, 60, afforded “cures” 
at dose levels as low as 12.5 mg/kg. Several other compounds showed potent activity against 
P-388 lymphocytic leukemia over a greater than fourfold dose range with no acute toxicity.80 
Studies on the structure-activity relationships (SAR) of 5-phenylpyrrolizines revealed that 
compounds having electron-donating substituent(s) (OMe) on the phenyl ring were generally 
more toxic than those compounds bearing electron-withdrawing substituent(s) (halogen). 
While, the in vivo antitumor activities were comparable or slightly less potent in compounds 
having an electron-donating substituent. These studies also suggested that the lipophilicity of 
compound might affect its antitumor potency. The water soluble analogues of 59 (Figure 14) 
were also prepared to study their antitumor effect against P388 lymphocytic leukemia and 
B16 melanocarcinoma in mice.81 Among these agents, compound 61b (where R = H) and 
61d (where R = COCH2N(CH3)2) showed comparable activity to 59 with a dose of 50 mg/kg 
and 80 mg/kg, respectively, against P388 lymphocytic leukemia in mice. Replacement of the 
C-2 methylene in 59 by S, S(O) or S(O)2 resulted in inactive compounds (62).82 
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Studies on the mechanism of action showed that the bis(carbamate)pyrroles (57a-j or 58a-i) 
or pyrrolizines derivatives (59-62) exert their antitumor effect by DNA interstrand cross-
linking probably via a SN1 electrophilic reaction (Figure 15).80,83 These derivatives are 
capable of forming DNA interstrand cross-link with the short oligonucleotide 5’-ACGT at 
the 5’-CG residues at the minor groove region.83  
These agents are not carbamoylating agents; instead the carbamate moieties are leaving 
groups in an alkyl-oxygen cleavage mechanism (64). The reactions take place on methylenic 
carbons bonded directly to a heteroaromatic nucleus (65). The role of the heteroaromatic 
system is to stabilize reaction transition states, and this provides a means to control the 
reactivity of the two electrophilic centers. Control may be achieved through alteration of the 
heteroaromatic system. Studies on comparison of nonbonding interactions in C-5-phenyl 
pyrroles (57a-j) and C-5-phenyl pyrrolizines (59-62) reveled that two significant nonbonded 
interactions exist in the 5-phenylpyrrole derivatives 57a between the ortho hydrogens of the 
phenyl substituent and the hydrogens on the N-1 methyl group and the C-4 methylene.84 
While, one of these nonbonded interactions is absent in the pyrrolizine compounds (59): the 
pyrrolizine C-3 methylene hydrogens lie outside the van der Waals radii of the ortho-
hydrogen atoms of the C-5 phenyl ring and demonstrated that the phenyl and pyrrole rings in 
59 are coplanar (or very nearly so).84 On the basis of this observation several angular tricyclic 
pyrrolo[2,1-a]isoquinolines (69a-b), pyrrolo[1,2-a]quinolines (70a-b), pyrrolo[2,1-
a]isobenzazepines (71a-d) and pyrrolo[1,2-a]benzazepines (72a-d) were designed and 
evaluated for antileukemic activity (Figure 16).84,85 It was sought that these tricyclic 
structures would limit the deviation from co-planarity of the phenyl and pyrrole rings. 
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The bis(carbamates) (69-72) were tested in vivo against P388 lymphocytic leukemia. It was 
demonstrated that the pyrrolo[2,1-a]isoquinolin-bis(carbamate) 69a exhibited the best 
activity of the compounds tested. In the pyrrolo[2,1-a]isoquinoline series (70a-b), the C-3 
methyl group had a more pronounced effect on activity and toxicity than the C-7 methoxy 
group where as pyrrolo[1,2-a]quinolines were less active.84,85 The pyrrolo[l,2-a]benzazepine-
bis(carbamates) 71c and 71d showed approximately equivalent activity to the comparable 
pyrrolo[1,2-a]quinolines 70a.85 The fused benzazepines 72a-d were less active and more 
toxic than the corresponding pyrrolo[2,1-a]isoquinoline (69a).85 It was also indicated that 
compounds with the phenyl ring attached directly to the pyrrole nitrogen will have different 
structure-activity requirements from the compounds in which the phenyl ring is attached to 
the pyrrole α-carbon. 
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Recently, Su et al. have designed and synthesized a series of DNA bifunctional alkylating 
agents (Figure 17), bis(hydroxymethyl)-8H-3a-azacyclopenta[a]indene-1-yl derivatives and 
their bis(carbamate) derivatives (73) for antitumor evaluation.86 These agents can be 
considered as “benzologues” of pyrrolizines and expliciting a similar mechanism of action 
that of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines or MMC. It was 
demonstrated that these compounds exhibited potent antiproliferative activity against human 
leukemia and various solid tumor cell growths in vitro and potent antitumor efficacy in vivo 
with a relatively low toxicity. Detailed SAR studies demonstrated that the size and electron 
properties of the substituent at C3 affected the cytotoxicity of these agents. Compounds 
74a,b and 75a,b were found to have potent therapeutic efficacy against human breast MX-1 
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xenograft in animal model. Complete tumor remission was achieved in nude mice bearing 
human breast carcinoma MX-1 xenograft by these derivatives. Interestingly, compound 75a 
was able to significantly suppress human prostate adenocarcinoma PC3 xenograft in nude 
mice. Studies on the DNA interstrand cross-linking suggested that the newly synthesized 
derivatives are potent bifunctional DNA cross-linking agents. Furthermore, both derivatives 
induced substantial G2/M phase arrested of the cell cycle.  
 
1.4 Rationale Drug Design (goals and perspective) 
 
The aim of current research is to design potent and stable DNA-directed alkylating agents. 
As described previously, N-mustard-9-anilinoacridine conjugates (such as BO-0742 and the 
related compounds) are chemically unstable. This can be explained by the fact that these 
agents are considered as alkyl N-mustard derivatives. The inductive effect of the alkyl 
function is thought to be able to enhance the formation of the reactive aziridium cation 
intermediate, which will rapidly alkylate DNA, proteins and other macromolecules. These 
side-reactions can be abridged by reducing the reactivity of the alkylating marphacophore. 
One design for achieving this is to put an aromatic ring on the nitrogen atom instead of an 
alkyl group; the lone pair electron of the nitrogen can be 'pulled toward' the phenyl ring and 
hence, the reactivity of the N-mustard can be reduced. As a result, the intermediate aziridine 
ion is less easily formed and only strong nucleophiles such as guanine will now react with it.  
Thus, to search for more potent and stable antitumor agents, several new DNA-directed 
alkylating agents were designed where phenyl N-mustard was used as DNA-alkylating 
pharmacophore linked with the various DNA-affinic carriers. These can be categoriezed as 
follows.  
1) Phenyl N-mustard-9-anilinoacridine conjugates via a urea linker (76) in which aniline 
N-mustards residue was attached with the aminofunctions of the aniline ring of 
AHMAs, ATs and AAs (Figure 18). 
2) The phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate 
linker (77,78) in which the phenol N-mustard residue was attached with the amino 
function of the aniline ring of AHMAs, ATs and AAs and aniline or phenol N-
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mustard residue with the hydroxyl substituent on the aniline ring of AHMA-
alkylcarbamates via a carbamate or carbonate linker (Figure 19). 
3) The water soluble phenyl N-mustard-aminobenzamide (79) or phenyl N-mustard-
alkoxybenzamine conjugates (80) via a urea linker (Figure 20). 
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Moreover, On the basis of potent antitumor activity of bifunctional DNA-alkylating agents, 
mitomycin C and 3a-azacyclopenta[a]indene-1-yl derivatives, a series of bis(hydroxymethyl) 
-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl derivatives (81, R2 = H, Figure 21) and their 
bis(methylcarbamate) derivatives (81, R2 = CONHMe) comprised of linear tricyclic ring 
system was designed and synthesized to study whether they have superior antitumor activity 
than that of the angular ring system (69 or 70). One can expect that the newly designed 
compounds (81) might be able to cross-link to the macromolecular DNA via a similar 
mechanism of action as that of pyrroles or pyrrolizines (Figure 22).  An alkyl or substituted 
phenyl moiety at C-3 of the 5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl were introduced to 
investigate their effects on antitumor activity. 
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dG = deoxy Guanine of DNA
Figure 22. Proposed mechanism of action of 5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl derivatives
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It was found that the all the newly designed compounds were much more stable than BO-
0742 and have long duration of action. Also, they displayed potent antiproliferative activity 
and therapeutic efficacy against several human xenografts in nude mice animal model.  The 
synthesis, antitumor activity, DNA cross-linking studies and rat plasma stability study of the 
newly designed phenyl N-mustard derivatives and isoquinolines is described in the 
subsequent sections. 
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CHAPTER 2 
 
Synthesis and Biological Activity of Stable and Potent Antitumor Agents, 
Aniline Nitrogen Mustards Linked to 9-Anilinoacridines via a Urea 
Linkage 
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2.1 Chemistry 
 
 
The synthesis of requisite 9-anilinoacridine derivatives; 3-(9-acridinylamino)-5-
hydroxymethyl-anilines (AHMA, 92),40,41 5-(9-acridinylamino)toluidines (93-96)43 and 5-(9-
acridinylamino)-anisidine (101-103)44 were prepared by following the methods developed by 
Su et al. (Scheme 1 & 2).  In short, the synthesis of AHMA (92a,b)40,41 was achieved by 
reacting 9-chloroacridines (87a-d)87-89 with 3,5-diaminobenzyl alcohol (88) in CHCl3/MeOH 
in the presence of 4-mehtylmorpholine at 0 oC. In a similar manner, the condensation of 
methyl substituted 1,3-phenylenediamines (8990 or 90) or methoxy substituted 1,3-
phenylenediamines (97 or 98) with the requisite 9-chloroacridines in a mixture of 
CHCl3/EtOH in the presence of 4-mehtylmorpholine (or catalytic con.HCl) yielded 5-(9-
acridinylamino)-m-toluidines (95a, AMTs), 5-(9-acridinylamino)-p-toluidines (96b,d, 
APTs), 5-(9-acridinylamino)-o-anisidines (100a,b, AOAs), and 5-(9-acridinylamino)-m-
anisidines (101a-c, AMAs), respectively, in good yield. The 5-(9-acridinylamino)-o-
toluidines (94a,b, AOTs) were synthesized by reaction of 4-methyl-3-nitroaniline (91) with 
87a,b, followed by reduction of the nitro intermediate (93a,b). Simmilarly, the 5-(9-
acridinylamino)-p-anisidines (103a,b APAs) prepared by treatment of 2-methoxy-5-
nitroaniline (99) with 9-chloroacridines (87a,b) followed by Pd/C-mediated reduction of 
nitroderivatives (102a,b). The known N,N-bis(2-chloroethyl)benzene-1,4-diamine 
dihydrochloride (107) was prepared by following the literature procedure53 with modification 
(Scheme 3). The commercially available 4-fluoronitrobenzene (104) was reacted with 
diethanolamine under refluxing to give 4-[N,N-bis(2-hydroxyethyl)amino]nitrobenzene 
(105), which was then converted to 4-[N,N-bis(2-chloroethyl)amino]nitrobenzene (106) by 
treating with thionyl chloride.  Catalytic hydrogenation (10% Pd/C, H2) of compound 106 in 
ethyl acetate afforded N,N-bis(2-chloroethyl)benzene-1,4-diamine (107), which was 
immediately treated with 2.5M HCl in ethyl acetate to yield aniline N-mustard hydrochloride 
salt (107). The hydrochloride salt 107 was then converted to isocyanate 10891 by treating 
with triphosgene in chloroform at -5 oC.  
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Scheme 1.  Synthetic routes for 3-(9-acridinylamino)-5-hydroxymethylanilines40,41 (AHMA, 
92), and 5-(9-acridinylamino) toluidines (93-96).43 
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Reaction conditions: (i) CHCl3/EtOH, 4-methyl morpholine (or cat. HCl); (ii) 5%Pd/C, H2, 
35 psi, 2-3 h. 
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Scheme 2.  Synthetic routes for the 5-(9-acridinylamino)-anisidine (100-103).44  
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Reaction conditions: (i) CHCl3/EtOH, 4-methyl morpholine (or cat. HCl); (ii) 5%Pd/C, H2, 
35 psi, 2-3 h. 
 
The freshly prepared 108 was then reacted with various above mentioned 9-anilinoacridines 
(92,94-101,103), in dry DMF in the presence of TEA or pyridine at room temperature to 
furnish the desired phenyl N-mustards linked to 9-anilinoacridine conjugates via a urea linker 
(109a-n) (Scheme 3). In a similar manner, treatment of 108 with 9-aminoacridine (110) 
afforded acridine-N-mustard conjugate 111 in good yield. The yields and physical properties 
of the new N-mustard conjugates are shown in Table 1. 
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Scheme 3. Synthetic route for the N-mustard-9-anilinoacridine conjugates via a urea linker 
(109a-n, 111). 
 
iv
NO2F
105
104
106
N(CH2CH2OH)2O2N N(CH2CH2Cl)2O2N
N(CH2CH2Cl)2H2N
107
i
ii
iii
R1 = CH2OH, Me, OMe
R2, R3 = H, Me, CONHCH2CH2NMe2
111
N(CH2CH2Cl)2NCO
N
NH2
110
N
HN
O
N
H
N(CH2CH2Cl)2
v v
4'
5'
4
108
92, 94-101,103
5
1'
2'
3'
6'
R1
N
HN
NH2
R3 R2
109a-n
N
HN
HN
O
N
H
N(CH2CH2Cl)2
R3 R2
R1
 
 
Reaction conditions: (i) NH(CH2CH2OH)2, 120 oC; (ii) SOCl2, CH2Cl2/pyridine, reflux; (iii) 
10%Pd/C, H2, 35 psi, 2 h and 2.5MHCl in EA; (iv) triphosgene/TEA, -10 oC, 30 min.; (v) 
TEA/pyridine, DMF, room temperature.  
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Table 1. Analytical data and yields of N-mustard linked to 9-anilinoacridines (109a-n and 
111). 
N
HN
HN
O
N
H
N(CH2CH2Cl2)2
R
3
R
2
1'
2'
3'
4'
5'
6'
45
R
1
 
 
Compd. R1 R2 R3 mp (oC) Yield (%) 
Analysis 
 
109a 5'-CH2OH H H 174-175 53.8 C, H, N 
109b 5'-CH2OH Me H 251-252 55.2 C, H, N 
109c 4'-Me H H 271-272 57.1 C, H, N 
109d 4'-Me Me H 267-268 83.8 C, H, N 
109e 5'-Me H H >280 39.0 C, H, N 
109f 6'-Me Me H 255-256 44.0 C, H, N 
109g 6'-Me CONH(CH2)2NMe2 Me >280 32.0 C, H, N 
109h 4'-OMe H H 263-264 70.2 C, H, N 
109i 4'-OMe Me H 255-256 60.2 C, H, N 
109j 5'-OMe H H 260-261 64.5 C, H, N 
109k 5'-OMe Me H 253-254 63.7 C, H, N 
109l 5'-OMe CONH(CH2)2NMe2 H 188-190 61.8 C, H, N 
109m 6'-OMe H H 268-269 80.4 C, H, N 
109n 6'-OMe Me H 270-272 48.8 C, H, N 
111  184-186 60 C, H, N 
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All of the synthesized compounds were characeterized by using 1H NMR and Elemental 
analysis. For compounds 109a-n, the characteristic peak for methylenic proton (i.e., 
N(CH2CH2Cl) appeared at 3.7 δ ppm. The 1H NMR signals for the phenyl N-mustards 
residue appeared as doublet (ortho coupling, J = 8.8-9.0 Hz) at 6.6 and 7.2 δ ppm. The 
characteristic peak for the urea linker (NHCONH) appeared at 8.3-9.7 δ ppm as D2O 
exchangeable singlet. The elemental analysis of the newly synthesized derivatives was within 
±0.4% range of the calculated C, H, N data.          
 
2.2 Biological Results and Discussion 
 
2.2.1 In vitro cytotoxicity. The antitumor 9-anilinoacridines including 3-(9-acridinylamino)-
5-hydroxymethylanilines (AHMAs),40 5-(9-acridinylamino) toluidines,43 and 5-(9-
acridinylamino)anisidines44 are potent inhibitors of topoisomerase II and capable of 
intercalating into DNA doubled strands. Hence, they are suitable as a carrier for constructing 
the new DNA-targeted compounds. Table 2 showed the cytotoxicity of the newly synthesized 
N-mustards (109a-n and 111) against human lymphoblastic leukemia (CCRF-CEM), breast 
carcinoma (MX-1) and colon carcinoma HCT-116 and was compared with BO-0742 (36) and 
the untargeted N-mustard 107. It was revealed that these conjugates possessed significant 
cytotoxicity with IC50 values in submicro molar range and did not exhibit cross-resistance to 
either vinblastine or taxol. The structure-activity relationships studies of the newly 
synthesized derivatives showed that the C4’-OMe and C5’-OMe substituted compounds were 
more cytotoxic than the corresponding C4’-Me and C5’-Me derivatives (109h vs. 109c, 109i 
vs. 109d, 109j vs. 109e) against CCRF-CEM cell growth in vitro. In contrast, the C4’-Me 
and C5’-Me substituted compounds were more potent than the corresponding C4’-OMe and 
C5’-OMe derivatives (109c vs. 109h, 109d vs. 109i, 109e vs. 109j) in inhibiting MX-1 cell 
growth. Although, the C6’-Me substituted compounds were more cytotoxic than the 
corresponding C6’-OMe derivatives (109f vs. 109m and 109g vs. 109n) against CCRF-CEM 
cell growth, they (109f vs. 109m) were equally potent against MX-1 cell growth. The 
cytotoxicity of the series of OMe substituted compounds against CCRF-CEM showed that 
the C4’-OMe derivatives (109h and 109i) were about 2–5 folds more potent than the 
corresponding C5’-OMe (109j and 109k) and C6’-OMe (109m and 109n) conjugates. As for  
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Table 2. Cytotoxicity of new N-mustards against human lymphoblastic leukemia (CCRF-
CEM) and its drug-resistant sublines (CCRF-CEM/Taxol and CCRF-CEM/VBL) and solid 
tumors (MX-1 and HCT-116) cell growth in vitro.a 
 
IC50 nM 
Compd CCRF-CEM CCRF-CEM/Taxolb CCRF-CEM/VBLb MX-1 HCT-116 
109a 56.2±1.1 17180±142[304×]c 64140±2000[1141×] 369.0±11 216.0±19 
109b 31.1±0.08 393.5±6.6[12.7×] 1789±331[57.5×] 124.7±4.5 262.6±6.0 
109c 16.7±0.60 34.7±0.80[2.08×] 33.4±1.0[2.00×] 583.6±26.4 264.5±4.7 
109d 77.8±2.3 91.8±15.7[1.18×] 127.9±2.2[1.64×] 239.7±35.6 437.4±1.8 
109e 141.0±3.3 384.2±2.0[2.72×] 593.2±2.0[4.20×] 529.0±21.9 815.5±10.1
109f 11.4±0.46 23.0±0.5[2.02×] 24.5±1.1[2.15×] 588.6±52.3 158.1±3.2 
109g 11.9±0.30 175.7±5.6[14.7×] 303.1±0.30[25.4×] 60.1±1.1 60.0±2.8 
109h 7.7±0.14 33.8±1.4[4.39×] 54.9±1.8[7.13×] 1203±40.6 256.3±8.1 
109i 9.2±0.24 11.5±0.50[1.25×] 24.6±0.07[2.76×] 367.3±12.5 74.9±2.7 
109j 37.5±1.2 50.4±0.80[1.34×] 54.8±0.10[1.46×] 1109±61.7 495.6±0.53
109k 29.6±0.60 49.8±1.1[1.68×] 43.3±0.50 [1.46×] 868.0±47.8 242.0±1.6 
109l 13.2±0.43 30.2±0.20[2.29×] 951.4±3.0[72.0×] 638.0±2.0 110.2±5.3 
109m 44.2±0.32 58.8±0.20[1.33×] 54.8±3.7[1.24×] 590.6±4.2 187.8±6.1 
109n 29.7±0.30 57.4±0.10[1.93×] 30.6±2.8[1.30×] 1810.4±100 571.2±18.5
111 228.9±23.9 385.4±21.3[1.68×] 378.1±17.8[1.65×] 810.1±19.3 899.8±23.6
107 43.4±0.50 33.8±0.40[0.78×] 25.7±0.10[0.59×] 84.4±1.7 340.8±4.9 
36 7±1.5 34±0.70[4.9×] 7.5±0.40[1.1×] 35±0.60 5.5±1.2 
Taxol 1.3±0.36 429.0±112.6[330×] 1.274 ±468[980×] 35.0±0.51 1.3±0.45 
Vinbla-
stine 
0.73±0.12 78.0±14.8[106.2×] 496.0±280.9[679.5×] 2.9±0.083 1.8±0.37 
aCell growth inhibition was measured by the XTT assay92 for leukemic cells and the SRB assay93 for solid 
tumor cells after 72 h incubation using a microplate spectrophotometer as described previously.94 IC50 
values were determined in duplicate or triplicate from dose-effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin95 based on the median-
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effect principle and plot96,97 and serial deletion analysis. Ranges given for taxol and vinblastine were mean 
± SE (n = 4).  
bCCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 330-fold resistant 
to taxol, and 680-fold resistant to vinblastine, respectively, when comparing with the IC50 of the parent cell 
line.  
cNumbers in the brackets are fold of cross-resistant determined by comparison with the corresponding IC50 
of the parent cell line. 
 
the inhibitory effect of these conjugates against HCT-116 cell growth in culture, it showed 
that C4’-Me and C4’-OMe derivatives were more cytotoxic than the C5’-Me and C5’-OMe 
conjugates (109c vs. 109e, 109h vs. 109j, 109i vs. 109k).  It is of great interest to note that 
the cytotoxicity of these agents can be increased by addition of Me group at C4 (109b, 109f, 
109k, and 109n), or CONHCH2CH2NMe2 and Me at C4 and C5 (109g and 109l), 
respectively (except for compounds 109a and 109d against HCT-116 cell growth where the 
cytotoxicity of 109a > 109b and 109c > 109d). 
These results clearly demonstrated that the changes in the cytotoxicity profile by modifying 
substituent(s) in the anilino or acridine ring may attribute to the appropriate increasing 
lipophilicity and DNA-binding affinity. Of these derivatives, compound 109h was the most 
cytotoxic with IC50 value of 7.7 nM. As for the in vitro cytotoxicity of N-mustard linked to 
acridine, it showed that compound 111 was less cytotoxic than compounds having 9-
anilinoacridines as a carrier. It is worthwhile to note that most compounds linking to 9-
anilinoacridines were equally potent or in some cases more cytotoxic than the unmasked N-
mustard 107, but this finding was not observed in compound 111. This suggested that the 9-
anilinoacridines were more favorable for using as a DNA-affinic carrier than acridine. 
 
2.2.2 In vivo therapeutic activity. The therapeutic effects of the representative new N-
mustards (109a, 109b, 109d, 109e) against human breast carcinoma MX-1 and human 
Glioma U87 MG xenografts in nude mice were evaluated. Under the experimental conditions 
as indicated, 109b and 109d (Figure 23) achieved complete tumor remission (CR) in nude 
mice bearing MX-1 xenograft at the doses of 30 and 100 mg/kg, intravenous injection (i.v.), 
Q2D×5 (n = 3). Remarkably, both compounds (109b and 109d) with only one cycle 5-dose-
treatments, complete remission was achieved and maintained for over 70 days without any 
relapse in 3 out of 3 mice (Fig. 23A).  
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Figure 23. The therapeutic effects of 109a (50 mg/kg, Q2D×8, i.v. injection), 109b (30 
mg/kg, Q2D×5, i.v. injection) and 109d (100 mg/kg, Q2D×5, i.v. injection) in nude mice 
bearing MX-1 xenograft (n = 3); average tumor size changes (Fig. 23A); and average body 
weight changes (Fig. 23B). The values for the treated vs the untreated group from Day 16 – 
Day 24 are <0.0006, <0.0003 and <0.0003 for 109a, 109b and 109d respectively. 
                           23A 
 
             23B 
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Figure 24. The therapeutic effects of 109d (100 mg/kg) and cyclophosphamide (CY) (80 
mg/kg) in nude mice bearing human glioma U87 MG xenograft (i.v. inj., Q2D×5, n = 3); 
average tumor size changes (Fig. 24A); and body weight changes (Fig. 24B). The values for 
the treated vs the untreated group from Day 18 – Day 30 are <0.0001 and <0.0012 for 
cyclophosphamide and 109d, respectively.  
24A 
 
24B 
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Compound 109a also led to complete tumor suppression but not complete tumor remission at 
the dose of 50 mg/kg, Q2D×8 (n = 3). The maximal toxicity of these agents as shown in 
Figure 23B by body weight decrease was about 10% drop from the initial pretreatment body 
weight (on day 8), after four treatment. However, the body weight showed recovery after 
cession of treatment. Similar result was found for 109e, which also resulted in tumor 
complete remission at the dose of 75 mg/kg (QD×8, i.v. injection) in nude mouse bearing 
MX-1 xenograft (Figure not shown). Compound 109d was further selected to evaluate its 
therapeutic effect in nude mice bearing human glioma U87 MG xenograft (Figure 24). The 
results showed that 109d was more potent than cyclophosphamide with low toxicity to the 
host (15% body-weight drop). These studies demonstrated that the newly synthesized 
compounds possess potent antitumor therapeutic efficacy with a relatively mild toxicity. 
Interestingly, we found that the complete tumor-suppression was observed in mice on day-16 
(last dose) and remained continuously for over 70 days without relapse. 
 
Figure 25. DNA interstrand cross-linking study. 
 
 
H1299 cells were used to determine the DNA cross-linking study by a modified comet assay. Mephalan 
and cisplatin were used as positive controls. Data represents the mean of three individual experiments 
(Mean±SD). 
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2.2.3 DNA interstand cross-linking Study. Compound 109d was found to be cytotoxic to 
human non-small lung cancer H1299 cell line with IC50 value of 0.51 μM.  This agent was 
selected and subjected to DNA cross-linking studies in human non-small lung cancer H1299 
cells by modified comet assay.98,99 The DNA cross-linking caused by 109d was compared 
with that of mephalan and cisplatin. It revealed that 109d was capable of inducing DNA 
cross-linking in a dose-dependent manner (Figure 25).  
 
2.2.4 Chemical stability. To realize whether the new conjugates are more stable than BO-
0742, the comparative chemical stability of the 109a, 109b, 109d and BO-0742 was 
investigated in intravenous injection vehicle (1 mg of compound in DMSO/Tween 80/normal 
saline: 0.5:0.4:1.6 v/v/v) by thin-layer chromatography (SiO2, solvent: CHCl3/MeOH, 10:1 
v/v) and parallel confirmed by HPLC (Mightysil RP-18; mobile phase: acetonitril/H2O 80:20, 
elution rate: 1 mL/min). It revealed that the half-life (t1/2, time required for 50% 
decomposition of compound) of 109a, 109b, 109d were 55, 59, and 36 days, respectively. 
The t1/2 value for BO-0742 could not be detected by HPLC analysis, since this agent 
decomposed during eluation from column. However, the TLC analysis showed that BO-0742 
had a t1/2 value of 2 h demonstrating that the newly synthesized compound were significantly 
more stable than BO-0742 although they were less cytotoxic than the latter. Compound 109d 
was further selected to study its chemical stability in rat plasma. The degradation of this 
agent was detected by HPLC. The detection limit is 20 ng/ml for the authentic 109d in the rat 
plasma. It revealed that 109d is a very stable N-mustard derivative in rat plasma with a long 
half-life (t1/2 = 54.18+0.96 h, n = 4). These results demonstrate that the newly prepared N-
mustards are chemically and metabolically stable derivatives. 
 
2.3 Conclusion 
 
In this study, a series of chemically stable DNA-directed alkylating agents, in which the 
phenyl N-mustard residue is linked to DNA-intercalating 9-anilinoacridines via a urea spacer, 
was synthesized for antitumor studies. It demonstrated that these agents exhibited potent 
antitumor efficacy in vivo with a relatively low toxicity. Among these derivatives, compound 
109d was revealed to have potent antitumor effect in nude mice bearing human breast MX-1 
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xenograft; complete remission was achieved and maintained for over 70 days without any 
relapse with only one cycle of treatments. Compound 109d also effectively suppressed 
human glioma U87 MG xenograft in nude mice. Moreover, it was also found that this agent 
is able to cross-link with DNA and has a long half-life in rat plasma suggesting that this 
agent is a promising candidate for preclinical studies. 
 
2.4 Experimental Section 
 
Melting points were determined on a Fargo melting point apparatus and are uncorrected. 
Column chromatography was carried out on silica gel G60 (70-230 mesh, ASTM; Merck and 
230-400 mesh, Silicycle Inc.). Thin-layer chromatography was performed on silica gel G60 
F254 (Merck) with short-wavelength UV light for visualization. Elemental analyses were done 
on a Heraeus CHN-O Rapid instrument. HPLC was performed on Waters Delta Prep4000 
using Mightysil RP-18 reverse phase column (250×4.6 mm). Compounds were detected by 
UV at 260 nm. The mobile phase was MeCN:H2O (80:20 v/v) with flow rate 1 mL/min. 1H 
NMR spectra were recorded on a 600 MHz, Brucker AVANCE 600 DRX and 400 MHz, 
Brucker Top-Spin spectrometers. The chemical shifts were reported in ppm (δ) relative to 
TMS. 
 
Synthesis of 9-anilinoacridine derivatives (92-103) 
 
[3-(Acridin-9-ylamino)-5-amino-phenyl]-methanol (92a).40,41 A mixture of 3,5-
diaminobenzyl alcohol dihydrochloride (12.66 g, 0.06 mol) and 4-methylmorpholine (12.2 g, 
0.12 mol) in EtOH (400 mL) was stirred for 1 h in an ice bath. A solution of 9-chloro 
acridine (12.8 g, 0.06 mol) in a mixture of EtOH:CHC13 (100 mL, v/v 1:l) containing 4-
methylmorpholine (7.0 g, 0.07 mol) was-then added drop wise to this mixture. After being 
stirred for 2 h at 0°C, the mixture was warmed to room temperature and continuously stirred 
for an additional 1 h. The solid product formed was collected by filtration; the filter cake was 
washed successively with cold 95% EtOH, acetone, and ether and dried to give 92a, yield: 
17.4 g (92%); mp 251–252 °C (dec); 1H NMR (DMSO- d6) δ 4.38 (2H, s, CH2), 5.20 (1H, 
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brs, exchangeable, OH), 5.52 (2H, brs, NH2), 6.45, 6.50 and 6.62 (each lH, s, 3×ArH), 7.44, 
7.98, 8.05, and 8.31 (each 2H, m, 8×ArH), 11.39 ( 1H, brs, exchangeable, NH).  
Acridin-9-yl-(4-methyl-5-nitrophenyl)amine (93a).43 A solution of 9-chloroacridine (2.16 
g, 10.0 mmol) in CHCl3 (10 mL) was added dropwise to a mixture of 4-amino-2-nitrotoluene 
( 1.6 g, 11 mmol) and conc. HCl (0.2 mL) in EtOH (20 mL) cooled in an ice bath. After the 
reaction mixture was stirred for 3 h, the solid was collected by filtration and was 
recrystallized from EtOH to give 93a, yield: 3.10 g (84%), mp > 280 °C; 1H NMR (DMSO-
δ6) δ 2.56 (3H, s, Me), 7.48–7.63 (4H, m, 4×ArH), 8.01–8.05 (2H, m, 2×ArH), 8.10 (1H, s, 
ArH), 8.11–8.20 (2H, m, 2×ArH), 8.31–8.33 (2H, m, 2×ArH), 12.01 (1H, brs, exchangeable, 
NH). 
4-methyl-N-(4-methyl-3-nitrophenyl)acridin-9-amine (93b).43 A solution of 9-Chloro-4-
methyl-acridine (4.55 g, 20 mmol) in CHCl3 (10 mL) was added dropwise to a mixture of 4-
amino-2-nitrotoluene ( 3.35 g, 22 mmol) and conc. HCl (0.2 mL) in EtOH (20 mL) cooled in 
an ice bath. After the reaction mixture was stirred for 4 h, the solid was collected by filtration 
and was recrystallized from EtOH to give 93b, yield: 6.61 g (86%), mp > 280 °C; 1H NMR 
(DMSO-δ6) δ 2.57 (3H, s, Me), 7.50–7.61 (4H, m, 4×ArH), 8.02–8.05 (2H, m, 2×ArH), 8.00 
(1H, m, ArH), 8.16–8.18 (1H, m, ArH), 8.30–8.34 (1H, m, ArH), 11.70 (1H, brs, 
exchangeable, NH). 
N1-Acridin-9-yl-4-methyl-benzene-1,3-diamine (94a).43 A mixture of acridin-9-yl-(4-
methyl-5-nitrophenyl)amine) (93a, 3.0 g, 10.0 mmol) and 5% Pd/C (1.8 g) in MeOH (250 
mL) containing conc. HCl (6.0 mL) was hydrogenated at 50 psi for 2 h. The reaction mixture 
was filtered through a pad of Celite and the filter cake was washed well with MeOH. The 
combined filtrate and washings were evaporated in vacuo to dryness. The solid product was 
recrystallized from MeOH to give 94a, 2.0 g (70%): mp > 280 °C; 1H NMR (DMSO-δ6) δ 
2.40 (3H, s, Me), 7.14–7.16 (1H, m, ArH), 7.32–7.34 (1H, m, ArH), 7.44–7.51(3H, m, 
3×ArH) 7.98–8.02 (2H, m, 2×ArH), 8.18–8.29 (2H, m, 2×ArH), 8.31–8.36 (2H, m, 2×ArH), 
11.69 (1H, brs, exchangeable, NH) 
4-Methyl-N1-(4-methylacridin-9-yl)benzene-1,3-diamine (94b).43 A mixture of 4-methyl-
N-(4-methyl-3-nitrophenyl)acridin-9-amine (93b, 3.31 g, 10.0 mmol) and 5% Pd/C (1.8 g) in 
MeOH (250 mL) containing conc. HCl (5.0 mL) was hydrogenated at 50 psi for 2.5 h. The 
reaction mixture was filtered through a pad of Celite and the filter cake was washed well with 
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MeOH. The combined filtrate and washings were evaporated in vacuo to dryness. The solid 
product was recrystallized from MeOH to give 94b, 2.4 g (80%): mp > 280 °C; 1H 
NMR(DMSO-δ6) δ 2.38 (3H, s, Me), 2.83 (3H, s, Me), 7.04–7.12 (1H, m, ArH), 7.28–7.45 
(4H, m, 4×ArH), 7.81–7.90 (1H, m, ArH), 7.94–8.02 (1H, m, ArH), 8.22–8.28 (2H, m, 
2×ArH), 8.61–8.70 (1H, m, ArH), 11.74 (1H, brs, exchangeable, NH), 13.01 (2H, brs, 
exchangeable, NH). 
N-Acridin-9-yl-5-methybenzene-1,3-diamine (95a).43 A suspension of 3,5-diamintoluidine 
(2.11 g, 12 mmol) and 4-methylmorpholine (4.8 mL, 43.6 mmol) in ethanol (30 mL) was 
stirred in an ice-methanol bath for 10 min. A solution of 9-chloroacridine (3.44 g, 16 mmol) 
in CHCl3 (50 mL) was then added dropwise to the above mixture and stirred at -5 °C for 3 h 
and then at room temperature overnight. The resulting solid product was collected by 
filtration and then recrystallized from EtOH to give 95a, 2.0 g (71%); mp 245–246 °C; 1H 
NMR δ 2.25 (3H, s, Me), 6.89–5.58 (3H, m, ArH), 7.56–7.49 (2H, m, ArH), 8.00–8.03 (2H, 
m, ArH), 8.16 (2H, d, J = 8.5 Hz, ArH), 8.31 (2H, d, J = 8.5 Hz, ArH), 11.53 (1H, brs, 
exchangeable NH). 
4-Methyl-N3-(4-methylacridin-9-yl)benzene-1,3-diamine (96b).43 A solution of 9-Chloro-
4-methyl-acridine (4.55 g, 20 mmol) in CHCl3 (10 mL) was added dropwise to a mixture of 
2,4-diaminotoluidine (3.0 g, 22 mmol) and conc. HCl (0.2 mL) in EtOH (20 mL) cooled in 
an ice bath. After the reaction mixture was stirred for 3 h, the solid was collected by filtration 
and was recrystallized from EtOH to give 96b, yield: 6.0 g (83%), mp >280 °C; 1H NMR 
(DMSO-δ6) δ 2.57 (3H, s, Me), 7.50–7.61 (4H, m, 4×ArH), 8.02–8.05 (2H, m, 2×ArH), 8.00 
(1H, m, ArH), 8.16–8.18 (1H, m, ArH), 8.30–8.34 (1H, m, ArH), 11.70 (1H, brs, 
exchangeable, NH). 
9-(5-amino-2-methylphenylamino)-N-(2-(dimethylamino)ethyl)-5-methylacridine-4-
carboxamide (96d).43 A solution of 9-chloro-N-(2-(dimethylamino)ethyl)-5-methylacridine-
4-carboxamide (6.83 g, 20 mmol) in CHCl3 (20 mL) was added dropwise to a mixture of 1,3-
diaminotoluidine (3.0 g, 22 mmol) and conc. HCl (0.2 mL) in EtOH (20 mL) cooled in an ice 
bath. After the reaction mixture was stirred for 5 h, the solid was collected by filtration and 
was recrystallized from EtOH to give 96d, yield: 6.8 g (80%); mp > 280 °C; 1H NMR 
(DMSO-δ6) δ 2.32 (3H, s, Me), 2.72 (3H, s, Me), 2.87 (6H, s, NMe2), 3.42 (2H, s, CH2), 2.82 
(3H, s, CH2), 6.94–6.96(1H, m, ArH), 7.24–7.27 (2H, m, 2×ArH), 7.40 (1H, t, J = 8.1Hz, 
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ArH), 7.56 (1H, t, J = 8.0 Hz, ArH), 7.92 (1H, d, J = 6.8 Hz, ArH), 8.21 (1H, d, J = 6.5 Hz, 
ArH), 8.58 (1H, d, J = 8.5 Hz, ArH), 8.90 (1H, d, J = 7.2 Hz, ArH), 10.03, 11.70, 11.96 
(each1H, brs, exchangeable, NH). 
N1-Acridin-9-yl-4-methoxybenzene-1,3-diamine (100a).44 A suspension of 2,4-diamino 
anisole dihydrochloride (4.22 g, 20 mmol) and 4-methylmorpholine (4.8 mL, 43.6 mmol) in 
ethanol (60 mL) was stirred in an ice-methanol bath for 10 min. A solution of 9-
chloroacridine (4.0 g, 20 mmol) in CHCl3 (50 mL) was then added dropwise to the above 
mixture and stirred at -5 °C for 2 h and then at room temperature overnight. The resulting 
solid product was collected by filtration and then recrystallized from EtOH to give 100a, 
yield: 5.76 g (81%); mp 283–284 °C; 1H NMR (DMSO- d6) δ 3.84 (3H, s, OMe), 5.16 
(2H,brs, exchangeable, NH2), 6.58 (1H, m, ArH), 6.70 (1H, m, ArH), 6.90 (1H, m, ArH), 
7.40(2H, m, 2×ArH), 7.95 (2H, m, 2×ArH), 8.09 (2H, m, 2×ArH), 8.28 (2H, m, 2×ArH), 
8.35(1H, m, ArH), 11.43 (1H, brs, exchangeable, NH). 
4-Methoxy-N1-(4-methylacridin-9-yl)benzene-1,3-diamine (100b).44 A suspension of 2,4-
diaminoanisole dihydrochloride (4.22 g, 20 mmol) and 4-methylmorpholine (4.8 mL, 43.6 
mmol) in ethanol (60 mL) was stirred in an ice-methanol bath for 10 min. A solution of 9-
chloro-4-methyl-acridine (4.55 g, 20 mmol) in CHCl3 (50 mL) was then added dropwise to 
the above mixture and stirred at -5 °C for 2 h and then at room temperature overnight. The 
resulting solid product was collected by filtration and then recrystallized from EtOH to give 
100b, yield: 5.66 g (86%); mp 280–281 °C; 1H NMR (DMSO- d6) δ 2.79 (3H, s, Me), 3.83 
(3H, s, OMe), 5.15 (2H, brs, exchangeable, NH2), 6.55 (1H, m, ArH), 6.66 (1H, m, ArH), 
6.88 (1H, m, ArH), 7.33 (1H, m, ArH), 7.39 (1H, m, ArH), 7.80 (1H, m, ArH), 7.93 (1H, m, 
ArH), 8.23 (2H, m, 2×ArH), 8.35 (1H, m, ArH), 11.47 (1H, brs, exchangeable, NH). 
N-Acridin-9-yl-5-methoxybenzene-1,3-diamine (101a).44 A suspension of 3,5-
diaminoanisole dihydrochloride (2.11 g, 10 mmol) and 4-methylmorpholine (4.8 mL, 43.6 
mmol) in ethanol (30 mL) was stirred in an ice-methanol bath for 10 min. A solution of 9-
chloroacridine (13a, 3.44 g, 16 mmol) in CHCl3 (50 mL) was then added dropwise to the 
above mixture and stirred at -5 °C for 2 h and then at room temperature overnight. The 
resulting solid product was collected by filtration and then recrystallized from EtOH to give 
101a, 2.24 g (71%); mp 235–236 °C; 1H NMR (DMSO- d6) δ 3.84 (3H, s, OMe); 5.58 (2H, 
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br s, exchangeable, NH2), 6.17 (1H; s, ArH), 6.23 (2H, brs, 2×ArH); 7.45 (2H, m, 2×ArH), 
7.97 (2H, m, 2×ArH); 8.11 (2H, m, 2×ArH), 8.35 (2H, m, 2×ArH). 
5-Methoxy-N-(4-methylacridin-9-yl)benzene-1,3-diamine (101b).44 By following the 
procedure described for 101a, compound 101b was prepared from 3,5-diaminoanisol 
dihydrochloride (2.11 g, 10 mmol), 87b (2.28 g, 10 mmol) and 4-methylmorpholine (3.3 mL, 
30 mmol). Yield 2.26 g (69%); mp 224–225 °C; 1H NMR (DMSO- d6) δ 2.85 (3H, s, Me), 
3.66 (3H, s, OMe), 4.80 (2H, brs, exchangeable, NH2), 6.72 (2H, brs, 2×ArH), 7.41 (1H, m, 
ArH), 7.49 (1H, m, ArH), 7.88 (1H, m, ArH), 8.02 (1H, m, ArH), 8.28 (1H, m, ArH), 8.33 
(1H, m, ArH), 8.66 (1H, m, ArH). 
9-(3-Amino-5-methoxyphenylamino)acridin-4-carboxylic acid (2-dimethylamino ethyl) 
amide (101c).44 By following the procedure described for 101a, compound 101c was 
prepared from 3,5-diaminoanisol dihydrochloride (1.44 g, 6.8 mmol) and 87c (7.03 g, 6.19 
mmol). Yield 1.42 g (55%); mp 257–258 °C; 1H NMR (DMSO-d6) δ 2.89 (6H, s, NMe2), 
3.41 (2H, t, J = 5.5 Hz, NCH2), 3.67 (3H, s, OMe), 3.80 (2H, t, J = 5.5 Hz, CONHCH2), 6.55 
(2H, brs, 2×ArH ), 6.59 (1H, s, ArH), 7.52 (1H, m, ArH), 7.59 (1H, m, ArH), 8.03 (1H, m, 
ArH), 8.19 (1H, m, ArH), 8.33 (1H, m, ArH), 8.56 (1H, m, ArH), 8.68 (1H, m, ArH). 
Acridin-9-yl-(2-methoxy-5-nitrophenyl)amine (102a).44 By following the procedure 
described for 93a, compound 102a was prepared from 2-methoxy-5-nitroaniline (1.68 g, 10 
mmol) and 87a (2.14 g, 10.0 mmol) in presence of catalytic amount of conc. HCl. Yield 3.43 
g (90%); mp 239–240 °C; 1H NMR (DMSO-d6) δ 3.61 (3H, s, OMe), 7.40 (1H, m, ArH), 
7.46 (2H, m, 2×ArH), 8.01 (2H, m, 2×ArH), 8.10 (2H, m, 2×ArH), 8.26 (2H, m, 2×ArH), 
8.34 (1H, m, ArH), 8.45 (1H, m, ArH), 11.58 (1H, brs, exchangeable, NH). 
(2-methoxy-5-nitrophenyl)4-methylacridin-9-yl)amine (102b).44 By following the 
procedure described for 93a, compound 102b was prepared from 2-methyl-5-nitroaniline 
(3.36 g, 20 mmol) and 87b (4.56 g 20.0 mmol). Yield 5.31g (74%); mp 207–209 °C; 1H 
NMR (DMSO-d6) δ 2.82 (3H, s, Me), 3.47 (3H, s, OMe), 7.38–7.41 (2H, m, 2×ArH), 7.54 
(1H, m, ArH), 7.87 (1H, m, ArH), 8.00 (1H, m, ArH), 8.22 (2H, m, 2×ArH), 8.32 (1H, m, 
ArH), 8.45 (1H, s, ArH), 8.56 (1H, m, ArH), 11.61 (1H, brs, exchangeable, NH).  
N-Acridin-9-yl-4-methoxybenzene-1,3-diamine (103a).44 A mixture of 102a (1.15 g, 3.0 
mmol) and 5% Pd/C in methanol (250 mL) containing concd HCl (0.5 mL) was 
hydrogenated at 50 psi for 25 min. The mixture was filtered through a pad of Celite and the 
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solid cake was washed with methanol. The filtrate and washing were combined and 
evaporated under reduced pressure to dryness. The residue was chromatographed on a silica 
gel column using CHCl3/MeOH (10:1 v/v) as the eluent. Fractions containing main product 
were combined and concentrated under reduced pressure. The residue was recrystallized 
from EtOH/acetone to give 103a, 667 mg (70%); mp 243–245 °C; 1H NMR (DMSO-d6) δ 
3.36 (3H, s, OMe), 6.73 (1H, m, ArH), 6.78 (1H, m, ArH), 6.96 (1H, m, ArH), 7.39 (2H, m, 
2×ArH), 7.94 (2H, m, 2×ArH), 8.05 (2H, m, 2×ArH), 8.27 (2H, m, 2×ArH), 10.36 (2H, brs, 
exchangeable, NH2), 11.49 (1H, brs, exchangeable, NH). 
4-Methoxy-N3-(4-methylacridin-9-yl)benzene-1,3-diamine (103b).44 By following the 
method described for 103a, compound 103b was prepared from 102b (0.783 g, 2.18 mmol). 
Yield 0.605g (84%); mp 230–231 oC; 1H NMR (DMSO-d6) δ 2.84 (3H, s, Me), 3.41 (3H, s, 
OMe), 7.25 (1H, m, ArH), 7.37–7.45 (3H, m, 3×ArH), 7.60 (1H, m, ArH), 7.88 (1H, m, 
ArH), 8.00 (1H, m, ArH), 8.21 (1H, m, ArH), 8.25 (1H, m, ArH), 8.63 (1H, m, ArH), 10.50 
(2H, brs, exchangeable, NH2), 11.49 (1H, brs, exchangeable, NH). 
 
Synthesis of Aniline Nitrogen mustard 
 
2-[(2-Hydroxyethyl)-(4-nitrophenyl)amino]ethanol (105).53 A mixture of p-flouro 
nitrobenzene (104, 28.0 g, 198 mmol) and diethanolamine (30.0 g, 285 mmol) was heated at 
120 oC for 2 h. The reaction mixture was cooled to 60 oC and an aqueous solution of 0.6 % 
NaOH (900 mL) was added slowly into the mixture. The separated yellow precipitate was 
collected by filtration, washed well with water, and dried to 105, yield: 42.6 g (95%); mp 
104–105 oC (lit.46 103–104 oC); 1H NMR(CHCl3-d6) δ 3.55–3.62 (8H, m, 4×CH2), 4.88 (2H, 
t, J = 4.4 Hz, exchangeable 2×OH), 6.81 (2H, d, J = 9.5 Hz, 2×ArH), 8.01 (2H, d, J = 9.5 Hz, 
2×ArH).  
Bis(2-chloroethyl)-(4-nitrophenyl)amine (106).53 To a mixture of 2-[(2-hdroxyethyl)-(4- 
nitrophenyl)amino]ethanol (105, 16.0 g, 71 mmol) in dry dichloromethane (200 mL) 
containing dry pyridine (10.0 mL) was added dropwise thionylchloride (14.0 mL) at 0 oC. 
The reaction mixture was heated with stirring at refluxed for 3 h and then cooled to room 
temperature.  The mixture was diluted with dichloromethane (100 mL), carefully washed 
with water, 10% KHSO4 solution (100 mL) and brine (100 mL).  The organic layer was dried 
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over Na2SO4, and evaporated to dryness under reduce pressure to give 106, yield 16.7 g 
(89%); mp 91–93 oC (lit.53 92–94 oC) 1H NMR (CHCl3-d6) δ 3.81 (4H, t, J = 6.6 Hz, 2×CH2), 
3.89 (4H, t, J = 6.6 Hz, 2×CH2), 6.93 (2H, d, J = 9.5 Hz, 2×ArH), 8.07 (2H, d, J = 9.5 Hz, 
2×ArH). 
N,N-Bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (107).53 A mixture bis(2-
chloroethyl)-(4-nitrophenyl)amine (106, 10.0 g, 38 mmol) in ethyl acetate (100 mL) and 10 
% Pd/C (1.0 g) was sonicated for 5 min.  The mixture was then hydrogenated (H2) at 35 psi 
for 2 h. and monitored by TLC (SiO2, ethyl acetate/Hexane: 1:1 v/v). After completion of 
reaction, the reaction mixture was filtered through a pad of Celite and the filtrate was cooled 
to 0 oC.  A solution of 2.5M HCl in ethyl acetate (20.0 mL) was slowly added into the filtrate 
with stirring. The white solid separated was collected by filtration and dried to give 107, 
yield: 9.18 g (80%), mp 212–214 oC (lit.53 213–215 oC); 1H NMR(DMSO-d6) δ 3.92 (8H, s, 
4×CH2), 6.83 (2H, d, J = 8.8 Hz, 2×ArH), 7.24 (2H, d, J = 8.8 Hz, 2×ArH), 10.2 (2H, brs, 
exchangeable, NH2). 
 
General procedure for the preparation of new N-mustard-9-anilinoacridine conjugates. 
N,N-Bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (107) was converted into 
isocyanate 108 by reaction of triphosgene in presence of TEA at –10 oC. The freshly 
prepared 108 was then condensed with appropriate 9-anilinoacridines (92, 94-103) 
previously synthesized by Su et al.40,43,44 and the commercially available 9-aminoacridine 
hydrochloride (110) in dry DMF in the presence of TEA or pyridine to give corresponding 
109a-n and 111. The final products were purified either by recrystallization from an 
appropriate solvent or by column chromatography using (SiO2, CHCl3/MeOH, v/v 100:2). 
The detailed procedure is described below: 
 
4-[N,N-bis(2-chloroethyl)amino]phenylisocyanate (108). To a suspension of N,N-bis(2- 
chloroethyl)benzene-1,4-diamine hydrochloride (107, 1.68 g, 5.4 mmol) in dry chloroform 
(30 mL) was added triethylamine (2.5 mL) at -10 oC. The clear solution obtained was then 
added dropwise into a solution of triphosgene (0.623 g, 2.1 mmol) in dry chloroform (10 mL) 
at -10 oC. The reaction mixture was allowed to stand at room temperature. After being stirred 
for 30 min, the reaction mixture was evaporated to dryness under reduce pressure. The solid 
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residue was triturated with dry THF (100 mL), filtered and washed with small amount of 
THF. The combined filtrate and washings was evaporated to dryness to give the crude 
isocyanate 10891 which was used directly for next reaction without further purification. 
1-[3-(Acridin-9-ylamino)-5-hydroxymethyl-phenyl]-3-{4-[bis(2-chloroethyl)amino]phe- 
nyl}- urea (109a). A solution of isocyanate 108, freshly prepared from 107 (0.672 g, 2.2 
mmol), in dry DMF (10 mL) was added dropwise to a solution of 3-(9-acridinylamino)-5-
hydroxymethylaniline (92a, 0.752 g, 2.0 mmol)40 in dry DMF (40 mL) containing 
triethylamine (2.0 mL) at 0 oC. After being stirred for 18 h at room temperature, the reaction 
mixture was evaporated to dryness in vacuo, the residue was dissolved in a mixture of 
CHCl3/MeOH containing silica gel (5.0 g) and then evaporated to dryness. The residue was 
put on the top of a silica gel column (2×20 cm) and purified by using CHCl3/MeOH (100:5 
v/v) as an eluent. The fractions containing the main product were combined and evaporated 
in vacuo to dryness and the residue was recrystallized from CHCl3/MeOH to give 109a, 618 
mg (53.8%); mp 174–175 oC; 1H NMR (DMSO-d6) δ 3.65–3.71 (8H, m, 4×CH2), 4.41 (2H, d, 
J = 6.0 Hz, CH2), 5.16 (1H, t, J = 6.0 Hz, exchangeable, OH), 6.37 ( 1H, s, ArH), 6.68 (2H, 
d, J = 9.1 Hz, 2×ArH), 6.81 (1H, s, ArH), 7.01–7.05 (3H, m, 3×ArH), 7.24 ( 2H, d, J = 9.1 
Hz, 2×ArH), 7.54 (4H, brs, 4×ArH) 8.05 (2H, brs, 2×ArH), 8.25, 8.46 and 10.84 (each 1H, 
brs, exchangeable, 3×NH). Anal. (C31H29Cl2N5O2·0.5H2O) C, H, N.  
 
By following the same procedure the following compounds were synthesized. 
 
1-{4-[Bis(2-chloroethyl)amino]phenyl}-3-[3-hydroxymethyl-5-(4-methylacridin-9-ylami- 
no)phenyl]urea (109b). Compound 109b was synthesized from 108 (freshly prepared from 
107, 1.377 g, 4.5 mmol) and 5-hydroxymethyl 3-(4-methyl-9-acridinylamino)aniline (92b, 
0.988 g, 3.0 mmol)40 in dry DMF (25 mL) containing pyridine (2.0 mL): yield 986 mg 
(55.2%); mp 251–252 oC; 1H NMR (DMSO-d6) δ 2.79 (3H, s, Me), 3.66–3.69 (8H, m, 
4×CH2), 4.45 (2H, d, J = 5.9 Hz, CH2), 5.30 (1H, brs, exchangeable, OH), 6.68 (2H, d, J = 
8.8 Hz, 2×ArH), 6.87 (1H, s, ArH), 7.24 (2H, d, J = 8.8 Hz, 2×ArH), 7.34 (1H, s, ArH), 
7.39–7.41 (1H, m, ArH), 7.47–7.48 (1H, m, ArH), 7.57 (1H, s, ArH), 7.86 (1H, d, J = 7.0 Hz, 
ArH), 8.00 (1H, s, ArH), 8.21–8.26 (2H, m, 2×ArH), 8.45 (1H, d, J = 8.5 Hz, ArH), 8.82, 
9.62 and 11.49 (each 1H, brs, exchangeable, 3×NH). Anal. (C32H31Cl2N5O2·3H2O) C, H, N. 
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1-(5-(Acridin-9-ylamino)-2-methylphenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea 
(109c). Compound 109c was synthesized from 108 (freshly prepared from 107, 1.683 g, 5.4 
mmol) and N1-(acridin-9-yl)amino-4-methylbenzene-1,3-diamine (94a, 0.898 g 3.0 mmol)43 
in dry DMF (15 mL) containing triethylamine (2.5 mL): yield 771 mg (57.1%); mp 271–272 
oC (dec); 1H NMR (DMSO-d6) δ 2.35 (3H, s, Me), 3.66–3.69 (8H, m, 4×CH2), 6.69 (2H, d, J 
= 8.8 Hz, 2×ArH), 6.86–6.88 (1H, m, ArH), 7.25–7.27 (1H, m, ArH), 7.28 (2H, d, J = 8.8 
Hz, 2×ArH), 7.42–7.45 (2H, m, 2×ArH), 7.90–8.00 (4H, m, 4×ArH), 8.19 (1H, s, ArH), 8.26 
(2H, m, 2×ArH), 8.30, 9.37 and 11.49 (each 1H, brs, exchangeable, 3×NH). Anal. 
(C31H29Cl2N5O·2.5H2O) C, H, N. 
1-{4-[Bis(2-chloroethyl)amino]phenyl}-3-[2-methyl-5-(4-methylacridin-9-ylamino)phe- 
nyl]urea (109d). Compound 109d was synthesized from 108 (freshly prepared from 107, 
1.836 g, 6 mmol) and 4-methyl-N1-(4-methylacridin-9-yl)benzene-1,3-diamine (94b, 1.065 g, 
3.4 mmol)43 in dry DMF (50 mL) containing pyridine (2.0 mL): yield 1.631 g (83.8%); mp 
267–268 oC; 1H NMR (DMSO-d6) δ 2.34 (3H, s, Me), 2.78 (3H, s, Me), 3.65–3.70 (8H, m, 
4×CH2), 6.68 (2H, d, J = 9.2 Hz, 2×ArH), 6.86–6.89 (1H, m, ArH), 7.24–7.27 (1H, m, ArH), 
7.28 (2H, d, J = 9.2 Hz, 2×ArH), 7.37–7.41 (1H, m, ArH), 7.43–7.48 (1H, m, ArH), 7.86–
7.87 (1H, m, ArH), 7.97–8.01 (1H, m, ArH), 8.20–8.23 (3H, m, 3×ArH), 8.33 (1H, brs, 
exchangeable, NH), 8.42–8.44 (1H, m, ArH), 9.35 and 11.51 (each 1H, brs, exchangeable, 
2×NH). Anal. (C32H31Cl2N5O·2H2O) C, H, N. 
1-[3-(Acridin-9-yl)amino-5-methylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea 
(109e). Compound 109e was synthesized from 108 (freshly prepared from 107, 0.918 g, 3.0 
mmol) and N1-(acridin-9-yl)amino-5-methylbenzene-1,3-diamine (95a, 0.517 g, 1.7 mmol)43 
in dry DMF (25 mL) containing pyridine (2 mL): yield 375 mg (39%); mp > 280 oC; 1H 
NMR (DMSO-d6) δ 2.26 (3H, s, Me), 3.68 (8H, s, 4×CH2), 6.68 (2H, d, J = 9.0 Hz, 2×ArH), 
6.79 (1H, s, ArH), 7.25–7.27 (3H, m, 3×ArH), 7.46–7.49 (2H, m, 2×ArH), 7.54 (1H, s, ArH), 
8.00–8.07 (4H, m, 4×ArH), 8.28–8.30 (2H, m, 2×ArH), 8.95, 9.38 and 11.51 (each 1H, brs, 
exchangeable, 3×NH). Anal. (C31H29Cl2N5O·2.9H2O) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-methyl-3-(4-methylacridin-9-ylamino)phen- 
yl)- urea (109f). Compound 109f was synthesized from 108 (freshly prepared from 107, 
1.683 g, 5.4 mmol) and 6-methyl-N1-(4-methylacridin-9-yl)benzene-1,3-diamine (96b, 0.910 
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g 3.0 mmol)43 in dry DMF (15 mL) containing triethylamine (2.5 mL): yield 576 mg (44%); 
mp 255–256 oC (dec); 1H NMR (DMSO-d6) δ 2.34 (3H, s, Me), 2.78 (3H, s, Me), 3.65–3.71 
(8H, m, 4×CH2), 6.69 (2H, d, J = 9.0 Hz, 2×ArH), 6.81–6.83 (1H, m, ArH), 7.21–7.24 (1H, 
m, ArH), 7.28 (2H, d, J = 9.0 Hz, 2×ArH), 7.34–7.38 (1H, m, ArH), 7.41–7.45 (1H, m, ArH), 
7.82–7.83 (1H, m, ArH), 7.93–7.97 (1H, m, ArH), 8.15–8.22 (3H, m, 3×ArH), 8.31 (1H, brs, 
exchangeable, NH), 8.39–8.42 (1H, m, ArH), 9.40 and 12.45 (each 1H, brs, exchangeable, 
2×NH). Anal. (C32H31Cl2N5O·2.7H2O) C, H, N. 
9-[5-(3-{4-[Bis(2-chloroethyl)amino]phenyl}ureido)-2-methylphenylamino]-5-methyl- 
acridi-ne-4-carboxylic acid (2-dimethylaminoethyl)amide (109g). Compound 109g was 
synthesized from 108 (freshly prepared from 107, 0.918 g, 3.0 mmol) and 9-(5-amino-2-
methylphenylamino)-5-methylacridine-4-carboxylic acid (2-dimethylaminoethyl)amide (96d, 
0.732 g, 1.7 mmol)43 in dry DMF (25 mL) containing pyridine (2 mL): yield 385 mg (32 %); 
mp > 280 oC; 1H NMR (DMSO-d6) δ 2.19 (3H, s, Me), 2.67 (6H, brs, 2×NMe), 2.85 (3H, s, 
Me), 3.14 (2H, brs, CH2), 3.63–3.70 (8H, m, 4×CH2), 3.85 (2H, s, CH2), 6.40–6.41 (1H, m, 
ArH), 6.65 (2H, d, J = 9.0 Hz, 2×ArH), 6.97–6.99 (1H, m, ArH), 7.24 (2H, d, J = 9.0 Hz, 
2×ArH), 7.45 (1H, m, ArH), 7.51 (1H, m, ArH), 7.74 (2H, brs, 2×ArH), 7.93 (1H, brs, 
exchangeable, NH), 8.08–8.10 (1H, m, ArH), 8.39–8.41 (1H, m, ArH), 8.67–8.69 (1H, m, 
ArH), 9.04, 9.45 and 12.18 (each 1H, brs, exchangeable, 3×NH). Anal. 
(C37H41Cl2N7O2·5.7H2O) C, H, N. 
1-(5-(Acridin-9-ylamino)-2-methoxyphenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea- 
(109h). Compound 109h was synthesized from 108 (freshly prepared from 107, 1.683 g, 5.4 
mmol) N1-(acridin-9-yl)-4-methoxybenzene-1,3-diamine (100a, 0.946 g, 3.0 mmol,)44 in dry 
DMF (15 mL) containing triethylamine (2.5 mL): yield 923 mg (70.2%); mp 263–264 oC 
(dec); 1H NMR (DMSO-d6) δ 3.67–3.68 (8H, m, 4×CH2), 3.96 (3H, s, OMe), 6.68 (2H, d, J = 
8.5 Hz, 2×ArH), 6.95–6.96 (1H, m, ArH), 7.12–7.13 (1H, m, ArH), 7.26 (2H, d, J = 8.5 Hz, 
2×ArH), 7.42–7.44 (2H, m, 2×ArH), 7.95–7.97 (2H, m, 2×ArH), 8.00–8.02 (2H, m, 2×ArH), 
8.24–8.27 (2H, m, 2×ArH), 8.33 (1H, brs, ArH), 8.44, 9.29 and 11.47 (each 1H, brs, 
exchangeable, 3×NH). Anal. (C31H29Cl2N5O2·2.6H2O) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(2-methoxy-5-(4-methylacridin-9-ylamino)phe- 
nyl) urea (109i). Compound 109i was synthesized from 108 (freshly prepared from 107, 
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0.841 g, 2.7 mmol) and 4-methoxy-N1-(4-methylacridin-9-yl)benzene-1,3-diamine (100b, 
0.493 g 1.5 mmol)44 in dry DMF (10 mL) containing triethylamine (2.0 mL): yield 428 mg 
(60.2%); mp 255–256 oC (dec); 1H NMR (DMSO-d6) δ 2.50 (3H, s, Me), 3.65–3.68 (8H, m, 
4×CH2), 3.94 (3H, s, OMe), 6.68 (2H, d, J = 9.0 Hz, 2×ArH), 6.93–6.95 (1H, m, ArH), 7.10 
(1H, m, ArH), 7.26 (2H, d, J = 9.0 Hz, 2×ArH), 7.35–7.37 (1H, m,  ArH), 7.41–7.43 (1H, m, 
ArH), 7.82–7.83 (1H, m, ArH), 7.94–7.96 (1H, m, ArH), 8.21–8.22 (2H, m, 2×ArH), 8.31–
8.32 (1H, m, ArH), 8.50 (1H, brs, ArH), 8.51, 9.44 and 11.55 (each 1H, brs, exchangeable, 
3×NH). Anal. (C32H31Cl2N5O2·2.4H2O) C, H, N. 
1-(3-(Acridin-9-ylamino)-5-methoxyphenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea- 
(109j). Compound 109j was synthesized from 108 (freshly prepared from 107, 0.841 g, 2.7 
mmol) and N1-(acridin-9-yl)-5-methoxybenzene-1,3-diamine (101a, 0.473 g 1.5 mmol)44 in 
dry DMF (10 mL) containing triethylamine (2.0 mL): yield 452 mg (64.5%); mp 260–261 oC 
(dec); 1H NMR (DMSO-d6) δ 3.67 (3H, s, OMe), 3.68–3.70 (8H, m, 4×CH2), 6.56 (1H, s, 
ArH), 6.69 (2H, d, J = 8.9 Hz, 2×ArH), 7.15 (1H, s, ArH), 7.19 (1H, s, ArH), 7.25 (2H, d, J = 
8.9 Hz, 2×ArH), 7.47–7.50 (2H, m, 2×ArH), 7.98–8.00 (2H, m, 2×ArH), 8.04–8.06 (2H, m, 
2×ArH), 8.29–8.31 (2H, m, 2×ArH), 8.88, 9.39 and 11.45 (each 1H, brs, exchangeable, 
3×NH). Anal. (C31H29Cl2N5O2·2.2H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-methoxy-5-(4-methylacridin-9-ylamino) 
phenyl) urea (109k). Compound 109k was synthesized from 108 (freshly prepared from 
107, 0.841 g, 2.7 mmol) and 5-methoxy-N1-(4-methylacridin-9-yl)benzene-1,3-diamine 
(101b, 0.493 g 1.5 mmol)44 in dry DMF (10 mL) containing triethylamine (2.0 mL): yield 
459 mg (63.7%); mp 253–254 oC (dec); 1H NMR (DMSO-d6) δ 2.80 (3H, s, Me), 3.66 (3H, 
s, OMe), 3.67–3.70 (8H, m, 4×CH2), 6.54 (1H, s, ArH), 6.69 (2H, d, J = 9.0 Hz, 2×ArH), 
7.14 (1H, s, ArH), 7.17 (1H, s, ArH), 7.25 (2H, d, J = 9.0 Hz, 2×ArH), 7.40–7.42 (1H, m, 
ArH), 7.47–7.50 (1H, m, ArH), 7.85–7.86 (1H, m, ArH), 7.98–8.00 (1H, m, ArH), 8.23–8.27 
(2H, m, 2×ArH), 8.48–8.50 (1H, m, ArH), 8.97, 9.51 and 11.47 (each 1H, brs, exchangeable, 
3×NH). Anal. (C32H31Cl2N5O2·2.5H2O) C, H, N. 
1-(3-(4-((2-(Dimethylamino)ethyl)carbamoyl)acridin-9-ylamino)-5-methoxyphenyl)-3-
(4-(bis(2-chloroethyl)amino)phenyl)urea (109l). Compound 109l was synthesized from 
108 (freshly prepared from 107, 0.550 g, 1.8 mmol) and 9-(3-amino-5-
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methoxyphenylamino)-N1-(2- (dimethylamino)ethyl)acridine-4-carboxamide (101c, 0.429 g 
1.0 mmol)61 in dry DMF (10 mL) containing triethylamine (2.0 mL): yield 359 mg (61.8%); 
mp 188–190 oC (dec); 1H NMR (DMSO-d6) δ 2.88 (6H, brs, 2×NMe), 3.44 (2H, s, CH2), 
3.60–3.68 (11H, m, 4×CH2, OMe), 3.73 (1H, brs, CH), 3.97 (1H, s, CH), 6.04 (1H, s, 
exchangeable, NH), 6.67–6.68 (2H, m, 2×ArH), 6.78–6.87 (1H, m, ArH), 7.21 (2H, brs, 
2×ArH), 7.53–7.57 (2H, m, 2×ArH), 7.87 (1H, s, ArH), 8.24 (1H, s, ArH), 8.34–8.43 (1H, m, 
ArH), 8.68 (1H, s, ArH),  8.86 (1H, brs, ArH), 9.11–9.33 (1H, m, ArH), 9.57 (1H, s, ArH), 
10.48 and 12.01 (each 1H, brs, exchangeable, 2×NH).  Anal. (C36H39Cl2N7O3·6.9H2O) C, H, 
N. 
1-(3-(Acridin-9-ylamino)-4-methoxyphenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea- 
(109m). Compound 109m was synthesized from 108 (freshly prepared from 107, 0.841 g, 2.7 
mmol) and N1-(acridin-9-yl)-6-methoxybenzene-1,3-diamine (103a, 0.473 g 1.5 mmol)44 in 
dry DMF (10 mL) containing triethylamine (2.0 mL): yield 563 mg (80.4%); mp 268–269 oC 
(dec); 1H NMR (DMSO-d6) δ 3.41 (3H, s, OMe), 3.67–3.70 (8H, m, 4×CH2), 6.70 (2H, d, J = 
9.0 Hz, 2×ArH), 7.14–7.15 (1H, m, ArH), 7.28 (2H, d, J = 9.0 Hz, 2×ArH), 7.43–7.47 (3H, 
m, 3×ArH), 7.81 (1H, brs, ArH), 7.98–8.00 (2H, m, 2×ArH), 8.04–8.06 (2H, m, 2×ArH), 
8.26–8.28 (2H, m, 2×ArH), 8.88, 9.30 and 11.32 (each 1H, brs, exchangeable, 3×NH). Anal. 
(C31H29Cl2N5O2·3.4H2O) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-methoxy-3-(4-methylacridin-9-ylamino)phe- 
nyl) urea (109n). Compound 109n was synthesized from 108 (freshly prepared from 107, 
0.841 g, 2.7 mmol) and 6-methoxy-N1-(4-methylacridin-9-yl)benzene-1,3-diamine (103b, 
0.493 g 1.5 mmol)44 in dry DMF (10 mL) containing triethylamine (2.0 mL): yield 347 mg 
(48.8%); mp 270–272 oC (dec); 1H NMR (DMSO-d6) δ 2.79 (3H, s, Me), 3.39 (3H, s, OMe), 
3.67–3.70 (8H, m, 4×CH2), 6.69 (2H, d, J = 8.8 Hz, 2×ArH), 7.12–7.13 (1H, m, ArH), 7.28 
(2H, d, J = 8.8 Hz, 2×ArH), 7.37–7.39 (1H, m, ArH), 7.42–7.45 (2H, m, 2×ArH), 7.78 (1H, 
brs, ArH), 7.85–7.86 (1H, m, ArH), 7.97–7.99 (1H, m, ArH), 8.18–8.23 (2H, m, 2×ArH), 
8.46–8.50 (1H, m, ArH), 8.93, 9.35 and 11.32 (each 1H, brs, exchangeable, 3×NH). Anal. 
(C32H31Cl2N5O2·3.2H2O) C, H, N. 
1-Acridin-9-yl-3-{4-[bis-(2-chloroethyl)amino]-phenyl}-urea (111). Compound 111 was 
synthesized from 108 (freshly prepared from 107, 0.306 g, 1 mmol) and 9-aminoacridine- 
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hydrochloride (110, 0.248 g, 1mmol) in dry DMF (10 mL) containing triethylamine (0.5 
mL): yield 273 mg (60%); mp 184–186 oC; 1H NMR (DMSO-d6) δ 3.69–3.71  (8H, m, 
4×CH2), 6.72 (2H, d, J = 8.8 Hz, 2×ArH), 7.10–7.14 (2H, m, 2×ArH), 7.39–7.48  (3H, m, 
3×ArH), 7.58–7.62 (2H, m, 2×ArH), 7.84–7.86 (1H, m, ArH), 8.14–8.16 (2H, m, 2×ArH), 
9.37 and 11.33 (each 1H, brs, exchangeable, 2×NH). Anal. (C24H22Cl2N4O) C, H, N.  
 
Biological Experiments 
 
Cytotoxicity Assays. The effects of the compounds on cell growth were determined in T-cell 
acute lymphocytic leukemia CCRF-CEM) and their resistant subcell lines (CCRF-
CEM/Taxol and CCRF-CEM/VBL) by the XTT assay92 and human solid tumor cells (i.e. 
breast carcinoma MX-1 and colon carcinoma HCT-116) the SRB assay93 in a 72 h incubation 
using a microplate spectrophotometer as described previously.94 After the addition of 
phenazine methosulfate-XTT solution at 37 oC for 6 h, absorbance at 450 and 630 nm was 
detected on a microplate reader (EL 340; Bio-Tek Instruments Inc., Winooski, VT).  IC50 
values were determined from dose-effect relationship at six or seven concentrations of each 
drug by using the CompuSyn software by Chou and Martin95 based on the median-effect 
principle and plot.96,97 Ranges given for taxol and vinblastine were mean ± SE (n = 4). 
 
In vivo studies. Athymic nude mice bearing the nu/nu gene were used for human breast 
tumor MX-1 and human glioma U87 MG xenograft. Outbred Swiss-background mice were 
obtained from the National Cancer Institute (Frederick, MD). Male mice 8 weeks old or older 
weighing 22 g or more were used for most experiments. Drug was administrated via the tail 
vein by i.v. injection.  Tumor volumes were assessed by measuring length × width × height 
(or width) by using caliper.  Vehicle used was 50 μL DMSO and 40 μL Tween 80 in 160 μL 
saline. The maximal tolerate dose of the tested compound was determined and applied for the 
in vivo therapeutic efficacy assay. All animal studies were conducted in accordance with the 
guidelines of the National Institutes of Health Guide for the Care and Use of Animals and the 
protocol approved by the Memorial Sloan-Kettering Cancer Center’s Institutional Animal 
Care and Use Committee. 
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Determination of half-life of 109d in rat plasma. The chromatographic system consisted of 
a photodiode-array system (Shimadzu SPD-M20A, Tokyo, Japan), chromatographic pump 
(Shimadzu LC-20AT), an auto-sampler (Shimadzu SIL-20AC) equipped with a 20 µL 
sample loop. Compound 109d was separated from rat plasma using a revise phase column  
(Agilent RP-C8, 30×150 mm, particle size 5 µm, Palo Alto, CA, USA) maintained at an 
ambient temperature (25±1 oC) to perform the ideal chromatographic system. The detector 
wavelength was set at 266 nm. The mobile phase comprised methanol:10 mM NaH2PO4 
(60:40, v/v), which was adjusted to pH 3.0 with 85% of H3PO4. Analysis was run at a flow 
rate of 0.8 mL/min and the samples were quantified using peak area. An aliquot of plasma 
sample (100 µL, with 109d 5 µg/mL) was vortex-mixed with acetonitrile (1:2, v/v) for 
protein precipitation and centrifuged at 10,000 × g for 10 min. The supernatant was passed 
through a 0.45 µm filter for injected into the HPLC. 
Determination of DNA interstand Cross-linking.  
The level of DNA interstrand crosslinking was determined using a modified comet assay.98,99 
All steps were carried out under subdued lighting. Briefly, H1299 cells (2×105 cells) were 
plated in a 60 mm dish and incubated at 37 oC with 5% CO2 for 32 h. The growing cells were 
treated with alkylating agent (72d, mephalan or cisplatin). After being treated with 1 h, the 
cells were exposed to 20 Gy irradiation to induce DNA strand breaks. An aliquot of 5×105 
cells were suspended in 50 μl of phosphate-buffered saline, mixed with a 250 μl of 1.2% low 
melting point agarose, and subjected to comet assay. The tail moment of 100 cells were 
analyzed for each treatment by aid of the COMET assay software (Perceptive instruments, 
Haverhill, UK). The degree of DNA interstrand cross-linking presented at a drug-treated 
sample was determined by comparing the tail moment of the irradiated control, which was 
calculated by the following formula. Percentage of DNA with interstrand cross-linking = [1- 
(TMdi- TMcu / TMci- TMcu)] ×100%, where TMdi = tail moment of drug-treated irradiated 
sample, TMcu = tail moment of untreated unirradiated control, and TMci = tail moment of 
untreated irradiated control. 
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Table 3. Elemental analysis of newly synthesized N-mustards. 
 
C, H, N Analysis 
Anal.Calcd. Found Compd Molecular Formula MW 
C% H% N% C% H% N% 
109a C31H29Cl2N5O2·0.5H2O 583.53 63.81 5.18 12.00 64.07 5.26 11.67 
109b C32H31Cl2N5O2·3H2O 642.59 59.81 5.80 10.89 59.74 5.79 10.67 
109c C31H29Cl2N5O·2.5H2O 603.54 61.69 5.20 11.60 61.83 5.17 11.53 
109d C32H31Cl2N5O·2H2O 608.57 63.15 3.42 11.00 63.38 3.52 10.97 
109e C31H29Cl2N5O·2.9H2O 609.78 61.06 5.23 11.48 61.08 5.11 11.32 
109f C32H31Cl2N5O·2.7H2O 621.18 61.87 5.43 11.27 61.84 5.44 11.43 
109g C37H41Cl2N7O2·5.7H2O 789.38 56.21 6.69 11.42 56.25 6.72 11.44 
109h C31H29Cl2N5O2·2.6H2O 601.36 61.92 5.23 11.64 61.96 5.21 11.59 
109i C32H31Cl2N5O2·2.4H2O 631.75 60.83 5.24 11.08 60.89 5.25 10.93 
109j C31H29Cl2N5O2·2.2H2O 614.15 60.62 5.05 11.40 60.64 5.05 11.24 
109k C32H31Cl2N5O2·2.5H2O 633.56 60.66 5.22 11.05 60.64 5.23 10.95 
109l C36H39Cl2N7O3·6.9H2O 812.96 53.19 5.57 12.06 53.18 5.56 12.03 
109m C31H29Cl2N5O2·3.4H2O 635.77 58.56 5.22 11.01 58.50 5.24 11.09 
109n C32H31Cl2N5O2·3.2H2O 646.17 59.48 5.32 10.84 59.49 5.35 10.82 
111 C24H22Cl2N4O 453.38 63.58 4.89 12.36 63.35 5.05 12.09 
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2.5 1H NMR spectrum for compound 93a and 96b. 
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1H NMR spectrum for compound 105 and 107. 
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1H NMR spectrum for compound 109d and 109e. 
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1H NMR spectrum for compound 109f and 109i. 
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1H NMR spectrum for compound 109k and 109m. 
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CHAPTER 3 
 
Synthesis and Antitumor Activity of Phenyl N-mustard-9-Anilino-        
acridine Conjugates via a Carbamate or Carbonate Linker 
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3.1 Chemistry 
 
 
The synthesis of N-mustards linked to the amino function of aniline ring of 9-anilinoacridine 
conjugates via a carbamate linker (119a-k) is shown in scheme 4. The 9-anilinoacridines 
such as AHMAs (92a,b),40 ATs (94-96),43AAs (100,101,103)44 were prepared as described 
previously. These agents were used as the DNA-directed carriers for constructing the new N-
mustard-9-anilinoacridine conjugates (Scheme 4). The key intermediate, 4-(bis(2-
chloroethyl)amino)phenyl 4-nitrophenyl carbonate (118) was synthesized by the known 
procedures with modification.54,91,100,101 For instance, reaction of 4-hydroxyaniline (112) with 
2-chloroethanol in the presence of Na2CO3 followed with benzyl bromide gave 114.100 
Treatment of 114 with methanesulfonyl chloride/pyridine yielded 4-N,N-bis(2-
chloroethyl)aminophenyl benzyl ether 115. The O-benzyl protecting function of 115 was 
removed by catalytic hydrogenation to give the desired phenol mustard 116 which was 
converted to stable intermediate 4-[N,N-bis(2-chloroethyl)aminophenyl-4-nitrophenyl 
carbonate (118)91 by reacting with 4-nitro phenylchlroformate (117) in presence of 
triethylamine.  The condensation of 9-anilinoacridine (98-103) with carbonate intermediate 
118 proceeded smoothly in dry DMF in the presence of pyridine at room temperature to 
furnish 119a-k in a fair to good yield (Table 4). The preparation of N-mustards linked to the 
hydroxymethyl function of AHMA-alkylcarbamates (120a-c) via a carbamate or carbonate 
linkage is shown in Scheme 5. The intermediate N,N-bis(2-chloroethyl)benzene-1,4-diamine 
hydrochloride (107),53 and 4-[N,N-bis(2-chloroethyl)-amino]-phenylisocyanate (108)91  were 
synthesized as described previously. The requisite AHMA-alkylcarbamates (120a-c) were 
synthesized by following the methods previously developed by Su et al.42 The freshly 
prepared 108 (generated from 107 by treating with triphosgene) in anhydrous DMF in 
presence of TEA gave the corresponding N-mustard-AHMA-alkylcarbamate conjugates 
having a carbamate spacer (121a-c) in moderate yields (Table 5). 
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Scheme 4. Synthetic route for the new N-mustard-9-anilinoacridine conjugates via a 
carbamate linker (119a-k) 
 
 
NH2HO N(CH2CH2OH)2HO N(CH2CH2OH)2C6H5CH2O
i ii
iii
112 113 114
115
92-103
119a-k
a: R1 = H, R2 = 5'-CH2OH           g: R
1 = H, R2 = 4'-OMe
b: R1 = Me, R2 = 5'-CH2OH         h: R
1 = Me, R2 = 4'-OMe
c: R1 = Me, R2 = 2'-Me                 i: R1 = H, R2 = 5'-OMe
d: R1 = H, R2 = 4'-Me                   j: R1 = H, R2 = 6'-OMe
e: R1 = Me, R2 = 4'-Me                k: R1 = Me, R2 = 6'-OMe
f: R1 = Me, R2 = 6'-Me
O N(CH2CH2Cl)2O
O
O2N
N(CH2CH2Cl)2C6H5CH2ON(CH2CH2Cl)2HO
NO2
OCOCl
iv
v
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N
HN
HN
O
O
N(CH2CH2Cl)2
R
1
R
21'
2'
3'
4'
5'
6'
N
HN
R
1
NH2
R
2
 
 
Reaction conditions: (i) 2-Chloroethanol, Na2CO3, water, reflux; (ii) benzylchloride, KOH, 
EtOH, reflux; (iii) MsCl/pyridine, 70-75 oC; (iv) 10%Pd/C, H2, 35 psi; (iv) CHCl3/TEA, 
room temperature; (v) DMF/pyridine, room temperature.  
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Scheme 5. Synthesis of N-mustard-AHMA-alkylcarbamate conjugates via a carbamate or 
carbonate linker (121a-c and 122a) 
 
108
121a-c
120a-c
iii
a: R1 = H, R2 = Et
b: R1 = H, R2 = iso-Pro.
c: R1 = Me, R2 = tert-Bu   
107
ii
N
HN
NHCOOR2
O
R1
N
O
N(CH2CH2Cl)2
H
122a
N
HN
NHCOOR2
OH
R1
N
HN
NHCOOEt
O O
O
N(CH2CH2Cl)2
N(CH2CH2Cl)2
NCO
N(CH2CH2Cl)2
NH2
118
i
 
 
Reaction conditions: (i) DMF/pyridine, DMAP, room temperature; (ii) triphosgene, 
CHCl3/TEA, -10 oC; (iii) DMF/TEA, room temperature. 
 
While, the coupling of 120a-c with 118 to prepare N-mustard-AHMA-alkylcarbamate 
conjugates bearing a carbonate linker was carried out in anhydrous DMF in presence of 
pyridine/DMAP at room temperature.  However, only 122a was obtained in 25% after 
purification by liquid flash column chromatography. Attempts to prepare 122b,c under 
various reaction conditions were failed; a mixture of complex decomposition products was 
observed by silica gel thin-layer chromatography. 
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All of the synthesized compounds were characeterized by using 1H NMR and Elemental 
analysis. For compounds 119a-k, 121a-c and 122a the characteristic peak for methylenic 
proton (i.e., N(CH2CH2Cl) appeared at 3.7 δ ppm. The 1H NMR signals for the phenyl N-
mustards residue appeared as doublet (ortho coupling, J = 8.8-9.0 Hz) at 6.6-6.7 and 7.0- 7.2 
δ ppm. The characteristic peak for the carbonate linker (NHCOO) appeared at 9.0-10.5 
δ ppm as D2O exchangeable singlet. The elemental analysis of the newly synthesized 
derivatives were within ±0.4% range of the calculated C, H, N data.        
 
Table 4. Yields and analytical data of the newly synthesized N-mustard conjugates (119a-k)  
 
N
HN
HN
O
O
N(CH2CH2Cl)2
R
1
R
2
1'
2'
3'
4'
5'
6'
 
Compd. R1 R2 mp (oC) Yield (%) Analysis 
119a  H 5'-CH2OH 241-242 79 C, H, N 
119b  Me 5'-CH2OH 240-242 61 C, H, N 
119c  Me 2'-Me 202-203 69 C, H, N 
119d  H 4'-Me 138-139 59 C, H, N 
119e  Me 4'-Me 154-156 52 C, H, N 
119f  Me 6'-Me 104-105 49 C, H, N 
119g  H 4'-OMe 190-192 63 C, H, N 
119h  Me 4'-OMe 195-196 47 C, H, N 
119i  H 5'-OMe 179-180 21 C, H, N 
119j  H 6'-OMe 194-195 78 C, H, N 
119k  Me 6'-OMe 186-188 52 C, H, N 
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Table: 5. Yields and analytical data of newly prepared N-mustad-AHMA-alkylcarbamte 
conjugates (121a-c and 122a) 
N
HN
NHCOOR2
O X
O
R1
N
Cl
Cl
 
 
Compd. R1 R2 X mp (oC) Yield (%) Analysis 
121a H Et NH 178-179 60 C, H, N 
121b H iso-Pro. NH 120-122 13 C, H, N 
121c Me tert-But. NH 228-230 34 C, H, N 
122a H Et O 131-133 25 C,H,N 
 
3.2 Biological results and discussion 
 
3.2.1 In vitro cytotoxicity. Table 6 shows the antiproliferative activities of the newly 
synthesized N-mustard-9-anilinoacridine conjugates (119a-k, 121a-c and 122a) against 
human lymphoblastic leukemia (CCRF-CEM) and its drug-resistant sublines (CCRF-
CEM/Taxol and CCRF-CEM/VBL) cell growth in vitro. It demonstrated that the newly 
synthesized conjugates possess significant cytotoxicity with IC50 in submicro molar range. 
The following discussion of structure-activity relationship (SAR) was based on their in vitro 
cytotoxicity in inhibiting CCRF-CEM since this cell line has been used as a comparative 
standard for our drug discovery program.  In ATs series, C4’-Me substituted compound 
(119d) was more cytotoxic than the corresponding C2’-Me (119c) or C6’-Me (119f). In the 
AAs series, the C4’-OMe derivatives (119g and 119h) were about 3–20 fold more potent 
than the C5’-OMe (119i) or C6’-OMe (119j and 119k) derivatives. It is interesting to note 
that in the series of AA conjugates, the cytotoxicity was increased by adding the methyl 
group at C4 position of the acridine ring (119g vs. 119h, 119j vs. 119k). In contrast, the C4-
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Me substituted compound (119e) was less active than the C4-unsubtituted derivative (119d). 
The N-mustard derivatives bearing CH2OH substituent (119a and 119b) were as potent as 
C4’-Me (119d) and C4’-OMe (119g) derivatives. Of these derivatives, 119h (C4’-OMe-C4-
Me) was the most cytotoxic with the IC50 value of 0.024 μM. The SAR study of the N-
mustard-AHMA-alkylcarbamate conjugates (121a-c) showed that AHMA-ethylcarbamate 
(122a) was more potent than the corresponding iso-propyl and tert-butylcarbamates (121b 
and 121c). In comparison of the cytotoxicity of the conjugates having carbamate and 
carbonate linker (121a vs. 122a, respectively), 121a was more cytotoxic than 122a.  
New N-mustard conjugates (119a-k, 121a-c and 122a) were also evaluated for their 
antiproliferative activities against MX-1 and HCT-116 solid tumor cell growth (Table 6). In 
general, the position of the N-mustard residue either linked to the amino function of AHMAs, 
ATs or AAs (119a-k) or to the hydroxymetnyl of AHMA-alkylcarbamates (121a-c or 122a) 
did not greatly affect their cytotoxicity against both cell lines. Among the new conjugates 
tested against MX-1 cell growth in vitro, 119a, 119b, and 122a were shown to have 
significant cytotoxicity with IC50 values of 0.099, 0.084, and 0.089 μM, respectively. In 
addition, all new conjugates (119a-k, 121a-c and 122a) possessed a comparable cytotoxicity 
against HCT-116 cell line. To explore further, compounds 119a, 119b, 119f, 119h, 121b and 
122a were selected to study their cell growth inhibitory effect against other solid tumor such 
as non-small cell lung cancer (H1299), human prostate cancer (PC3), human lung 
adenocarcinoma (CL1-0), and CL1-5  and human breast adenocarcinoma (MCF-7) (Table 7). 
The SAR study revealed that these agents were more cytotoxic in inhibiting H1299 cell 
growth with IC50 value in sub micro molar range than PC3, CL1-0, CL1-5 or MCF-7 cell 
lines. Importantly, all the selected derivatives were about 1-140 fold more potent than the 
cisplatin against CL1-0, CL1-5 and MCF-7 cell growth. Among these agents, compound 
119a was the most potent in inhibiting H1299 cell growth with IC50 value of 0.284 μM. 
As shown in Table 6, the newly synthesized derivatives have little or no cross-resistance to 
either taxol or vinblastine. This suggests that all new conjugates are neither a good substrate 
of membrane multi-drug resistance transporters (i.e., p-glycoprotein) nor mutated tubulin. 
Thus, the newly synthesized compounds are effective against multiple drug resistant tumors. 
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Table 6. Cytotoxicity of new N-mustard conjugates, 119a-k, 121a-c and 122a against human 
lymphoblastic leukemia (CCRF-CEM) and its drug-resistant sublines (CCRF-CEM/Taxol 
and CCRF-CEM/VBL) and solid tumors (MX-1 and HCT-116) cell growth in vitro.a 
 
IC50 (µM) 
Compd. 
CCRF-CEM CCRF-CEM/Taxolb CCRF-CEM/VBLb MX-1 HCT-116 
119a 0.075±0.016 0.140±0.032[1.9×]c 0.184±0.028[2.5×] 0.099±0.004 0.568±0.037 
119b 0.067±0.013 0.097±0.018[1.4×] 0.127±0.019[1.9×] 0.084±0.003 0.438±0.036 
119c 0.16±0.026 0.174±0.004[1.09×] 0.142±0.003[0.89×] 0.181±0.008 0.320±0.010 
119d 0.076±0.014 0.216±0.004[2.8×] 0.158±0.006[2.1×] 0.214±0.004 0.434±0.021 
119e 0.132±0.016 0.169±0.011[1.3×] 0.157±0.011[1.2×] 0.286±0.025 0.607±0.038 
119f 0.132±0.053 0.138±0.062[1.05×] 0.093±0.014[0.7×] 0.163±0.014 0.263±0.055 
119g 0.085±0.034 0.16±0.042[1.9×] 0.119±0.013[1.4×] 0.181±0.005 0.186±0.003 
119h 0.024±0.013 0.027±0.006[1.1×] 0.19±0.001[7.9×] 0.138±0.012 0.238±0.006 
119i 0.200±0.002 0.309±0.003[1.5×] 0.108±0.001[0.54×] 0.340±0.007 1.712±0.012 
119j 0.541±0.025 0.583±0.003[1.08×] 0.254±0.004[0.14×] 1.555±0.034 0.709±0.017 
119k 0.205±0.052 0.210±0.001[1.0×] 0.11±0.004[0.54×] 0.338±0.02 0.841±0.044 
121a 0.085±0.001 0.243±0.001[2.9×] 0.319±0.006[3.9×] 0.597±0.007 0.752±0.009 
121b 0.189±0.047 0.648±0.057[3.4×] 0.753±0.022[4×] 1.13±0.045 0.301±0.053 
121c 0.750±0.17 3.358±0.22[4.5×] 1.416±0.018[1.9×] 5.933±0.657 2.403±0.106 
122a 0.315±0.004 0.509±0.004[1.6×] 0.482±0.004[1.5×] 0.089±0.001 0.639±0.005 
36 0.007 0.0340[4.9×] 0.0075[1.1×] 0.0035 0.0055 
92a 0.753 0.600[0.8×] 1.60[2.70×] 0.0035 NDd 
Taxol 0.0031±0.0001 0.429±0.042[330×] 1.274±0.052[980×] 0.046±0.0007 0.0011±0.0003
Vinblastine 0.00073±0.0009 0.078±0.011[106.2×] 0.496±0.121[679.5×] 0.0022±0.0002 0.0011±0.0003
aCell growth inhibition was measured by the XTT92 assay for leukemic cells and the SRB assay93 for solid 
tumor cells after 72 h incubation using a microplate spectrophotometer as described in experimental section. 
IC50 values were determined in duplicate or triplicate from dose–effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin95 based on the median-effect 
principle and plot and serial deletion analysis. Ranges given for taxol and vinblastine were mean ± SE (n = 4). 
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bCCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 330-fold resistant to 
Taxol, and 680-fold resistant to Vinblastine, respectively, when comparing with the IC50 of the parent cell line. 
cNumbers in the brackets are fold of cross-resistant determined by comparison with the corresponding IC50 of 
the parent cell line. 
dND= not determined 
 
Table 7. Cytotoxicity of new N-mustard conjugates, 119a, 119b, 119f, 119h, 121b and 122a 
against non-small cell lung cancer (H1299), human prostate cancer (PC3), human lung 
adenocarcinoma (CL1-0 and CL1-5)  and human breast adenocarcinoma (MCF-7) cell 
growth in vitro.a 
 
IC50 (µM)b 
Compd. 
H1299 PC3 CL1-0 CL1-5 MCF-7 
119a 0.284±0.083 1.609±0.340 2.695±0.773 5.064±1.459 4.797±0.531
119b 0.457±0.040 5.977±1.912 1.869±0.789 12.648±1.723 9.01±0.918 
119f 0.623±0.023 4.469±1.796 4.657±1.432 10.588±2.476 5.713±0.972
119h 0.357±0.043 1.576±0.585 2.251±0.806 8.85±1.28 3.433±0.991
121b 9.171±0.195 15.980±4.062 3.996±0.507 6.629±1.352 7.012±0.773
122a 0.527±0.071 23.331±4.974 0.410±0.242 4.56±3.313 19.802±6.596
cisplatin 4.707±0.574 11.803±5.775 56.917±16.984 27.741±3.913 19.872±1.885
aCell growth inhibition was measured by the WST-1 assay102 after 72 h incubation using a microplate 
spectrophotometer as described in experimental section.  
bThe values are averages of at least two separate determinations. 
 
3.2.2 In vivo therapeutic effect. Compounds 119a, 119b, 119e, 119i, and 122a were 
selected for evaluating their antitumor therapeutic efficacy in animal model which is based 
on their in vitro cytotoxicity, solubility and toxicity to the host. Figure 26 shows the 
therapeutic effects of 119a, 119b, 119i and 122a in nude mice bearing mammary MX-1 
xenografts at the maximal tolerated doses [50 mg/kg, Q2D×5; 40 mg/kg, Q2D×5, 100 mg/kg, 
QD×6 and 10 mg/kg, Q2D×3, respectively, via intravenous injection (iv injection)]. 
Remarkably, in all cases, total tumor remission (or complete remission, CR) was achieved 
with only one cycle treatment (Fig. 26A). No tumor relapse was found in mice treated with-  
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Figure 26.  The therapeutic effects of 119a, 119b, 119i, and 122a in nude mice bearing MX-
1 (iv injection, n = 5). Fig. 26A for average tumor size changes; p values for 119a, 119b, 
119i, and 122a are <0.0001 (D14-20), <0.0008 (D14-20), <0.0001 (D16-18), and <0.0005 
(D16-18), respectively. Fig. 26B for average body weight changes.  
26A 
 
26B 
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Figure 27.  The therapeutic effects of 119e in nude mice bearing MX-1 (iv injection, n = 5). 
Fig. 27A for average tumor size changes; p value <0.0001 (D27-29); Fig. 27B for average 
body weight changes. 
  
27A 
 
27B 
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Figure 28.  The therapeutic effects of 119a and 119e in nude mice bearing HCT-116 
xenografts (iv injection, n = 4). Fig. 28A for average tumor size changes; p value <0.0001; 
Fig. 28B for average body weight changes. 
28A 
 
28B 
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119a and partial mice treated with 119b on Day 129 of experimentation. Compound 119e 
also led to complete tumor remission at the dose of 50 mg/kg, Q2D×9 (Fig. 27A). Figure 28 
shows the therapeutic effects of 119a and 119e in nude mice bearing colon HCT-116 
xenografts. Compound 119a and 119e showed, at the doses of 50 and 50 mg/kg, respectively, 
significant tumor growth inhibition (98% and 89%, respectively) in comparison to untreated 
control. Although 8-15% body-weight change was found during maximal tolerated treatment 
(Fig. 26B, 27B, and 28B), the body-weight of mice was readily recovered after cession of 
treatment suggesting that the tested compounds have relatively low toxicity to the hosts. 
 
3.2.3 DNA interstand cross-linking Study. To realize whether the newly synthesized 
conjugates are able to cross-link to DNA doubled strands, the single cell gel electrophoresis 
assay (modified comet assay)98,99 was employed to determine the level of DNA interstrand 
cross-linking. The representative compound 119a was subjected to DNA cross-linking 
studies in human non-small lung cancer H1299 cells by the modified comet assay and was 
compared with melphalan.  The results showed that 119a was capable of inducing DNA 
interstrand cross-linking in a dose-dependent manner (Figure 29). At the dose of 10 μM, this 
agent induced 74.2% DNA cross-linking, while, melphalan induced 39.7% DNA cross-
linking at the dose of 200 μM under the same experimental conditions.  
Figure 30 shows the distribution of tail moment in H1299 cells.  The production of an 
essentially random distribution of single-strand breaks is obtained by means of 20 Gy X rays. 
As cross-linking agents connect DNA with DNA and or histone proteins, they decreased 
DNA migration in the comet assay. The comet images clearly show the concentration-
dependent reduction of DNA migration in all H1299 cells with increasing concentrations of 
the cross-linker 119a.  The results suggested that DNA interstand cross-linking may be the 
main mechanism of action of 119a and the related compounds.  
 
Figure 29.  DNA cross-linking in H1299 cells measured by the modified comet assay. 
Results were generated as described in the Experimental Section. The experiments were 
performed in duplicate and repeated three times. Data points represent the mean±SE of each 
test condition. 
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Figure 30.  Typical comet images from H1299 cell treated ex vivo with 119a and melphalan. 
The presence of cross-links retards the electrophoretic mobility of alkaline denatured cellular 
DNA. Cross-links are, therefore, quantitated as the decrease in comet tail moment compared 
with irradiated control. a. control; b. 20 Gy irradiation; c. melphalan (200 μM); d. 119a 0.05 
μM; e. 119a 1 μM; f. 119a 5 μM; g. 119a 10 μM. 
 
  
a b c  
   
d e f g 
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3.2.4 Stability in rat plasma. Compound 119a was further selected to study its chemical 
stability in rat plasma. The degradation of this agent was detected by HPLC. The detection 
limit is 20 ng/ml of the authentic 119a in the rat plasma. It revealed that 119a is a stable N-
mustard derivative in rat plasma with long half-life (t1/2 = 6.41±0.86 h, n = 3). These results 
demonstrate that the newly prepared N-mustards are chemically and metabolically stable 
derivatives.  
 
3.3 Conclusion 
 
In these studies, a series of DNA-directed alkylating agents by linking the phenyl N-mustard 
pharmacophore with the amino function of the aniline ring of various 9-anilinoacridine 
derivatives via a carbamate linker (119a-k) or to the hydroxymethyl function of AHMA-
alkylcarbamates via a carbamate or carbonate spacer (121a-c and 122a, respectively) was 
designed and synthesized for antitumor evaluation. The SAR studies showed that, 
compounds 119a-k are more cytotoxic or as potent as 121a-c. The antitumor therapeutic 
efficacy studies against human tumor xenografts demonstrated that the newly synthesized 
conjugates exhibited potent antitumor efficacy against breast carcinoma MX-1 and colon 
carcinoma HCT-116 xenografts. For MX-1 xenograft, complete tumor remission was 
achieved after treatment of 119a, 119b, 119e, 119i, and 122a and maintain no relapse on Day 
129 by 119a and 119b. For HCT-116 xenografts, tumor growth inhibition was 98% and 89 % 
by 119a and 119e, respectively. Moreover, it was also found that 119a is able to induce DNA 
interstrand cross-linking and the DNA cross-linking capability is much more effective than 
that of melphalan.  The previous studies demonstrated that urea linker in phenyl N-mustard-
9-anilinoacridine conjugates plays a very important role, especially for stabilizing the 
reactive N-mustard residue. The current studies also show that the carbamate or carbonate 
linkers play an important role in enhancing drug’s therapeutic effects, DNA interstrand cross-
linking and stability.   
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3.4 Experimental Section 
 
Melting points were determined on a Fargo melting point apparatus and are uncorrected.  
Column chromatography was carried out on silica gel G60 (70-230 mesh and 230-400 mesh). 
Thin-layer chromatography was performed on silica gel G60 F254 with short-wavelength UV 
light for visualization. Elemental analysis was done on a Heraeus CHN-O Rapid instrument. 
1H NMR spectra were recorded on 400 MHz spectrometers. The chemical shifts were 
reported in ppm (δ) relative to TMS. 
 
4-[Bis-(2-hydroxy-ethyl)-amino]-phenol (113).100 To a solution of Na2CO3 (29.04 g, 274 
mmol) in water (250 mL) was added 4-aminophenol (112, 15 g) and stirred for 15 min. 2-
Chloroethanol (66.17 g, 822 mmol) was added slowly and the reaction mixture was heated to 
reflux for 25 h, cooled to 0 oC and neutralize by saturated NaHCO3 solution to adjust pH 7.0-
7.5. The white solid separated out was filtered and dried to give 113, yield: 25.18 g (92%); 
mp 140–141 oC; 1H NMR (DMSO-d6) δ 3.27 (4H, t, J = 6.6 Hz, 2×CH2), 3.47 (4H, q, J = 5.8 
Hz, 2×CH2), 4.63 (2H, t, J = 5.8 Hz, exchangeable, 2×OH), 6.56 (4H, d, J = 8.8 Hz, 4×ArH), 
8.42 (1H, s, exchangeable, OH). 
2-[(4-Benzyloxy-phenyl)-(2-hydroxy-ethyl)-amino]-ethanol (114).101 A mixture of 4-[Bis-
(2-hyd-roxyethyl)amino]phenol (113, 9.862 g, 50 mmol), KOH (2.85 g, 50 mmol) and 
benzylbromide (8.55 g, 50 mmol) in EtOH (50 mL) was heated at reflux for 3.5 h. The 
Reaction mixture was concentrated in vacuo and poured into water. The separated white solid 
was filtered, washed with water and dried to give 114, yield: 15.16 g (91%); mp 98–99 oC; 
1H NMR (DMSO-d6) δ 3.32 (4H, t, J = 5.8 Hz, 2×CH2), 3.49 (4H, q, J = 5.8 Hz, 2×CH2), 
4.07 (2H, t, J = 5.8 Hz, exchangeable, 2×OH), 4.97 (2H, s, CH2), 6.61 (2H, d, J = 9.5 Hz, 
2×ArH), 6.84 (2H, d, J = 9.5 Hz, 2×ArH), 7.18–7.24 (5H, m, 5×ArH).  
(4-Benzyloxyphenyl)-bis(2-chloroethyl)amine (115).101 The (bis-hydroxyethylamino)phen- 
yl ether  (114, 28.73 g, 100 mmol) was dissolved in anhydrous pyridine (100 mL) and cooled 
to 0 oC. MsCl (45.80 g, 400 mmol) was added dropwise and the reaction mixture stirred at 2–
4 oC for 20 min, then heated at 70–80 oC for 30 min. The Solvent was removed under vacuo 
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and the residue was partitioned between ethyl acetate (300 mL) and water (300 mL). The 
organic layer was collected, dried over anh.Na2SO4, filtered, and the filtrate was concentrated 
in vacuo. The oily residue was purified by column chromatography using dichloromethane as 
eluent to give 115, 17.0 g (53%); mp 108–109 oC; 1H NMR (DMSO-d6) δ 3.57–3.72 (8H, m, 
4×CH2), 4.98 (2H, s, CH2), 6.70 (2H, d,  J = 8.7 Hz, 2×ArH), 6.89 (2H, d , J = 8.7 Hz, 
2×ArH), 7.30 (1H, t, J = 7.3 Hz, ArH), 7.37 (2H, t, J = 7.3 Hz, 2×ArH), 7.42 (2H, d, J = 7.8 
Hz, 2×ArH).  
4-[Bis-(2-chloro-ethyl)-amino]-phenol hydrochloride (116).101 Hydrogen chloride gas was 
bubbled through a solution of the (4-benzyloxyphenyl)-bis(2-chloroethyl)amine (115, 7.0 g, 
21.5 mmol) in methanol (75 mL) until complete dissolution occurred. The solution was 
filtered and 10 % palladium on carbon (0.350 g) was added. The reaction mixture was stirred 
under hydrogen atmosphere at pressure 35 psi. for 40 h. The reaction mixture filtered through 
a pad of Celite and evaporated to dryness under reduce pressure to give 116 as a white solid, 
yield: 5.1 g (87%); mp 172–175 oC; 1H NMR (DMSO-d6) δ 3.60 (4H, t J = 6.2 Hz, 4×CH2,), 
δ 3.72 (4H, t, J = 6.2 Hz, 4×CH2), 6.78 (2H, d , J = 9.0 Hz, 2×ArH), 7.02 (2H, d , J = 9.0 Hz, 
2×ArH), 9.04 (1H, s, exchangeable ,OH). 
4-[bis-(2-chloro-ethyl)-amino]-phenyl ester 4-nitro-phenyl ester (118).101 4-[N,N-bis(2-
chloro-ethyl)amino]-phenol hydrochloride (116, 9.94 g, 36.5 mmol) was suspended in dry 
CHCl3 (60 mL) and cooled to 0 oC. Triethylamine (14 mL, 100 mmol) was slowly added 
followed by dropwise addition of 4-Nitrophenyl chloroformate (117, 7.35 g, 36.5 mmol) in 
chloroform (20 mL). The Reaction mixture was stirred at room temperature for 3 h, washed 
with water (100 mL), 5% KHSO4 solution (50 mL) and brine (100 mL). Organic layer 
collected and dried over anh.Na2SO4, filtered, and evaporated to dryness in vacuo. The 
separated yellow oil purified by column chromatography using dichloromethane as an eluent. 
The yellow oil solidified on standing to give carbonate compound 118, yield: 13.4 g (91%); 
mp 98–99 oC; 1H NMR (DMSO-d6) δ 3.74 (8H, s, 4×CH2), 6.80 (2H, d, J= 9.0 Hz, 2×ArH), 
7.22 (2H, d , J= 9.0 Hz, 2×ArH), 7.68 (2H, d, J= 9.0 Hz, 2×ArH), 8.35 (2H, d , J= 9.0 Hz, 
2×ArH). 
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General procedure for the preparation of N-mustard linked to the amino function of 9-
anilinoacridines via a carbamic acid ester linkage (119a-k)  
 
9-Anilinoacridines such as AHMAs (92),40 ATs (94-96),43 AAs (100,101,103),44 and 
AHMA-alkylcarbamates (120a-c)42 were synthesized by the methods previously developed 
by Su et al.  These agents were used as the DNA-directed carriers for constructing the N-
mustard-9-anilinoacridine conjugates.  The key intermediate, 4-[bis-(2-chloroethyl)amino] 
phenyl ester 4-nitro-phenyl ester (118),54,91,100,101 N,N-Bis(2-chloroethyl)benzene-1,4-diamine 
hydrochloride (107),53 and 4-[N,N-bis(2-chloroethyl)amino]phenyl-isocyanate (108)91 were 
prepared by following the literature methods. The reaction of 118 with appropriate 9-
anilinoacridines (92,94-96,100-103) was carried out in dry DMF in the presence of pyridine 
to give 119a-k. The final products were purified either by recrystallization from an 
appropriate solvent or by column chromatography using (SiO2, CHCl3/MeOH, v/v 100:1). 
The detailed procedure was described as follows: 
 
[3-(Acridin-9-ylamino)-5-hydroxymethyl-phenyl] carbamic acid 4-[bis(2-chloroethyl)-
amino]-phenyl ester (119a). Compound 118 (1.123 g, 2.7 mmol) was added into a solution 
of [3-(acridin-9-ylamino)-5-amino-phenyl] methanol (92a, 1.130 g, 2.73 mmol)40 in dry 
DMF (20 mL) containing pyridine (5 mL) at room temperature and stirred for 48 h. The 
Reaction mixture was evaporated under reduced pressure to dryness and the solid residue 
was dissolved in a mixture of CHCl3/MeOH containing silica gel (5 g) and then evaporated 
in vacuo to dryness. The residue was put on the top of a silica gel column (20×4 cm) and 
purified by using CHCl3/MeOH (100/1 v/v) as an eluent. The fraction containing the main 
product were combined and evaporated in vacuo to dryness and the residue was 
recrystallized from CHCl3/MeOH to give 119a, 1.169 g (79%); mp 241–242 °C; 1H NMR 
(DMSO-d6) δ 3.72 (8H, s, 4×CH2), 4.46 (2H, s, CH2), 5.36 (1H, brs, exchangeable, OH), 
6.74 (2H, d, J = 9.0 Hz, 2×ArH), 7.02 (1H, brs, ArH), 7.03 (2H, d, J = 9.0 Hz, 2×ArH), 7.46–
7.51 (4H, m, 4×ArH), 7.99–8.02  (2H, m, 2×ArH), 8.11–8.12 (2H, m, 2×ArH), 8.28–8.30 
(2H, m, 2×ArH), 10.38 and 11.53 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C31H28Cl2N4O3) C, H, N. 
 
 79
By following the same procedure, the following compounds were synthesized. 
 
[3-Hydroxymethyl-5-(4-methyl-acridin-9-ylamino)-phenyl] carbamic acid 4-[bis(2-
chloroethyl)-amino] phenyl ester (119b). Compound 119 was prepared from 118 (1.196 g, 
3 mmol) and [3-amino-5-(4-methyl-acridin-9-ylamino)-phenyl]methanol (92b, 0.987 g, 3 
mmol):40 Yield 1.053 g (61%); mp 240–242 °C; 1H NMR (DMSO-d6) δ 2.81 (3H, s, Me), 
3.72 (8H, s, 4×CH2), 4.57 (2H, s, CH2), 5.35 (1H, brs, exchangeable, OH), 6.74 (2H, d, J = 
9.0 Hz, 2×ArH), 6.98 (1H, brs, ArH), 7.03 (2H, d, J = 9.0 Hz, 2×ArH), 7.38–7.40 (2H, m, 
2×ArH), 7.46–7.49 (2H, m, 2×ArH), 7.86–7.87 (1H, m, ArH), 7.99–8.00 (1H, m, ArH), 
8.21–8.27 (2H, m, 2×ArH), 8.54–8.56 (1H, m, ArH), 10.37 and 11.77 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C32H30Cl2N4O3), C, H, N. 
[2-Methyl-3-(4-methyl-acridin-9-ylamino)-phenyl] carbamic acid 4-[bis(2-chloroethyl)-
amino] phenyl ester (119c). Compound 119c was prepared from 118 (2.0 g, 5 mmol) and 2-
methyl-N-(4-methyl-acridin-9-yl)-benzene-1,3-diamine (0.689 g, 2.2 mmol):43 Yield 0.786 g 
(69%);  mp 202–203 °C; 1H NMR (DMSO-d6) δ 2.02 (3H, s, Me), 2.49 (3H, s, OMe), 3.73 
(8H, s, 4×CH2), 6.40–6.42 (1H, m, ArH), 6.74–6.77 (4H, m,  4×ArH), 7.03 (2H, d, J = 8.6 
Hz, 2×ArH), 7.06–7.10 (3H, m, 3×ArH), 7.33–7.45 (2H, m, 2×ArH), 7.69–7.70 (1H, m, 
ArH), 8.06 (1H, brs, ArH), 9.33 and 9.71 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C32H30Cl2N4O2) C, H, N. 
[5-(Acridin-9-ylamino)-2-methyl-phenyl] carbamic acid 4-[bis(2-chloroethyl)-amino] 
phenyl ester (119d). Compound 119d was prepared from 118 (1.20 g, 3 mmol) and N1-
acridin-9-yl-4-methyl-benzene-1,3-diamine (94a, 0.600 g, 2 mmol):43 Yield 0.663 g (59%); 
mp 138–139 °C; 1H NMR (DMSO-d6) δ 2.26 (3H, s, Me), 3.71 (8H, s, 4×CH2), 6.47–6.50 
(1H, m, ArH), 6.76–6.78 (3H, m, 3×ArH), 6.94 (2H, brs, 2×ArH), 7.00 (2H, d, J = 8.7 Hz, 
2×ArH), 7.11–7.13 (2H, m, 2×ArH), 7.35–7.50 (4H, m, 4×ArH), 8.21 (1H, m, ArH), 9.24 
and 10.84 (each 1H, brs, exchangeable, 2×NH). Anal. (C31H28Cl2N4O2) C, H, N. 
[2-Methyl-5-(4-methyl-acridin-9-ylamino)-phenyl] carbamic acid 4-[bis(2-chloroethyl)-
amino] phenyl ester (119e). Compound 119e was prepared from 118 (1.197 g, 3 mmol) and 
4-methyl-N1-(4-methyl-acridin-9-yl)-benzene-1,3-diamine (94b, 0.940 g, 3 mmol):43 Yield 
0.905 g (52%); mp 154–156 °C; 1H NMR (DMSO-d6) δ 2.36 (3H, s, Me), 2.81 (1H, s, Me), 
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3.71 (8H, s, 4×CH2), 6.72 (2H, d, J = 9.0 Hz, 2×ArH), 6.96–7.00 (2H, m, 2×ArH), 7.12–7.13 
(1H, m, 2×ArH), 7.33–7.44 (3H, m, 3×ArH), 7.62 (1H, brs, ArH), 7.83–7.84 (1H, m, ArH), 
7.96–7.97 (1H, m, ArH), 8.21–8.27 (2H, m, 2×ArH), 8.57–8.58 (1H, m, ArH), 9.52 and 
11.65 (each 1H, brs, exchangeable, 2×NH). Anal. (C32H30Cl2N4O2) C, H, N. 
[4-Methyl-3-(4-methyl-acridin-9-ylamino)-phenyl] carbamic acid 4-[bis(2-chloroethyl)-
amino] phenyl ester (119f). Compound 119f was prepared from 118 (1.197 g, 3 mmol) and 
4-methyl-N1-(4-methyl-acridin-9-yl)-benzene-1,3-diamine (96b) (0.627 g, 2 mmol):43 Yield 
0.563 g (49%); mp 104–105 °C; 1H NMR (DMSO-d6) δ 2.21 (3H, s, Me), 2.80 (3H, s, Me), 
3.70 (8H, s, 4×CH2), 6.46–6.47 (1H, m, ArH), 6.70–6.72 (2H, m,  2×ArH), 6.96 (5H, brs, 
5×ArH), 7.32–7.42 (2H, m, 2×ArH), 7.60–7.72 (2H, m, 2×ArH), 8.01–8.11 (2H, m, 2×ArH), 
9.04 and 9.15 (each 1H, brs, exchangeable, 2×NH). Anal. (C32H30Cl2N4O2) C, H, N. 
[5-(Acridin-9-ylamino)-2-methoxy-phenyl] carbamic acid 4-[bis(2-chloroethyl)-amino] 
phenyl ester (119g). Compound 119g was prepared from 118 (0.800 g, 2 mmol) and N1-
acridin-9-yl-4-methoxy-benzene-1,3-diamine (100a, 0.630 g, 2 mmol):44 Yield 0.718 g 
(63%); mp 190–192 °C; 1H NMR (DMSO-d6) δ 3.70 (8H, s, 4×CH2), 3.92 (3H, s, OMe), 
6.73 (2H, d, J = 8.3 Hz , 2×ArH), 7.00 (2H, d, J = 8.7 Hz, 2×ArH), 7.19 (2H, s, 2×ArH), 
7.39–7.44 (2H, m, 2×ArH), 7.84 (1H, s, ArH), 7.94–7.98 (2H, m, 2×ArH), 8.10–8.12 (2H, m, 
2×ArH), 8.26–8.29 (2H, m, 2×ArH), 9.25 and 11.62 (each 1H, brs, exchangeable, 2×NH). 
Anal. (C31H28Cl2N4O3) C, H, N. 
[2-Methoxy-5-(4-methyl-acridin-9-ylamino)phenyl] carbamic acid 4-[bis(2-
chloroethyl)amino] phenyl ester (119h). Compound 119h was prepared from 118 (1.197 g, 
3 mmol) and 4-methoxy-N1-(4-methyl-acridin-9-yl)-benzene-1,3-diamine (100b, 0.66 g, 2 
mmol):44 Yield 0.559 g (47%); mp 195–196 °C; 1H NMR (DMSO-d6) δ 2.78 (3H, s, Me), 
3.71 (8H, s, 4×CH2), 3.79 (3H, s, OMe), 6.48 (1H, s, ArH), 6.70–6.72 (2H, m,  2×ArH), 
6.96–6.98 (3H, m, 3×ArH), 7.28–7.39 (3H, m, 3×ArH), 7.58–7.69 (2H, m, 2×ArH), 8.04–
8.13 (2H, m, 2×ArH), 8.86 (1H, s, ArH), 8.99 and 9.67 (each 1H, brs, exchangeable, 2×NH). 
Anal. (C32H30Cl2N4O3) C, H, N. 
[3-(Acridin-9-ylamino)-5-methoxyphenyl] carbamic acid 4-[bis(2-chloroethyl)-amino] 
phenyl ester (119i). Compound 119i was prepared from 118 (1.19 g, 3 mmol) and N1-
acridin-9-yl-5-methoxy-benzene-1,3-diamine (101a, 0.945 g, 3 mmol):44 Yield 0.317 g 
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(21%);  mp 179–180 °C; 1H NMR (DMSO-d6) δ 3.66 (3H, s, OMe), 3.70–3.72 (8H, m,  
4×CH2), 6.13 (1H, brs, ArH), 6.57 (1H, brs, ArH), 6.74 (2H, d, J = 9.0 Hz, 2×ArH),  6.90 
(1H, brs, ArH), 7.02 (2H, d, J = 9.0 Hz, 2×ArH), 7.10 (2H, brs, 2×ArH), 7.51–7.59 (4H, m, 
4×ArH), 7.95 (2H, brs, 2×ArH), 10.05 and 11.23 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C31H28Cl2N4O3) C, H, N. 
[3-(Acridin-9-ylamino)-4-methoxyphenyl] carbamic acid 4-[bis(2-chloroethyl)-amino] 
phenyl ester (119j). Compound 119j was prepared from 118 (2.0 g, 5 mmol) and N1-acridin-
9-yl-4-methoxy-benzene-1,3-diamine (103a, 0.701 g, 2.2 mmol):44 Yield 0.912 g (78%); mp 
194–195 °C; 1H NMR (DMSO-d6) δ 3.41 (3H, s, OMe), 3.73 (8H, s, 4×CH2), 6.76 (2H, d, J 
= 9.0 Hz , 2×ArH), 7.06 (2H, d, J = 9.0 Hz, 2×ArH), 7.18–7.20  (1H, m, ArH), 7.43–7.47 
(2H, m, 2×ArH), 7.58–7.60 (1H, m, ArH), 7.76 (1H, s, ArH), 7.98–8.02 (2H, m, 2×ArH), 
8.11–8.13 (2H, m, 2×ArH), 8.26–8.28 (2H, m, 2×ArH), 10.31 and 11.37 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C31H28Cl2N4O3) C, H, N. 
[4-Methoxy-3-(4-methyl-acridin-9-ylamino) phenyl] carbamic acid 4-[bis(2-
chloroethyl)-amino] phenyl ester (119k). Compound 119k was prepared from 118 (1.50 g, 
3.7 mmol) and 4-methoxy-N1-(4-methyl-acridin-9-yl)-benzene-1,3-diamine (103b, 0.548 g, 
1.6 mmol):44 Yield 0.489 g (52%);  mp 186–189 °C; 1H NMR (DMSO-d6) δ 2.58 (3H, s, 
Me), 3.58 (3H, s, OMe), 3.71 (8H, s, 4×CH2), 6.70–6.72 (4H, m, 4×ArH), 6.95–6.97 (4H, m, 
4×ArH), 7.12 (2H, s, 2×ArH), 7.44–7.56 (2H, m, 2×ArH), 8.00–8.02 (2H, m, 2×ArH), 8.22 
and 9.80 (each 1H, brs, exchangeable, 2×NH). Anal. (C32H30Cl2N4O3) C, H, N. 
 
General procedure for the preparation of N-mustard linked to the hydroxyl function of 
AHMA-alkylcarbamates via a carbamic acid ester linkage (121a-c) 
 
N,N-Bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (107) was prepared as described 
previously.  Isocyanate 10891 (freshly prepared from 107 by treating with triphosgene in 
CHCl3 at -10 oC) was then reacted with appropriate 9-anilinoacridines carbamates (120a-c)42 
in dry DMF in the presence of triethylamine to give 121a-c. The final products were purified 
either by recrystallization from an appropriate solvent or by column chromatography using 
(SiO2, CHCl3/MeOH, v/v 100:2).  
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The detailed procedure for the synthesis of 121a-c is described as follows: 
 
4-[N,N-bis(2-chloroethyl)amino]phenylisocyanate (108).  To a suspension of N,N-bis(2- 
chloroethyl)benzene-1,4-diamine hydrochloride (107) (1.683 g, 5.4 mmol)87 in dry 
chloroform (30 mL) was added triethylamine (2.5 mL) at 0 oC. The clear solution obtained 
was then added dropwise into a solution of triphosgene (0.623 g, 2.1 mmol) in dry 
chloroform (10 mL) at –10 oC. The reaction mixture was allowed to stand at room 
temperature. After being stirred for 30 min, the reaction mixture was evaporated to dryness 
under reduce pressure. The solid residue was triturated with dry THF (100 mL), filtered and 
washed with small amount of THF. The combined filtrate and washings was evaporated to 
dryness to give the crude isocyanate 10891 which was used directly for next reaction without 
further purification. 
 
(3-(Acridin-9-ylamino)-5-{4-[bis(2-chloroethyl)amino]phenylcarbamoyloxymethyl}-
phenyl)  carbamic acid ethyl ester (121a).  A solution of isocyanate 108 (freshly prepared 
from 107, 0.44 g, 1.4 mmol) in dry DMF (5 mL) was added drop wise to a solution of [3-
(acridin-9-ylamino)-5-hydroxymethyl-phenyl] carbamic acid ethyl ester (120a, 0.30 g, 0.8 
mmol)87 in dry DMF (15 mL) containing triethylamine (1 mL) at  room temperature. The 
reaction mixture was stirred for 26 h at room temperature. The solid separated out was 
filtered and recrystallized from CHCl3/MeOH to give 121a; 0.30 g (60%), mp 178–179 °C; 
1H NMR (DMSO-d6) δ 1.23 (3H, t, J = 7.0 Hz, Me), 3.69 (8H, s, 4×CH2), 4.11 (2H, q, J = 
7.0 Hz, CH2), 5.06  (2H, s, CH2), 6.69 (2H, d, J = 8.4 Hz, 2×ArH), 7.04 (1H, s, ArH), 7.25 
(2H, brs, 2×ArH), 7.43–7.48 (2H, m, 2×ArH), 7.54–7.57 (2H, m, 2×ArH), 7.96–8.00 (2H, m, 
2×ArH), 8.14–8.16 (2H, m, 2×ArH), 8.26–8.29 (2H, m, 2×ArH), 9.40, 9.98 and 11.54 (each 
1H, brs, exchangeable, 3×NH). Anal. (C34H33Cl2N5O4) C, H, N. 
 
By following the similar procedures, the following compounds were synthesized. 
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(3-(Acridin-9-ylamino)-5-{4-[bis(2-chloroethyl)amino]phenylcarbamoyloxymethyl}- 
phenyl)-carbamic acid iso-butyl ester (121b).  Compound 121b was synthesized from 108 
(freshly prepared from 107, 1.530 g, 5 mmol) and [3-(acridin-9-ylamino)-5-hydroxymethyl-
phenyl] carbamic acid iso-propyl ester (120b, 0.830 g, 2 mmol):87 Yield 0.158 g (13%), mp 
120–122 °C; 1H NMR (DMSO-d6) δ 0.89 (6H, d, J = 6.4 Hz, 2×Me), 1.86–1.90 (1H, m, CH), 
3.67 (8H, s, 4×CH2), 3.82 (2H, d, J = 6.1 Hz, CH2), 5.01 (2H, s, CH2), 6.49 (1H, m, ArH), 
6.67–6.69 (2H, m, 2×ArH), 6.84 (2H, m, 2×ArH), 7.18–7.26 (5H, m, 5×ArH), 7.52 (3H, m, 
3×ArH), 8.30 (2H, m, 2×ArH), 9.37, 9.57 and 10.94 (each 1H, brs, exchangeable, 3×NH). 
Anal. (C36H37Cl2N5O4) C, H, N. 
[3-{4-[Bis-(2-chloroethyl)amino]phenylcarbamoyloxymethyl}-5-(4-methylacridin-9-
ylamino)phenyl] carbamic acid tert-butyl ester (121c). Compound 121c was synthesized 
from 108 (freshly prepared from 107, 1.530 g, 5 mmol) and [3-hydroxymethyl-5-(4-
methylacridin-9-ylamino)phenyl] carbamic acid tert-butyl ester (120c, 0.858 g, 2 mmol):87 
Yield 0.462 g (34%), mp 228–230 °C; 1H NMR (DMSO-d6) δ 0.90 (6H, d, J = 6.7 Hz, 
2×Me), 1.82–1.89 (1H, m, CH), 2.81 (3H, s, Me), 3.68–3.70  (8H, m, 4×CH2), 3.85 (2H, d, J 
= 6.6 Hz, CH2), 5.05 (2H, s, CH2), 6.69 (2H, d, J = 8.8 Hz, 2×ArH), 6.99 (1H, s, ArH), 7.25 
(2H, d, J = 6.1 Hz, 2×ArH), 7.35–7.39 (1H, m, ArH), 7.44–7.54 (3H, m, 3×ArH), 7.82 (1H, 
d, J = 7.0 Hz, ArH), 7.95–7.99 (1H, m, ArH), 8.19–8.25 (2H, m, 2×ArH), 8.51–8.53 (1H, m, 
ArH), 9.38, 9.95 and 11.54 (each 1H, brs, exchangeable, 3×NH). Anal. (C37H39Cl2N5O4) C, 
H, N. 
Carbonic acid 3-(acridin-9-ylamino)-5-ethoxycarbonylamino-benzyl ester 4-[bis-(2-
chloro-ethyl)-amino] phenyl ester (122a). Compound 118 (0.80 g, 2 mmol) was added into 
a solution of [3-(acridin-9-ylamino)-5-hydroxymethylphenyl] carbamic acid ethyl ester 
(120a, 0.77 g, 2 mmol)87 in dry DMF (20 mL) containing pyridine (5 mL) and DMAP (10 
mg) at room temperature and stirred for 48 h. The Reaction mixture was evaporated under 
reduced pressure to dryness and the solid residue was dissolved in a mixture of 
CHCl3/MeOH containing silica gel (5 g) and then evaporated in vacuo to dryness. The 
residue was put on the top of a silica gel column (20×4 cm) and purified by using 
CHCl3/MeOH (100/1 v/v) as an eluent. The fraction containing the main product were 
combined and evaporated in vacuo to dryness and the residue was recrystallized from 
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CHCl3/MeOH to give 122a; 0.31 g (25%); mp 131–133 °C; 1H NMR (DMSO-d6) δ 1.22 
(3H, t, J = 7.0 Hz, Me), 3.71 (8H, s, 4×CH2), 4.09 (2H, q, J = 7.0 Hz, CH2,), 5.13 (2H, s, 
CH2), 6.53 (1H, brs, ArH), 6.73 (2H, d, J = 9.0 Hz, 2×ArH), 6.96 (1H, brs, ArH), 7.01 (2H, 
d, J = 9.0 Hz, 2×ArH), 7.04 (2H, brs, 2×ArH), 7.25 (1H, s,  ArH), 7.59 (4H, brs, 4×ArH), 
7.95 (2H, brs, 2×ArH), 9.66 and 11.17 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C34H32Cl2N4O5) C, H, N. 
 
Biological Experiments 
 
Cytotoxicity Assays. The cytotoxic effects of the newly synthesized compounds were 
determined in T-cell acute lymphocytic leukemia (CCRF-CEM) and their resistant subcell 
lines (CCRF-CEM/Taxol and CCRF-CEM/VBL) by the XTT assay92 and human solid tumor 
cells (i.e. breast carcinoma MX-1 and colon carcinoma HCT-116) the SRB assay93 in a 72 h 
incubation using a microplate spectrophotometer as described previously.94 After the addition 
of phenazine methosulfate-XTT solution, incubated  at 37 oC for 6 h and absorbance at 450 
and 630 nm was detected on a microplate reader (EL 340). The cytotoxicity of the newly 
synthesized compounds against non-small cell lung cancer (H1299), human prostate cancer 
cell line (PC3), human breast adenocarcinoma cell line (MCF-7), human lung 
adenocarcinoma (CL1-0 and CL1-5) cell lines were determined by the WST-1 assay102 in a 
72 h incubation using a microplate spectrophotometer as described previously. After the 
addition of WST-1 solution, it was incubated at 37 oC for 4 h.  Absorbance at 460 and 630 
nm was detected on a microplate reader. IC50 values were determined from dose-effect 
relationship at six or seven concentrations of each drug by using the CompuSyn software by 
Chou and Martin95 based on the median-effect principle and plot.96,97 Ranges given for 
Taxol, Vinblastine and Cisplatin were mean ± SE (n = 4). 
 
In vivo studies. Athymic nude mice bearing the nu/nu gene were used for human breast 
tumor MX-1 and human colon HCT-116 xenografts. Outbred Swiss-background mice were 
obtained from the National Cancer Institute (Frederick, MD). Male mice 8 weeks old or older 
weighing 22 g or more were used for most experiments. Drug was administrated via the tail 
vein by iv injection. Tumor volumes were assessed by measuring length × width × height (or 
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width) using caliper. Vehicle used was 50 μL DMSO and 40 μL Tween 80 in 160 μL saline. 
The maximal tolerate dose of the tested compound was determined and applied for the in 
vivo therapeutic efficacy assay. All animal studies were conducted in accordance with the 
guidelines of the National Institutes of Health Guide for the Care and Use of Animals and the 
protocol approved by the Memorial Sloan-Kettering Cancer Center’s Institutional Animal 
Care and Use Committee. 
 
Determination of DNA interstand Cross-linking.  The level of DNA interstrand cross-
linking was determined using a modified comet assay.98,99 All steps were carried out under 
subdued lighting. Briefly, H1299 cells (2×105 cells) were plated in a 60 mm dish and 
incubated at 37 oC with 5% CO2 for 32 h. The growing cells were treated with alkylating 
agent (119a or mephalan). After being treated with 1 h, the cells were exposed to 20 Gy X-
ray to induce DNA strand breaks. An aliquot of 5×105 cells were suspended in 50 μl of 
phosphate-buffered saline, mixed with a 250 μl of 1.2% low melting point agarose, and 
subjected to comet assay. The tail moment of 100 cells were analyzed for each treatment by 
aid of the COMET assay software. The degree of DNA interstrand cross-linking presented at 
a drug-treated sample was determined by comparing the tail moment of the irradiated control, 
which was calculated by the following formula. Percentage of DNA with interstrand cross-
linking = [1- (TMdi- TMcu / TMci- TMcu)] ×100%, where TMdi = tail moment of drug-
treated irradiated sample, TMcu = tail moment of untreated unirradiated control, and TMci = 
tail moment of untreated irradiated control. 
Determination of half-life of 119a in rat plasma. The chromatographic system consisted of 
a photodiode-array system, chromatographic pump, an auto-sampler equipped with a 40 µL 
sample loop. Compound 119a was separated from rat plasma using a revise phase column 
(30×150 mm, particle size 5 µm) maintained at an ambient temperature (25±1 oC) to perform 
the ideal chromatographic system. The detector wavelength was set at 266 nm. The mobile 
phase comprised methanol:10mM NaH2PO4 (60:40, v/v), which was adjusted to pH 3.0 with 
85% of H3PO4. Analysis was run at a flow rate of 0.5 mL/min and the samples were 
quantified using peak area. An aliquot of plasma sample (40 µL, with 119a 5 µg/mL) was 
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vortex-mixed with acetonitrile (1:2, v/v) for protein precipitation and centrifuged at 10,000×g 
for 10 min. The supernatant was passed through a 0.45 µm filter for injected into the HPLC. 
 
Table 8.  The Elemental analysis data of newly prepared N-mustards (119a-k, 121a-c and 
122a). 
 
C,H,N  Analysis 
Anal. Calcd. Found  Compd. M.F. MW 
C% H% N% C% H% N% 
119a C31H28Cl2N4O3 575.50 64.70 4.90 9.74 64.58 5.01 9.72 
119b C32H30Cl2N4O3 589.53 65.20 5.13 9.50 65.11 5.11 9.67 
119c C32H30Cl2N4O2 573.53 67.02 5.27 9.77 66.82 5.31 9.88 
119d C31H28Cl2N4O2 559.49 66.55 5.04 10.01 66.45 5.09 10.17 
119e C32H30Cl2N4O2 573.53 67.02 5.27 9.77 66.93 5.35 9.85 
119f C32H30Cl2N4O2 573.53 67.02 5.27 9.77 67.12 5.13 9.75 
119g C31H28Cl2N4O3 575.49 64.70 4.90 9.74 64.58 4.96 9.71 
119h C32H30Cl2N4O3 589.53 65.20 5.13 9.50 65.15 5.33 9.54 
119i C31H28Cl2N4O3  575.50 64.70 4.90 9.74 64.87 4.87 9.76 
119j C31H28Cl2N4O3 575.49 64.70 4.90 9.74 64.79 4.73 9.69 
119k C32H30Cl2N4O3 589.53 65.20 5.13 9.50 65.23 5.23 9.46 
121a C34H33Cl2N5O4 646.57 63.16 5.14 9.99 63.08 5.07 10.07 
121b C36H37Cl2N5O4 674.62 63.25 5.60 10.24 63.32 5.72 10.18 
121c C37H39Cl2N5O4 688.65 64.53 5.71 10.17 64.66 5.61 10.23 
122a C34H32Cl2N4O5 647.56 63.06 5.07 8.53 63.17 4.96 8.57 
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3.5 1H NMR spectrum for compound 113 and 114. 
 
 
 88
1H NMR spectrum for compound 118 and 119a. 
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1H NMR spectrum for compound 119c and 119i. 
 
 
 90
1HNMR spectrum for compound 121b and 122a. 
 
 
 91
 
 
 
 
 
 
CHAPER 4 
 
Synthesis and Antitumor Activity of Water Soluble Phenyl N-Mustard-
Aminobenzamide or Phenyl N-Mustard-Alkoxybenzamine Conjugates    
via a Urea Linkage 
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4.1 Chemistry 
 
 
The introduction of a basic tertiary amino-group, to permit the formation of a hydrochloride 
or quaternary salt, is possibly an effective method of increasing aqueous solubility. Thus, 
several dialkylaminocarbamoylphenyl (C6H4CONHCH2CH2NR2) and dialkylaminoalkoxy- 
phenyl (C6H4OCH2CH2NR2) moieties were attached with phenyl N-mustards via a urea 
spacer (Scheme 6 & 7).  
 
Scheme 6. Synthetic route for the water soluble N-mustard-aminobenzamide conjugates 
(126aa’-bf’). 
 
a': R =  CONHCH2CH2N(Me)2
b': R =   CONHCH2CH2CH2N(Me)2
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e': R = CONHCH2CH2N O
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b: p-COOEt
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ii
iii
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Reaction conditions: (i) Triphosgene/TEA, -10 oC, 30 min.; (ii) CHCl3/TEA, room 
temperature; (iii) con.HCl/AcOH (3:1, v/v), reflux, 6 h; (iv) alkylamines, DCC/HOBT, TEA, 
DMF, room temperature. 
 
The known N,N-bis(2-chloroethyl)benzene-1,4-diamine dihydrochloride (107) was prepared 
by following the methods previously described.53 Compound 107 was then converted to 
isocyanate 10891 by treating with triphosgene in chloroform at -10 oC. Crude isocyanate thus 
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obtained was directly treated with m-or p-aminobenzoate (123a,b) to give corresponding 
ester 124a,b.103 Hydrolysis of 124a,b using a mixture of con.HCl/AcOH (3/2, v/v) yielded 
acid 125a,b.103 The coupling reaction of various alkylamine with acid 125a,b was carried out 
by reacting with DCC/HOBT in dry DMF in presence of TEA at room temperature followed 
by treatment with 2.5MHCl in EA to furnish the corresponding 126aa’-bf’ as their 
hydrochlorides in moderate yields (Table 9).  
 
Scheme 7. Synthetic route for the water soluble N-mustard-alkoxybenzamine conjugates 
(131aa’-be’).  
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e': R = OCH2CH2N Oc': R =   OCH2CH2N
108
130aa'-be'131aa'-be'
iv
 
 
Reaction conditions: (i) KOH/EtOH; (ii) K2CO3/toluene, alkyl chlorides, reflux; (iii) 
10%Pd/C, H2, 35 psi; (ii) CHCl3/TEA, room temperature. 
 
 
The synthetic route for the water soluble phenyl N-mustard-alkoxybenzamine conjugates 
(131aa’-be’) is depicted in Scheme 7. The requisite known [(dialkylamino)alkoxy]anilines 
(130aa’-be’) were by prepared by following the reported methods.104-110 Reaction of 
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potassium salt of nitorphenols (128a,b) with β-(dialkylamino)alkyl chlorides in presence of 
K2CO3 gave [(dialkylamino)alkoxy]-nitrobenzenes (129aa’-be’). Catalytical reduction 
(Pd/C) of 129aa’-be’ afforded corresponding anilines 130aa’-be’.104-110 The 
[(dialkylamino)alkoxy]-anilines (130aa’-be’) then reacted with freshly prepared N-mustard 
isocyanate 108 in the presence of TEA followed by treatment with 2.5MHCl in EA to furnish 
the hydrochlorides 131aa’-be’ in moderate yields (Table 10). 
All of the newly synthesized compounds were characeterized by using 1H NMR and 
Elemental analysis. For compounds 1269aa’-bf’, 131aa’-be’ the characteristic peak for 
methylenic proton (i.e., N(CH2CH2Cl) appeared at 3.7 δ ppm. The 1H NMR signals for the 
phenyl N-mustards residue appeared as doublet (ortho coupling, J = 8.8-9.0 Hz) at 6.7-7.3 
δ ppm. The characteristic peak for the urea linker (NHCONH) appeared at 8.3-9.0 δ ppm as 
D2O exchangeable singlet. The elemental analysis of the newly synthesized derivatives were 
within ±0.4% range of the calculated C, H, N data.           
 
4.2 Biological Results and Discussion 
 
The antitumor evaluation of newly synthesized water soluble N-mustard derivatives is 
currently under progress. 
 
Preliminary Results: The preliminary antitumor studies showed that 126aa’ exhibited 
potent cytotoxicity against CCRF-CEM, MX-1 and HCT-116 cell growth in vitro with IC50 
values of 0.129±0.002, 0.568±0.017, and 0.687±0.026 μM . It also showed that this agent did 
not cross-resistant to Vinblastine and Taxol. Compound 126aa’ also exhibited potent in vivo 
antitumor effect against human breast MX-1 xenograft and human colon HCT-116 xenograft 
in animal model.  Figure 31 shows the therapeutic effects of 126aa’ in nude mice bearing 
mammary MX-1 xenografts at the maximal tolerated doses 30 mg/kg, via intravenous 
injection (iv injection)]. Remarkably, total tumor remission (or complete remission, CR) was 
achieved with only one cycle treatment (Fig. 31A).  Figure 32 shows the therapeutic effects 
of 126aa’ in nude mice bearing colon HCT-116 xenografts. Compound 126aa’ showed, at 
the doses of xxmg/kg, respectively, significant tumor growth inhibition (95%) in comparison 
to untreated control (Fig. 32A). Although 17% and 19% body-weight change, respectively,  
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Table 9. Yields and analytical data for the newly synthesized water soluble phenyl N-
mustard-aminobenzamide hydrochloride conjugates. 
N
H
N
Cl
Cl
N
H
O
R
 
 
Compd. R mp (oC) Yield (%) water solubility (mg/mL) 
Analysis 
 
124a m-COOEt    164-165 60 - 
C, H, N 
 
124b p-COOEt    221-223 66 - 
C, H, N 
 
125a m-COOH   191-192 89 - 
C, H, N 
 
125b p-COOH    238-241 90 - 
C, H, N 
 
126aa’ m-CONHCH2CH2N(Me)2  156-157 58 20 
C, H, N 
 
126ab’ m-CONHCH2CH2CH2N(Me)2 138-140 65 29 C, H, N  
126ac’  m-CONHCH2CH2N
 
129-131 56 35 C, H, N  
126ad’ m-CONHCH2CH2N
 
151-152 63 32 C, H, N  
126ae’ m-CONHCH2CH2N O
 
167-169 54 39 C, H, N  
126af’ m-CON N
 
118-119 60 24 C, H, N  
126ba’  p-CONHCH2CH2N(Me)2 189-190 72 21 
C, H, N 
 
126bb’ p-CONHCH2CH2CH2N(Me)2 203-205 69 25 C, H, N  
126bc’  p-CONHCH2CH2N
 
183-185 53 28 C, H, N  
126bd’ p-CONHCH2CH2N
 
198-200 49 21 C, H, N  
126be’ p-CONHCH2CH2N O
 
234-235 61 29 C, H, N  
126bf’ p-CON N
 
222-224 73 20 C, H, N  
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Table 10.  Yields and analytical data for the newly synthesized water soluble phenyl N-
mustard-alkoxybenzamine conjugates. 
 
N
H
N
Cl
Cl
N
H
O
R
 
 
 
Compd. R mp (oC) Yield (%)
water 
solubility 
(mg/mL) 
Analysis 
 
131aa’  m-OCH2CH2N(Me)2 143-145 46 3 
C, H, N 
 
131ab’  m-OCH2CH2CH2N(Me) 127-128 43 3 
C, H, N 
 
131ac’  m-OCH2CH2N
 
124-125 45 4 C, H, N  
131ad’ m-OCH2CH2N
 
86-88 55 2 C, H, N  
131ae’ m-OCH2CH2N O
 
168-169 31 10 C, H, N  
131ba’  p-OCH2CH2N(Me)2 203-205 60 2 
C, H, N 
 
131bb’  p-OCH2CH2CH2N(Me) 179-180 58 3 
C, H, N 
 
131bc’  p-OCH2CH2N
 
205-207 52 3 C, H, N  
131bd’ p-OCH2CH2N
 
211-212 56 5 C, H, N  
131be’ p-OCH2CH2N O
 
210-212 43 12 C, H, N  
 
 
was found during maximal tolerated treatment (Fig. 31B, and 32B), the body-weight of mice 
was readily recovered after cession of treatment suggesting that the tested compounds have 
relatively low toxicity to the hosts. 
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Figure 31.  The therapeutic effects of 126aa’in nude mice bearing MX-1 xenograft (iv 
injection, n = 3). Fig. 31A for average tumor size changes; p value <0.0001. Fig. 31B for 
average body weight changes.  
 
31A 
 
31B 
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Figure 32.  The therapeutic effects of 126aa’ in nude mice bearing HCT-116 xenograft (iv 
injection, n = 4). Fig. 32A for average tumor size changes; p values <0.0008. Fig. 32B for 
average body weight changes.  
    32A 
 
      32B    
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4.3 Conclusion 
 
Several new water soluble N-mustard derivatives were successfully prepared by the covalent 
attachment of various basic tertiary amino-groups with aniline N-mustard pharmacophore. 
Although, the antitumor evaluation of newly prepared N-mustards is under progress, the 
preliminary antitumor studies reveled that compound 126aa’ possessed significant 
cytotoxicity against CCRF-CEM, MX-1 and HCT-116 cell growths. Compound 126aa’ also 
did not exhibit cross-resistance either with vinblastine or taxol. It also demonstrated that 
126aa’ exhibited potent in vivo antitumor efficacy in nude mice bearing MX-1 xenografts 
(complete tumor remission was achieved). Thus one can anticipate that all the newly 
synthesized water soluble derivatives will have potent antitumor activity.   
 
4.4 Experimental 
 
Melting points were determined on a Fargo melting point apparatus and are uncorrected.  
Column chromatography was carried out on silica gel G60 (70-230 mesh and 230-400 mesh). 
Thin-layer chromatography was performed on silica gel G60 F254 with short-wavelength UV 
light for visualization. Elemental analysis was done on a Heraeus CHN-O Rapid instrument. 
1H NMR spectra were recorded on 400 MHz spectrometers. The chemical shifts were 
reported in ppm (δ) relative to TMS.  
 
Ethyl 3-[3-(4-(bis(2-chloroethyl)amino)phenyl)ureido]benzoate (124a). To a suspension 
of N,N-bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (107, 8.263 g, 26 mmol) in dry 
chloroform (100 mL) was added TEA (20 mL) at –10 oC. The clear solution obtained was 
then added dropwise into a solution of triphosgene (3.12 g, 10.5 mmol) in dry chloroform (25 
mL) at –10 oC. The reaction mixture was allowed to stand at room temperature. After being 
stirred for 30 min, the reaction mixture was evaporated to dryness under reduce pressure. The 
solid residue was triturated with dry THF (200 mL), filtered and washed with small amount 
of THF. The combined filtrate and washings was evaporated to dryness to give the crude 
isocyanate 4-[N,N-bis(2-chloroethyl)amino]phenylisocyanate (108). The crude isocyanate 
(108) was dissolved in dry CHCl3 (30 mL) and added dropwise into a solution of 3-
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aminoethylbenzoate (123a, 2.46 g, 15 mmol) in CHCl3 (40 mL) containing TEA (5 mL) and 
stirred at room temperature for 20 h. The reaction mixture was evaporated to dryness and the 
residue was purified by column chromatography using CH2Cl2:MeOH (100:2) as an eluent. 
The fraction containing the main products were combined and evaporated to dryness. The 
white residue was triturated with hexane and the white solid separated was filtered and dried 
to give 124a, yield: 3.81 g (60%); mp 164–165 oC; 1H NMR (DMSO-d6) δ 1.32 (3H, t, J = 
7.2 Hz, Me),  3.67–3.72 (8H, m, 4×CH2), 4.31 (2H, q, J = 7.2 Hz, CH2), 6.71 (2H, d, J = 8.8 
Hz, 2×ArH), 7.28 (2H, d, J = 8.8 Hz, 2×ArH), 7.40 (1H, t, J = 7.2 Hz, ArH), 7.53 (1H, d, J = 
8.0 Hz, ArH), 7.63–7.65 (1H, m, ArH), 8.12 (1H, s, ArH), 8.34 and 8.80 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C20H23Cl2N3O3) C, H, N. 
Ethyl 4-[3-(4-(bis(2-chloroethyl)amino)phenyl)ureido]benzoate (124b).103 To a 
suspension of N,N-bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (107, 4.13 g, 13.5 
mmol) in dry chloroform (100 mL) was added TEA (10 mL) at –10 oC. The clear solution 
obtained was then added dropwise into a solution of triphosgene (1.56 g, 5.25 mmol) in dry 
chloroform (20 mL) at –10 oC. The reaction mixture was allowed to stand at room 
temperature. After being stirred for 30 min, the reaction mixture was evaporated to dryness 
under reduce pressure. The solid residue was triturated with dry THF (100 mL), filtered and 
washed with small amount of THF. The combined filtrate and washings was evaporated to 
dryness to give the crude isocyanate 4-[N,N-bis(2-chloroethyl)amino]phenylisocyanate (108). 
The crude isocyanate (108) was dissolved in dry CHCl3 (20 mL) and added dropwise into a 
solution of 4-aminoethylbenzoate (123b, 1.23 g, 7.5 mmol) in CHCl3 (20 mL) containing 
TEA (3 mL) and stirred at room temperature for 20 h. The reaction mixture was evaporated 
to dryness and the residue was purified by column chromatography using CH2Cl2:MeOH 
(100:4) as an eluent. The fraction containing the main products were combined and 
evaporated to dryness. The white residue was triturated with hexane and the white solid 
separated was filtered and dried to give 124b, yield: 2.10 g (66%); mp 221–223 oC; 1H NMR 
(DMSO-d6) δ 1.30 (3H, t, J = 7.2 Hz, Me), 3.70–3.71 (8H, m, 4×CH2), 4.27 (2H, q, J = 7.2 
Hz, CH2), 6.72 (2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.56 (2H, d, J = 
8.8 Hz, 2×ArH), 7.86 (2H, d, J = 8.8 Hz, 2×ArH), 8.46 and 8.96 (each 1H, brs, exchangeable, 
2×NH). Anal. (C20H23Cl2N3O3) C, H, N. 
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3-[3-(4-(Bis(2-chloroethyl)amino)phenyl)ureido]benzoic acid (125a). A solution of 3-(3-
(4-(bis(2-chloroethyl)amino)phenyl)ureido)benzoate (124a, 4.253 g, 10 mmol) in mixture of 
con.HCl/AcOH (100 mL, 3/2 v/v) was heated at 100 oC for 6 h. The reaction mixture was 
cooled to rt, the separated white solid was filtered, washed with water and dried to give 125a, 
yield: 3.52 g (89%); mp 191–192 oC; 1H NMR (DMSO-d6) δ 3.70 (8H, s, 4×CH2), 6.74 (2H, 
d, J = 8.8 Hz, 2×ArH), 7.30 (2H, d, J = 8.8 Hz, 2×ArH), 7.30 (1H, t, J = 8.0 Hz, ArH), 7.51 
(1H, d, J = 7.6 Hz, ArH), 7.63–7.65 (1H, m, ArH), 8.09 (1H, s, ArH), 8.09 and 8.82 (each 
1H, brs, exchangeable, 2×NH). Anal. (C18H19Cl2N3O3) C, H, N. 
4-[3-(4-(Bis(2-chloroethyl)amino)phenyl)ureido]benzoic acid (125b).103 A solution of 4-
(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)benzoate (124b, 2.13 g, 5 mmol) in mixture of 
con.HCl/AcOH (70 mL, 3/2 v/v) was heated at 100 oC for 6 h. The reaction mixture was 
cooled to rt, the separated white solid was filtered, washed with water and dried to give 125b, 
yield: 1.78 g (90%); mp 238–241 oC; 1H NMR (DMSO-d6) δ 3.69–3.73 (8H, m, 4×CH2), 
6.74 (2H, d, J = 8.8 Hz, 2×ArH), 7.30 (2H, d, J = 8.8 Hz, 2×ArH), 7.54 (2H, d, J = 8.8 Hz, 
2×ArH), 7.83 (2H, d, J = 8.8 Hz, 2×ArH), 8.88 and 9.39 (each 1H, brs, exchangeable, 
2×NH). Anal. (C18H19Cl2N3O3) C, H, N. 
1-[3-((2-(Dimethylamino)ethyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phen- 
yl]urea hydrochloride (126aa’). A mixture of 3-(3-(4-(bis(2-chloroethyl)amino)phenyl) 
ureido) benzoic acid (125a, 0.792 g, 2 mmol), DCC (0.618 g, 3 mmol), HOBT (0.505 g, 3 
mmol), TEA (0.4 mL) and N,N-dimethylethylenediamine (0.264 g, 3 mmol) in dry DMF (25 
mL) was stirred at room temperature for 72 h. The reaction mixture was filtered to remove 
urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved in 
CH2Cl2 (250 mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 
mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:9) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (50 mL), treated with 
2.5 M HCl in ethyl acetate (5.0 mL) at 0 oC and desired product 126aa’ was collected by 
filtration. Yield: 580 mg (58%); mp 156–157 oC; 1H NMR (DMSO-d6) δ 2.20 (6H, s, 
N(Me)2), 2.42 (2H, t, J = 6.8 Hz, -CH2), 3.32–3.35 (2H, m, CH2), 3.68–3.70 (8H, m, 4×CH2), 
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6.71 (2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.34–7.39 (2H, m, 
2×ArH), 7.59 (1H, d, J = 7.6 Hz, ArH), 7.83 (1H, s, ArH), 8.29 (1H, t, J = 5.2 Hz, 
exchangeable, CONH), 8.40 and 8.72 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C22H29Cl2N5O2.HCl) C, H, N. 
1-[3-((3-(Dimethylamino)propyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phe- 
nyl]urea (126ab’). A mixture of 3-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)- benzoic 
acid (125a, 0.792 g, 2 mmol), DCC (0.618 g, 3 mmol), HOBT (0.505 g, 3 mmol), TEA (0.4 
mL)  and N,N-dimethylpropane-1,3-diamine (0.305 g, 3 mmol) in dry DMF (35 mL) was 
stirred at room temperature for 80 h. The reaction mixture was filtered to remove urea; the 
filtrate was evaporated to dryness under vacuo. The residue was dissolved in CH2Cl2 (250 
mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 mL) and brine 
(100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The filtrate was 
evaporated to dryness and the residue was purified by column chromatography using 
CH2Cl2:MeOH (100:9) as an eluent. The fractions containing the main products were 
combined, evaporated to dryness under vacuo and the residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (50 mL), treated with 
2.5 M HCl in ethyl acetate (5.0 mL) at 0 oC and the desired product 126ab’ was collected by 
filtration. Yield: 645 mg (65%); mp 138–140 oC; 1H NMR (DMSO-d6) δ 1.61–1.66 (2H, m, -
CH2), 2.13 (6H, s, N(Me)2), 2.25 (2H, t, J = 6.8 Hz, -CH2), 3.27 (2H, q, J = 6.8 Hz, -CH2), 
3.66–3.72 (8H, m, 4×CH2), 6.71 (2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 
2×ArH), 7.32–7.38 (2H, m, 2×ArH), 7.58 (1H, d, J = 8.0 Hz, ArH), 7.84 (1H, s, ArH), 8.40 
and 8.72 (each 1H, brs, exchangeable, 2×NH), 8.46 (1H, t, J = 5.2 Hz, exchangeable, 
CONH). Anal. (C23H31Cl2N5O2.HCl) C, H, N. 
1-[3-((2-(Pyrrolidin-1-yl)ethyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phen- 
yl]urea hydrochloride (126ac’). A mixture of 3-(3-(4-(bis(2-chloroethyl)amino)phenyl)- 
ureido) benzoic acid (125a, 0.792 g, 2 mmol), DCC (0.618 g, 3 mmol), HOBT (0.505 g, 3 
mmol), TEA (0.4 mL) and 1-(2-aminoethyl)pyrolidine (0.341g, 3 mmol) in dry DMF (35 
mL) was stirred at room temperature for 72 h. The reaction mixture was filtered to remove 
urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved in 
CH2Cl2 (250 mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 
mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
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filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:6) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (50 mL), treated with 
2.5 M HCl in ethyl acetate (5.0 mL) at 0 oC and desired product 126ac’ was collected by 
filtration. Yield: 591 mg (56%); mp 129–131 oC; 1H NMR (DMSO-d6) δ 1.87–1.91 (5H, m, -
CH), 3.0 (2H, t, d = 5.2 Hz, -CH2), 3.32 (2H, d, J = 6.0 Hz, -CH2), 3.62–3.64 (3H, m, -CH), 
3.72 (8H, s, 4×CH2), 6.73 (2H, d, J = 8.8 Hz, 2×ArH), 7.30 (2H, d, J = 8.8 Hz, 2×ArH), 
7.34–7.36 (2H, m, 2×ArH), 7.62 (1H, d, J = 9.2 Hz, ArH), 7.94 (1H, s, ArH), 8.78–8.79 (1H, 
m, exchangeable, CONH), 9.0 and 9.33 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C24H31Cl2N5O2.HCl) C, H, N. 
1-[3-((2-(Piperidin-1-yl)ethyl)carbamoyl)phenyl]-3-(4-(bis(2-chloroethyl)amino)phenyl)- 
urea hydrochloride (126ad’). A mixture of 3-(3-(4-(bis(2-chloroethyl)amino)phenyl) 
ureido)-benzoic acid (125a, 0.792 g, 2 mmol), DCC (0.618 g, 3 mmol), HOBT (0.505 g, 3 
mmol), TEA (0.4 mL)  and 1-(2-aminoethyl)piperidine (0.384 g) in dry DMF (35 mL) was 
stirred at room temperature for 75 h. The reaction mixture was filtered to remove urea; the 
filtrate was evaporated to dryness under vacuo. The residue was dissolved in CH2Cl2 (250 
mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 mL) and brine 
(100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The filtrate was 
evaporated to dryness and the residue was purified by column chromatography using 
CH2Cl2:MeOH (100:5) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (50 mL), treated with 
2.5 M HCl in ethyl acetate (5.0 mL) at 0 oC and desired product 126ad’ was collected by 
filtration. Yield: 683 mg (63%); mp 151–152 oC; 1H NMR (DMSO-d6) δ 1.38–1.51 (7H, m, -
CH), 2.41–2.45 (5H, m, -CH), 3.34–3.38 (2H, m, -CH), 3.66–3.72 (8H, m,  4×CH2), 6.71 
(2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.32–7.38 (2H, m, 2×ArH), 
7.58 (1H, d, J = 7.6 Hz, ArH), 7.84 (1H, s, ArH), 8.28 (1H, t, J = 5.2 Hz, exchangeable, 
CONH), 8.40 and 8.70 (each 1H, brs, exchangeable, 2×NH). Anal. (C25H33Cl2N5O2.HCl) C, 
H, N. 
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1-[3-((2-Morpholinoethyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phenyl]- 
urea hydrochloride (126ae’). A mixture of 3-(3-(4-(bis(2-chloroethyl)amino)phenyl) 
ureido)-benzoic acid (125a, 0.792 g, 2 mmol), DCC (0.618 g, 3 mmol), HOBT (0.505 g, 3 
mmol), TEA (0.4 mL)  and 1-(2-aminoethyl)morpholine (0.260 g, 3 mmol) in dry DMF (35 
mL) was stirred at room temperature for 73 h. The reaction mixture was filtered to remove 
urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved in 
CH2Cl2 (250 mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 
mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:5) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (50 mL), treated with 
2.5 M HCl in ethyl acetate (5.0 mL) at 0 oC and desired product 126ae’ was collected by 
filtration. Yield: 588 mg (54%); mp 167–169 oC; 1H NMR (DMSO-d6) δ 2.41–2.47 (5H, m, -
CH), 3.36–3.38 (2H, m, -CH), 3.57 (5H, brs, -CH), 3.69 (8H, s, 4×CH2), 6.71 (2H, d, J = 8.8 
Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.33–7.40 (2H, m, 2×ArH), 7.59 (1H, d, J = 
7.2 Hz, ArH), 7.91 (1H, s, ArH), 8.30 (1H, t, J = 5.6 Hz, exchangeable, CONH), 8.34 and 
8.66 (each 1H, brs, exchangeable, 2×NH). Anal. (C24H31Cl2N5O3.HCl) C, H, N. 
1-[4-(bis(2-chloroethyl)amino)phenyl]-3-[3-(4-(piperidin-1-yl)piperidine-1-carbonyl]ph- 
enyl)urea hydrochloride (126af’). A mixture of 3-(3-(4-(bis(2-chloroethyl)amino)phenyl)- 
ureido)- benzoic acid (125a, 0.792 g, 2 mmol), DCC (0.618 g, 3 mmol), HOBT (0.505 g, 3 
mmol), TEA (0.4 mL)  and 4-piperidino-piperidine (0.504 g, 3 mmol) in dry DMF (35 mL) 
was stirred at room temperature for 72 h. The reaction mixture was filtered to remove urea; 
the filtrate was evaporated to dryness under vacuo. The residue was dissolved in CH2Cl2 (250 
mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 mL) and brine 
(100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The filtrate was 
evaporated to dryness and the residue was purified by column chromatography using 
CH2Cl2:MeOH (100:6) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (50 mL), treated with 
2.5 M HCl in ethyl acetate (5.0 mL) at 0 oC and desired product 126af’ was collected by 
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filtration. Yield: 700 mg (60%); mp 118–119 oC; 1H NMR (DMSO-d6) δ 1.37–1.48 (8H, m, -
CH), 1.68–1.79 (2H, m, -CH), 2.47–2.50 (3H, m, -CH), 2.73 (1H, brs, -CH), 2.98 (1H, brs, -
CH), 3.37 (4H, brs, -CH), 3.66–3.72 (8H, m, 4×CH2), 6.71 (2H, d, J = 8.8 Hz, 2×ArH), 6.90–
6.92 (1H, d, J = 7.2 Hz, ArH) 7.27 (2H, d, J = 8.8 Hz, 2×ArH), 7.29–7.32 (1H, m, ArH), 7.41 
(1H, d, J = 8.0 Hz, ArH), 7.51 (1H, s, ArH), 8.42 and 8.71 (each 1H, brs, exchangeable, 
2×NH). Anal. (C28H37Cl2N5O2.HCl) C, H, N. 
1-[4-((2-(Dimethylamino)ethyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phen- 
yl]urea hydrochloride (126ba’). A mixture of 4-(3-(4-(bis(2-chloroethyl)amino)phenyl)-  
ureido) benzoic acid (125b, 0.396 g, 1 mmol), DCC (0.309 g, 1.5 mmol), HOBT (0.202 g, 
1.5 mmol), TEA (0.2 mL) and N,N-dimethylethylenediamine (0.132 g, 1.5 mmol) in dry 
DMF (15 mL) was stirred at room temperature for 72 h. The reaction mixture was filtered to 
remove urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved 
in CH2Cl2 (200 mL) and successively washed with water (100 mL), sat.NaHCO3 solution 
(100 mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:6) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (20 mL), treated with 
2.5 M HCl in ethyl acetate (2.0 mL) at 0 oC and desired product 126ba’ was collected by 
filtration. Yield: 340 mg (72%); mp 189–190 oC; 1H NMR (DMSO-d6) δ 2.17 (6H, s, 
N(Me)2), 2.38 (2H, brs, -CH2), 3.28 (2H, brs, -CH2), 3.69 (8H, brs, 4×CH2), 6.71 (2H, d, J = 
8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.49 (2H, d, J = 8.8 Hz, 2×ArH), 7.76 (2H, 
d, J = 8.8 Hz, 2×ArH), 8.18, 8.47 and 8.83 (each 1H, brs, exchangeable, 3×NH). Anal. 
(C22H29Cl2N5O2.HCl) C, H, N. 
1-[4-((3-(Dimethylamino)propyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phe- 
nyl]urea (126bb’). A mixture of 4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)- benzoic 
acid (125b, 0.594 g, 1.5 mmol), DCC (0.464 g, 2.25 mmol), HOBT (0.304 g, 2.25 mmol), 
TEA (0.3 mL) and N,N-dimethylpropane-1,3-diamine (0.229 g, 2.25 mmol) in dry DMF (35 
mL) was stirred at room temperature for 56 h. The reaction mixture was filtered to remove 
urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved in 
CH2Cl2 (200 mL) and successively washed with water (100 mL), sat.NaHCO3 solution (100 
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mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:9) as an eluent. The fractions containing the main products were 
combined, evaporated to dryness under vacuo and the residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (30 mL), treated with 
2.5 M HCl in ethyl acetate (3.0 mL) at 0 oC and the desired product 126bb’ was collected by 
filtration. Yield: 534 mg (69%); mp 203–205 oC; 1H NMR (DMSO-d6) δ 1.62–1.67 (2H, m, -
CH2), 2.13 (6H, s, N(Me)2), 2.25 (2H, t, J = 6.8 Hz, -CH2), 3.24 (2H, q, J = 6.8 Hz, -CH2), 
3.69–3.72 (8H, m, 4×CH2), 6.71 (2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 
2×ArH), 7.49 (2H, d, J = 8.8 Hz, 2×ArH), 7.75 (2H, d, J = 8.8 Hz, 2×ArH), 8.39 (1H, t, J = 
5.2 Hz, exchangeable, CONH), 8.49 and 8.86 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C23H31Cl2N5O2.HCl) C, H, N. 
1-[4-((2-(Pyrrolidin-1-yl)ethyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phen- 
yl]urea hydrochloride (126bc’). A mixture of 4-(3-(4-(bis(2-chloroethyl)amino)phenyl)- 
ureido) benzoic acid (125b, 0.594 g, 1.5 mmol), DCC (0.464 g, 2.25 mmol), HOBT (0.304 g, 
2.25 mmol), TEA (0.3 mL)  and 1-(2-aminoethyl)pyrolidine (0.256 g, 2.25 mmol) in dry 
DMF (35 mL) was stirred at room temperature for 65 h. The reaction mixture was filtered to 
remove urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved 
in CH2Cl2 (200 mL) and successively washed with water (100 mL), sat.NaHCO3 solution 
(100 mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:6) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (40 mL), treated with 
2.5 M HCl in ethyl acetate (3.0 mL) at 0 oC and desired product 126ac’ was collected by 
filtration. Yield: 419 mg (53%); mp 183–185 oC; 1H NMR (DMSO-d6) δ 1.05–2.00 (4H, m, -
CH), 3.02–3.04 (2H, m, -CH), 3.30–3.33 (2H, m, -CH), 3.42–3.45 (4H, m, -CH), 3.70 (8H, s, 
4×CH2), 6.72 (2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.52 (2H, d, J = 
8.8 Hz, 2×ArH), 7.85 (2H, d, J = 8.8 Hz, 2×ArH), 8.67–8.69 (1H, m, exchangeable, CONH), 
9.01 and 9.48 (each 1H, brs, exchangeable, 2×NH). Anal. (C24H31Cl2N5O2.HCl) C, H, N. 
 107
1-[4-((2-(Piperidin-1-yl)ethyl)carbamoyl)phenyl]-3-(4-(bis(2-chloroethyl)amino)phenyl)- 
urea hydrochloride (126bd’). A mixture of 4-(3-(4-(bis(2-chloroethyl)amino) phenyl) 
ureido)-benzoic acid (125b, 0.594 g, 1.5 mmol), DCC (0.464 g, 2.25 mmol), HOBT (0.304 g, 
2.25 mmol), TEA (0.3 mL) and 1-(2-aminoethyl)piperidine (0.288 g, 2.25 mmol) in dry 
DMF (15 mL) was stirred at room temperature for 72 h. The reaction mixture was filtered to 
remove urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved 
in CH2Cl2 (200 mL) and successively washed with water (100 mL), sat.NaHCO3 solution 
(100 mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:5) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (30 mL), treated with 
2.5 M HCl in ethyl acetate (3.0 mL) at 0 oC and desired product 126bd’ was collected by 
filtration. Yield: 400 mg (49%); mp 198–200 oC;  1H NMR (DMSO-d6) δ 1.37–1.39 (1H, m, 
-CH), 1.67–1.79 (5H, m, -CH), 2.98 (2H, s, -CH), 3.43–3.50 (4H, m, -CH), 3.67–3.71 (8H, 
m,  4×CH2), 6.71 (2H, d, J = 8.8 Hz, 2×ArH), 7.29 (2H, d, J = 8.8 Hz, 2×ArH), 7.49 (2H, d, J 
= 8.8 Hz, 2×ArH), 7.75 (2H, d, J = 8.8 Hz, 2×ArH), 8.30–8.31 (1H, m, exchangeable, 
CONH), 8.35 and 8.66 (each 1H, brs, exchangeable, 2×NH). Anal. (C25H33Cl2N5O2.HCl) C, 
H, N. 
1-[4-((2-Morpholinoethyl)carbamoyl)phenyl]-3-[4-(bis(2-chloroethyl)amino)phenyl]ur- 
ea hydrochloride (126be’). A mixture of 4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)- 
benzoic acid (125b, 0.594 g, 1.5 mmol), DCC (0.464 g, 2.25 mmol), HOBT (0.304 g, 2.25 
mmol), TEA (0.3 mL) and 1-(2-aminoethyl)morpholine (0.195 g, 2.25 mmol) in dry DMF 
(35 mL) was stirred at room temperature for 70 h. The reaction mixture was filtered to 
remove urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved 
in CH2Cl2 (200 mL) and successively washed with water (100 mL), sat.NaHCO3 solution 
(100 mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:6) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (30 mL), treated with 
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2.5 M HCl in ethyl acetate (3.0 mL) at 0 oC and desired product 126be’ was collected by 
filtration. Yield: 538 mg (61%); mp 234–235 oC; 1H NMR (DMSO-d6) δ 2.41–2.47 (6H, m, -
CH), 3.35–3.39 (2H, m, -CH), 3.56–3.57 (4H, m, -CH), 3.70–3.71 (8H, m, 4×CH2),  6.71 
(2H, d, J = 8.8 Hz, 2×ArH), 7.28 (2H, d, J = 8.8 Hz, 2×ArH), 7.49 (2H, d, J = 8.8 Hz, 
2×ArH), 7.75 (2H, d, J = 8.8 Hz, 2×ArH), 8.20–8.23 (1H, m, exchangeable, CONH), 8.42 
and 8.79 (each 1H, brs, exchangeable, 2×NH). Anal. (C24H31Cl2N5O3.HCl) C, H, N. 
1-[4-(bis(2-chloroethyl)amino)phenyl]-3-[4-(4-(piperidin-1-yl)piperidine-1-carbonyl]ph- 
enyl) urea hydrochloride (126bf’). A mixture of 4-(3-(4-(bis(2-chloroethyl)amino)phenyl)- 
ureido) benzoic acid (125b, 0.594 g, 1.5 mmol), DCC (0.464 g, 2.25 mmol), HOBT (0.304 g, 
2.25 mmol), TEA (0.3 mL) and 4-piperidino-piperidine (0.378 g, 2.25 mmol) in dry DMF 
(35 mL) was stirred at room temperature for 72 h. The reaction mixture was filtered to 
remove urea; the filtrate was evaporated to dryness under vacuo. The residue was dissolved 
in CH2Cl2 (200 mL) and successively washed with water (100 mL), sat.NaHCO3 solution 
(100 mL) and brine (100 mL). The organic layer was dried or anhy Na2SO4 and filtered. The 
filtrate was evaporated to dryness and the residue was purified by column chromatography 
using CH2Cl2:MeOH (100:8) as an eluent. The fractions containing the main products were 
combined and evaporated to dryness under vacuo. The residue was crystallized from ethyl 
acetate to give white solid. The solid was suspended in ethyl acetate (40 mL), treated with 
2.5 M HCl in ethyl acetate (3.0 mL) at 0 oC and desired product 126bf’ was collected by 
filtration. Yield: 638 mg (73%); mp 222–224 oC; 1H NMR (DMSO-d6) δ 1.38–1.50 (9H, m, -
CH), 1.75 (2H, brs, -CH), 2.51 (2H, brs, -CH), 2.84 (2H, brs, -CH), 3.32–3.40 (4H, m, -CH), 
3.68–3.72 (8H, m, 4×CH2), 5.75 (1H, s, -CH), 6.71 (2H, d, J = 8.8 Hz, 2×ArH), 7.27–7.31 
(4H, m, 4×ArH), 7.48 (2H, d, J = 8.8 Hz, 2×ArH), 8.46 and 8.81 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C28H37Cl2N5O2.HCl) C, H, N. 
 
Synthesis of water soluble N-mustard derivatives 131aa’-be’. 
 
Potassium 3-nitrophenolate (128a).  To a solution of KOH (4.1 g, 73 mmol) in EtOH (125 
mL) was added dropwise 3-nitrophenol (127a, 10 g, 71 mmol) in EtOH (50 mL) at 0 oC. The 
dark yellow reaction mixture was allowed to attain rt and stirred for 30 min., then evaporated 
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to dryness under reduce pressure. The yellow solid obtained was triturated with hexane and 
filtered to give 128a, yield: 12 g (94%). 
Potassium 4-nitrophenolate (128b).  To a solution of KOH (20.6 g, 368 mmol) in EtOH 
(500 mL) was added dropwise 4-nitrophenol (127b, 50 g, 360 mmol) in EtOH (200 mL) at 0 
oC. The yellow solid precipitate out was filtered to give 128b, yield: 48 g (75%). 
N,N-Dimethyl-2-(3-nitrophenoxy)ethanamine hydrochloride (129aa’).104-107 A solution of 
2-chloro-N,N-dimethylethylamine hydrochloride (7.0 g, 40 mmol) in water (40 mL) was 
treated with KOH solution (3.36 g in 20 mL water). The resulting aqueous solution was 
extracted with toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. 
To this dry toluene solution, the potassium 3-nitrophenolate (128a, 5.8 g, 40 mmol) was 
added and the reaction mixture was heated to reflux overnight. The reaction mixture was 
cooled to room temperature, filtered and the filtrate was evaporated to dryness under reduce 
pressure. The residue was dissolved in ethyl acetate (200 mL) and treated with 2.5M HCl in 
EA (5.0 mL) at 0 oC. The solid separated was filtered to give 129aa’, yield: 4.75 g (49%); 1H 
NMR (DMSO-d6) δ 2.83 (6H, s, 2×NMe), 3.53 (2H, t, J = 5.0 Hz, CH2), 4.52 (2H, t, J = 5.0 
Hz, CH2), 7.49–7.52 (1H, m, ArH), 7.63 (1H, t, J = 8.2 Hz, ArH), 7.82 (1H, t, J = 2.3 Hz, 
ArH), 7.86–7.89 (1H, m, ArH), 11.04 (1H, brs, exchangeable, HCl). 
N,N-dimethyl-3-(3-nitrophenoxy)propan-1-amine hydrochloride (129ab’).104-107 A 
solution of 3-chloro-N,N-dimethylpropylamine hydrochloride (3.16 g, 20 mmol) in water (40 
mL) was treated with KOH solution (1.68 g in 20 mL water). The resulting aqueous solution 
was extracted with toluene (2×50 mL), the toluene layer dried over anhyd Na2SO4 and 
filtered. To this dry toluene solution, the potassium 3-nitrophenolate (128a, 3.55 g, 20 mmol) 
was added and the reaction mixture was heated to reflux overnight. The reaction mixture was 
cooled to room temperature, filtered and the filtrate was evaporated to dryness under reduce 
pressure. The residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in 
EA (3.0 mL) at 0 oC. The solid separated was filtered to give 129ab’, yield: 3.13 g (60%); 1H 
NMR (DMSO-d6) δ 2.17–2.24 (2H, m, 2×CH), 2.72–2.77 (6H, m, 2×NMe), 3.19–3.24 (2H, 
m, 2×CH), 4.21 (2H, t, J = 6.0 Hz, CH2), 7.44 (1H, dd, J = 2.3 Hz and J = 8.2 Hz, ArH), 7.60 
(1H, t, J = 8.2 Hz, ArH), 7.73 (1H, t, J = 2.3 Hz, ArH), 7.82–7.84 (1H, m, ArH), 11.07 (1H, 
brs, exchangeable, HCl). 
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1-(2-(3-Nitrophenoxy)ethyl)pyrrolidine hydrochloride (129ac’).104-107 A solution of 1-(2-
chloroethyl)- pyrrolidine hydrochloride (6.8 g, 40 mmol) in water (100 mL) was treated with 
KOH solution (3.36 g in 40 mL water). The resulting aqueous solution was extracted with 
toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. To this dry 
toluene solution, the potassium 3-nitrophenolate (128a, 7.0 g, 40 mmol) was added and the 
reaction mixture was heated to reflux overnight. The reaction mixture was cooled to room 
temperature, filtered and the filtrate was evaporated to dryness under reduce pressure. The 
residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in EA (7.0 mL) at 
0 oC. The solid separated was filtered to give 129ac’, yield: 7.79 g (72%); 1H NMR (DMSO-
d6) δ 1.89–1.92 (2H, m, 2×CH), 1.95–2.03 (2H, m, 2×CH), 3.06–3.13 (2H, m, 2×CH), 3.60 
(4H, t, J = 4.9 Hz, 2×CH2), 4.52 (2H, t, J = 4.8 Hz, CH2), 7.51 (1H, dd, J = 2.2 Hz and J = 
8.2 Hz, ArH), 7.63 (1H, t, J = 8.2 Hz, ArH), 7.81 (1H, t, J = 2.2 Hz, ArH), 7.86–7.88 (1H, m, 
ArH), 11.33 (1H, brs, exchangeable, HCl). 
1-(2-(3-Nitrophenoxy)ethyl)piperidine hydrochloride (129ad’).104-107 A solution of 1-(2-
chloroethyl)piperidine hydrochloride (7.36 g, 40 mmol) in water (100 mL) was treated with 
KOH solution (3.36 g in 50 mL water). The resulting aqueous solution was extracted with 
toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. To this dry 
toluene solution, the potassium 3-nitrophenolate (128a, 7.0 g, 40 mmol) was added and the 
reaction mixture was heated to reflux overnight. The reaction mixture was cooled to room 
temperature, filtered and the filtrate was evaporated to dryness under reduce pressure. The 
residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in EA (7.0 mL) at 
0 oC. The solid separated was filtered to give 129ad’, yield: 9.19 g (81%); 1H NMR (DMSO-
d6) δ 1.38–1.43 (1H, m, CH), 1.68–1.91 (5H, m, 5×CH), 2.96–3.05 (2H, m, 2×CH), 3.50 (4H, 
t, J = 5.0 Hz, 2×CH2), 4.59 (2H, t, J = 5.0 Hz, CH2), 7.49 (1H, dd, J = 2.5 Hz and J = 8.0 Hz, 
ArH), 7.63 (1H, t, J = 8.2 Hz, ArH), 7.80 (1H, t, J = 2.3 Hz, ArH), 7.86–7.88 (1H, m, ArH), 
11.06 (1H, brs, exchangeable, HCl). 
1-(2-(3-Nitrophenoxy)ethyl)morpholine hydrochloride (129ae’).104-107 A solution of 1-(2-
chloroethyl)morpholine hydrochloride (7.44 g, 40 mmol) in water (100 mL) was treated with 
KOH solution (3.36 g in 50 mL water). The resulting aqueous solution was extracted with 
toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. To this dry 
toluene solution, the potassium 3-nitrophenolate (128a, 7.0 g, 40 mmol) was added and the 
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reaction mixture was heated to reflux overnight. The reaction mixture was cooled to room 
temperature, filtered and the filtrate was evaporated to dryness under reduce pressure. The 
residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in EA (5.0 mL) at 
0 oC. The solid separated was filtered to give 129ae’, yield: 6.28 g (55%); 1H NMR (DMSO-
d6) δ 3.20–3.23 (2H, m, 2×CH), 3.49–3.52 (2H, m, 2×CH), 3.58 (2H, brs, 2×CH), 3.87–3.94 
(4H, m, 4×CH), 4.60 (2H, t, J = 4.8 Hz, CH2), 7.50 (1H, dd, J = 2.3 Hz and J = 8.2 Hz, ArH), 
7.63 (1H, t, J = 8.2 Hz, ArH), 7.81 (1H, t, J = 2.2 Hz, ArH), 7.86–7.88 (1H, m, ArH), 11.84 
(1H, brs, exchangeable, HCl). 
N,N-Dimethyl-2-(4-nitrophenoxy)ethanamine hydrochloride (129ba’).108-110  A solution 
of 2-chloro-N,N-dimethylethylamine hydrochloride (5.8 g, 40 mmol) in water (100 mL) was 
treated with KOH solution (3.36 g in 40 mL water). The resulting aqueous solution was 
extracted with toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. 
To this dry toluene solution, the potassium 4-nitrophenolate (128b, 7.0 g, 40 mmol) was 
added and the reaction mixture was heated to reflux overnight. The reaction mixture was 
cooled to room temperature, filtered and the filtrate was evaporated to dryness under reduce 
pressure. The residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in 
EA (5.0 mL) at 0 oC. The solid separated was filtered to give 129ba’, yield: 7.0 g (72%); 1H 
NMR (DMSO-d6) δ 2.83 (6H, s, 2×NMe), 3.54 (2H, t, J = 5.0 Hz, CH2), 4.54 (2H, t, J = 5.0 
Hz, CH2), 7.21–7.25 (2H, m, 2×ArH), 8.23–8.27 (2H, m, 2×ArH), 11.99 (1H, brs, 
exchangeable, HCl). 
N,N-dimethyl-3-(4-nitrophenoxy)propan-1-amine hydrochloride (129bb’).108-110 A 
solution of 3-chloro-N,N-dimethylpropylamine hydrochloride (6.3 g, 40 mmol) in water (100 
mL) was treated with KOH solution (3.36 g in 40 mL water). The resulting aqueous solution 
was extracted with toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and 
filtered. To this dry toluene solution, the potassium 4-nitrophenolate (128b, 7.0 g, 40 mmol) 
was added and the reaction mixture was heated to reflux overnight. The reaction mixture was 
cooled to room temperature, filtered and the filtrate was evaporated to dryness under reduce 
pressure. The residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in 
EA (7.0 mL) at 0 oC. The solid separated was filtered to give 129bb’, yield: 6.5 g (64%); 1H 
NMR (DMSO-d6) δ 2.18–2.25 (2H, m, 2×CH), 2.76 (6H, s, 2×NMe), 3.19–3.23 (2H, m, 
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2×CH), 4.22–4.25 (2H, m, 2×CH), 7.14–7.18 (2H, m, 2×ArH), 8.20–8.24 (2H, m, 2×ArH), 
11.03 (1H, brs, exchangeable, HCl). 
1-(2-(4-Nitrophenoxy)ethyl)pyrrolidine hydrochloride (129bc’).108-110 A solution of 1-(2-
chloroethyl)pyrrolidine hydrochloride (8.16 g, 48 mmol) in water (40 mL) was treated with 
KOH solution (3.36 g in 40 mL water). The resulting aqueous solution was extracted with 
toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. To this dry 
toluene solution, the potassium 4-nitrophenolate (128b, 7.0 g, 40 mmol) was added and the 
reaction mixture was heated to reflux overnight. The reaction mixture was cooled to room 
temperature, filtered and the filtrate was evaporated to dryness under reduce pressure. The 
residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in EA (5.0 mL) at 
0 oC. The solid separated was filtered to give 129bc’, yield: 8.9 g (83%); 1H NMR (DMSO-
d6) δ 1.90–2.00 (4H, m, 4×CH), 3.09 (2H, brs, 2×CH), 3.61 (2H, brs, 2×CH), 4.52–4.55 (2H, 
m, 2×CH), 7.23 (2H, d, J = 9.2 Hz, 2×ArH), 8.25 (2H, d, J = 9.0 Hz, 2×ArH), 11.32 (1H, brs, 
exchangeable, HCl). 
1-(2-(4-Nitrophenoxy)ethyl)piperidine hydrochloride (128bd’).108-110 A solution of 1-(2-
chloroethyl)piperidine hydrochloride (7.36 g, 40 mmol) in water (100 mL) was treated with 
KOH solution (3.36 g in 50 mL water). The resulting aqueous solution was extracted with 
toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. To this dry 
toluene solution, the potassium 4-nitrophenolate (128b, 7.0 g, 40 mmol) was added and the 
reaction mixture was heated to reflux overnight. The reaction mixture was cooled to room 
temperature, filtered and the filtrate was evaporated to dryness under reduce pressure. The 
residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in EA (5.0 mL) at 
0 oC. The solid separated was filtered to give 129bd’, yield: 7.85 g (79%); 1H NMR (DMSO-
d6) δ 1.36–1.43 (1H, m, CH), 1.68–1.99 (5H, m, 5×CH), 2.97–3.04 (2H, m, 2×CH), 3.49–
3.51 (4H, m, 4×CH), 4.59–4.62 (2H, m, 2×CH), 7.20–7.24 (2H, m, 2×ArH), 8.22–8.27 (2H, 
m, 2×ArH), 11.10 (1H, brs, exchangeable, HCl). 
1-(2-(4-Nitrophenoxy)ethyl)morpholine hydrochloride (129be’).108-110 A solution of 1-(2-
chloroethyl)-morpholine hydrochloride (7.44 g, 40 mmol) in water (100 mL) was treated 
with KOH solution (3.36 g in 50 mL water). The resulting aqueous solution was extracted 
with toluene (2×100 mL), the toluene layer dried over anhyd Na2SO4 and filtered. To this dry 
toluene solution, the potassium 4-nitrophenolate (128b, 7.0 g, 40 mmol) was added and the 
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reaction mixture was heated to reflux overnight. The reaction mixture was cooled to room 
temperature, filtered and the filtrate was evaporated to dryness under reduce pressure. The 
residue was dissolved in ethyl acetate (100 mL) and treated with 2.5M HCl in EA (5.0 mL) at 
0 oC. The solid separated was filtered to give 129be’, yield: 6.68 g (68%); 1H NMR (DMSO-
d6) δ 3.20–3.22 (2H, m, 2×CH), 3.48–3.51 (2H, m, 2×CH), 3.59 (2H, brs, 2×CH), 3.86–3.96 
(4H, m, 4×CH), 4.62 (2H, t, J = 4.8 Hz, 2×CH), 7.23 (2H, d, J = 9.2 Hz, 2×ArH), 8.25 (2H, 
d, J = 9.2 Hz, 2×ArH), 11.86 (1H, brs, exchangeable, HCl). 
3-(2-(Dimethylamino)ethoxy)benzenamine hydrochloride (130aa’).104-107 To a solution of 
N,N-dimethyl-2-(3-nitrophenoxy)ethanamine hydrochloride (129aa’, 4.5 g, 18.24 mmol) in 
MeOH (100 mL) was added 10%Pd/C (500 mg).The mixture was sonicated for 5 min. and 
then hydrogenated at 35 psi for 2 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtered through pad of Celite and washed with MeOH. 
The combined filtrate and washing was evaporated to dryness under reduce pressure. The 
residue was triturated with ether and the separated solid product was collected by filtration. 
Yield: 3.7 g (94%); 1H NMR (DMSO-d6) δ 2.79 (6H, s, 2×NMe), 3.43 (2H, t, J = 5.2 Hz, 
CH2), 4.25 (2H, t, J = 5.2 Hz, CH2), 5.14 (2H, brs, exchangeable, NH2), 6.12 (1H, dd, J = 2.0 
Hz and J = 8.0 Hz, ArH), 6.17–6.21 (2H, m, 2×ArH), 6.92 (1H, t, J = 8.0 Hz, ArH), 10.87 
(1H, brs, exchangeable, HCl).   
3-(3-Dimethylamino)propoxy)benzenamine hydrochloride (130ab’).104-107 To a solution 
of N,N-dimethyl-3-(3-nitrophenoxy)propan-1-amine hydrochloride hydrochloride (129ab’, 
4.17 g, 16 mmol) in MeOH (100 mL) was added 10%Pd/C (500 mg). The mixture was 
sonicated for 5 min. and then hydrogenated at 35 psi for 2 h. The reaction was monitor by 
TLC. After completion of reaction, the reaction mixture was filtered through pad of Celite 
and washed with MeOH. The combined filtrate and washing was evaporated to dryness under 
reduce pressure. The residue was triturated with ether and the separated solid product was 
collected by filtration. Yield: 3.0 g (81%); 1H NMR (DMSO-d6) δ 2.07–2.14 (2H, m, 2×CH), 
2.74 (6H, s, 2×NMe), 3.13–3.17 (2H, m, 2×CH), 3.93 (2H, t, J = 6.0 Hz, CH2), 5.12 (2H, brs, 
exchangeable, NH2), 6.08 (1H, dd, J = 2.4 Hz and J = 8.2 Hz, ArH), 6.14–6.17 (2H, m, 
2×ArH), 6.89 (1H, t, J = 8.0 Hz, ArH), 10.93 (1H, brs, exchangeable, HCl). 
3-(2-(pyrrolidin-1-yl)ethoxy)benzenamine hydrochloride (130ac’).104-107 To a solution of 
1-(2-(3-nitrophenoxy)ethyl)pyrrolidine hydrochloride (129ac’, 7.5 g, 27.5 mmol) in MeOH 
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(200 mL) was added 10%Pd/C (0.750 mg). The mixture was sonicated for 5 min. and then 
hydrogenated at 35 psi for 3 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtered through pad of Celite and washed with MeOH. 
The combined filtrate and washing was evaporated to dryness under reduce pressure. The 
residue was triturated with ether and the separated solid product was collected by filtration. 
Yield: 6.5 g (98%); 1H NMR (DMSO-d6) δ 1.91–1.93 (4H, m, 4×CH), 3.09 (2H, s, 2×CH), 
3.50 (4H, t, J = 5.2 Hz, 2×CH2), 4.25 (2H, t, J = 5.2 Hz, CH2), 5.38 (2H, brs, exchangeable, 
NH2), 6.15 (1H, d, J = 8.0 Hz, ArH), 6.22 (2H, t, J = 8.0 Hz, 2×ArH), 6.93 (1H, t, J = 8.0 Hz, 
ArH), 11.25 (1H, brs, exchangeable, HCl). 
3-(2-(Piperidin-1-yl)ethoxy)benzenamine hydrochloride (130ad’).104-107 To a solution of 
1-(2-(3-nitrophenoxy)ethyl)piperidine hydrochloride (129ad’, 9.0 g, 31.3 mmol) in MeOH 
(250 mL) was added 10%Pd/C (900 mg).The mixture was sonicated for 5 min. and then 
hydrogenated at 35 psi for 2 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtred through pad of Celite and washed with MeOH. The 
combined filtrate and washing was evaporated to dryness under reduce pressure. The residue 
was triturated with ether and the separated solid product was collected by filtration. Yield: 
7.5 g (94%); 1H NMR (DMSO-d6) δ 1.38 (1H, brs, CH), 1.67–1.79 (6H, m, 6×CH), 2.97 (2H, 
s, 2×CH), 3.40 (3H, t, J = 5.2 Hz, 3×CH), 4.33 (2H, t, J = 5.2 Hz, CH2), 5.77 (2H, brs, 
exchangeable, NH2), 6.18 (1H, dd, J = 2.0 Hz and J = 8.0 Hz, ArH), 6.24–6.29 (2H, m, 
2×ArH), 6.95 (1H, t, J = 8.0 Hz, ArH), 10.99 (1H, brs, exchangeable, HCl).  
3-(2-Morpholinoethoxy)benzenamine hydrochloride (130ae’).104-107 To a solution of 1-(2-
(3-Nitrophenoxy)ethyl)morpholine hydrochloride (129ae’, 5.0 g, 17.3 mmol) in MeOH (150 
mL) was added 10%Pd/C (500 mg).The mixture was sonicated for 5 min. and then 
hydrogenated at 35 psi for 3 h. The reaction was monitored by TLC. After completion of 
reaction, the reaction mixture was filtred through pad of Celite and washed with MeOH. The 
combined filtrate and washing was evaporated to dryness under reduce pressure. The residue 
was triturated with ether and the separated solid product was collected by filtration. Yield:  
4.25 g (95%); 1H NMR (DMSO-d6) δ 3.34 (4H, brs, 4×CH), 3.52 (2H, t, J = 4.8 Hz, CH2), 
3.91 (4H, s, 4×CH), 4.39 (2H, t, J = 4.8 Hz, CH2), 6.49–6.52 (1H, m, ArH), 6.54–6.56 (2H, 
m,  2×ArH), 7.13 (1H, t, J = 8.0 Hz, ArH), 8.86 (1H, brs, exchangeable, HCl).   
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4-(2-(Dimethylamino)ethoxy)benzenamine hydrochloride (130ba’).108-110 To a solution of 
N,N-Dimethyl-2-(4-nitrophenoxy)ethanamine hydrochloride (129ba’, 4.17 g, 16 mmol) in 
MeOH (150 mL) was added 10%Pd/C (500 mg).The mixture was sonicated for 5 min. and 
then hydrogenated at 35 psi for 2 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtred through pad of Celite and washed with MeOH. The 
combined filtrate and washing was evaporated to dryness under reduce pressure. The residue 
was triturated with ether and the separated solid product was collected by filtration. Yield: 
3.55 g (96%); 1H NMR (DMSO-d6) δ 2.84 (6H, s, 2×NMe), 3.44 (2H, t, J = 5.2 Hz, CH2), 
4.16 (2H, t, J = 5.2 Hz, CH2), 6.61 (2H, d, J = 8.8 Hz, 2×ArH), 6.78 (2H, d, J = 8.8 Hz, 
2×ArH). 
4-(3-Dimethylamino)propoxy)benzenamine hydrochloride (130bb’).108-110 To a solution 
of N,N-dimethyl-3-(4-nitrophenoxy)propan-1-amine hydrochloride (129bb’, 4.17 g, 16 
mmol) in MeOH (200 mL) was added 10%Pd/C (500 mg).The mixture was sonicated for 5 
min. and then hydrogenated at 35 psi for 2 h. The reaction was monitor by TLC. After 
completion of reaction, the reaction mixture was filtred through pad of Celite and washed 
with MeOH. The combined filtrate and washing was evaporated to dryness under reduce 
pressure. The residue was triturated with ether and the separated solid product was collected 
by filtration. Yield: 4.0 g (96%); 1H NMR (DMSO-d6) δ 2.02–2.09 (2H, m, 2×CH), 2.79 (6H, 
s, 2×NMe), 3.17–3.21 (2H, m, 2×CH), 3.90–3.93 (2H, m, 2×CH), 6.60 (2H, d, J = 8.8 Hz, 
2×ArH), 6.71 (2H, d, J = 8.8 Hz, 2×ArH). 
4-(2-(Pyrrolidin-1-yl)ethoxy)benzenamine hydrochloride (130bc’).108-110 To a solution of 
1-(2-(4-nitrophenoxy)ethyl)pyrrolidine hydrochloride (129bc’, 7.5 g, 27.5 mmol) in MeOH 
(250 mL) was added 10%Pd/C (900 mg).The mixture was sonicated for 5 min. and then 
hydrogenated at 35 psi for 3 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtred through pad of Celite and washed with MeOH. The 
combined filtrate and washing was evaporated to dryness under reduce pressure. The residue 
was triturated with ether and the separated solid product was collected by filtration. Yield: 
6.3 g (94%); 1H NMR (DMSO-d6) δ 1.93 (4H, s, 4×CH), 3.45–3.48 (6H, m, 6×CH), 4.19–
4.22 (2H, m, 2×CH), 6.55–6.59 (2H, m, 2×ArH), 6.72 – 6.76 (2H, m, 2×ArH). 
4-(2-(Piperidin-1-yl)ethoxy)benzenamine hydrochloride (130bd’).108-110 To a solution of 
1-(2-(4-nitrophenoxy)ethyl)piperidine hydrochloride (129bd’, 4.5 g, 16 mmol) in MeOH 
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(100 mL) was added 10%Pd/C (500 mg).The mixture was sonicated for 5 min. and then 
hydrogenated at 35 psi for 2 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtred through pad of Celite and washed with MeOH. The 
combined filtrate and washing was evaporated to dryness under reduce pressure. The residue 
was triturated with ether and the separated solid product was collected by filtration. Yield: 
4.0 g (96%); 1H NMR (DMSO-d6) δ 1.52 (2H, s, 2×CH), 1.77–1.81 (4H, m, 4×CH), 3.09–
3.36 (6H, m, 6×CH), 4.26–4.28 (2H, m, 2×CH), 6.58 (2H, d, J = 8.8 Hz, 2×ArH), 6.74 (2H, 
d, J = 8.8 Hz, 2×ArH).  
4-(2-Morpholinoethoxy)benzenamine hydrochloride (130be’).108-110 To a solution of 1-(2-
(4-nitrophenoxy)ethyl)morpholine hydrochloride (129be’, 5.0 g, 17.3 mmol) in MeOH (100 
mL) was added 10%Pd/C (750 mg).The mixture was sonicated for 5 min. and then 
hydrogenated at 35 psi for 3 h. The reaction was monitor by TLC. After completion of 
reaction, the reaction mixture was filtred through pad of Celite and washed with MeOH. The 
combined filtrate and washing was evaporated to dryness under reduce pressure. The residue 
was triturated with ether and the separated solid product was collected by filtration. Yield: 
4.0 g (89%); 1H NMR (DMSO-d6) δ 3.20 (4H, s, 4×CH), 3.36 (2H, t, J = 5.2 Hz, CH2), 3.86 
(4H, t, J = 4.4 Hz, 2×CH2), 4.29 (2H, t, J = 5.2 Hz, CH2), 6.79 (2H, d, J = 8.8 Hz, 2×ArH), 
6.83 (2H, d, J = 8.8 Hz, 2×ArH), 8.35 (2H, brs, exchangeable, NH2). 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-(2-(dimethylamino)ethoxy)phenyl)urea 
(131aa’). A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and 
triphosgene (1.24 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) 
was added dropwise and the reaction mixture was stirred at -10 oC for 30 min then 3-(2-
(dimethylamino)ethoxy)benzenamine (130aa’, 1.384 g, 6 mmol) in CHCl3 (25 mL) 
containing TEA (3 mL) was added dropwise and the  mixture was stirred at room 
temperature for 16 h. After completion of reaction, the reaction mixture was washed with 
water (350 mL) and brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and 
filtered. The filtrate was evaporated to dryness under vacuo. The residue was purified by 
column chromatography using CH2Cl2:MeOH (100:6) as an eluent. The fraction containing 
main products were combined and evaporated to dryness. The white solid residue was 
triturated with hexane and filtered to give 131aa’, yield: 0.710 g (46%); mp 143–145 oC; 1H 
NMR (DMSO-d6) δ 2.21 (6H, s, 2×NMe), 2.61 (2H, s, 2×CH), 3.69 (8H, brs, 4×CH2), 4.00 
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(2H, s, 2×CH), 6.51–6.53 (1H, m, ArH), 6.70–6.72 (2H, m, 2×ArH), 6.88–6.90 (1H, m, 
ArH), 7.13–7.18 (2H, m, 2×ArH), 7.26–7.28 (2H, m, 2×ArH), 8.32 and 8.52 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C21H28Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-(3-(dimethylamino)propoxy)phenyl)urea 
(131ab’). A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and 
triphosgene (1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 3-(3-
(dimethylamino)propoxy)benzene-mine (130ab’, 1.384 g, 6 mmol) in CHCl3 (25 mL) 
containing TEA (3 mL) was added dropwise and the  reaction mixture was stirred at room 
temperature for 16 h. After completion of reaction, the reaction mixture was washed with 
water (350 mL) and brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and 
filtered. The filtrate was evaporated to dryness under vacuo. The residue was purified by 
column chromatography using CH2Cl2:MeOH(100:9) as an eluent. The fraction containing 
main products were combined and evaporated to dryness. The white solid residue was 
triturated with hexane and filtered to give 131ab’, yield: 1.247 g (43%); mp 127–128 oC; 1H 
NMR (DMSO-d6) δ 1.84–1.89 (2H, m, 2×CH), 2.21 (6H, s, 2×NMe), 2.44 (2H, t, J = 7.2 Hz, 
CH2), 3.69–3.70 (8H, m, 4×CH2), 3.95 (2H, t, J = 7.2 Hz, CH2), 6.48–6.51 (1H, m, ArH), 
6.70 (2H, d, J = 8.8 Hz, 2×ArH), 6.86 (1H, d, J = 8.0 Hz, ArH), 7.13 (1H, t, J = 8.0 Hz, 
ArH), 7.20 (1H, s, ArH), 7.27 (2H, d, J = 8.8 Hz, 2×ArH), 8.40 and 8.62 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C22H30Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-(2-(pyrrolidin-1-yl)ethoxy)phenyl)urea 
(131ac’). A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and 
triphosgene (1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 3-(2-
(pyrrolidin-1-yl)ethoxy)benzenamine (130ac’, 1.456 g, 6 mmol) in CHCl3 (25 mL) 
containing TEA (3 mL) was added dropwise and the reaction mixture was stirred at room 
temperature for 16 h. After completion of reaction, the reaction mixture was washed with 
water (350 mL) and brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and 
filtered. The filtrate was evaporated to dryness under vacuo. The residue was purified by 
column chromatography using CH2Cl2:MeOH (100:8) as an eluent. The fraction containing 
main products were combined and evaporated to dryness. The white solid residue was 
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triturated with hexane and filtered to give 131ac’, yield: 1.36 g (45%); mp 124–125 oC; 1H 
NMR (DMSO-d6) δ 1.68 (4H, s, 4×CH), 2.50 (4H, s, 4×CH), 2.77 (2H, s, 2×CH),  3.69 (8H, 
s, 4×CH2), 4.01 (2H, s, 2×CH), 6.51 (1H, d, J = 7.2 Hz, ArH), 6.70 (2H, d, J = 8.0 Hz, 
2×ArH), 6.88 (1H, d, J = 7.6 Hz, ArH), 7.13 (1H, t, J = 8.0 Hz, ArH), 7.18 (1H, s, ArH), 7.27 
(2H, d, J = 8.0 Hz, 2×ArH), 8.37 and 8.57 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C23H30Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)urea 
(131ad’). A suspension of aniline N-mustard HCl salt (107, 1.683 g, 5.4 mmol) and 
triphosgene (1.246 g, 4.2 mmol) in dry CHCl3 (50 mL) was cooled to -10 oC.  TEA (3 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 3-(2-
(piperidin-1-yl)ethoxy)benzenamine (130ad’, 0.75 g, 3 mmol) in CHCl3 (25 mL) containing 
TEA (2 mL) was added dropwise and the  reaction mixture was stirred at room temperature 
for 16 h. After completion of reaction, the reaction mixture was washed with water (250 mL) 
and brine (250 mL). The Organic layer was dried over anhy.Na2SO4 and filtered. The filtrate 
was evaporated to dryness under vacuo. The residue was purified by column chromatography 
using CH2Cl2:MeOH (100:2) as an eluent. The fraction containing main products were 
combined and evaporated to dryness. The white solid residue was triturated with hexane and 
filtered to give 131ad’, yield: 0.850 g (55%); mp 86–88 oC; 1H NMR (DMSO-d6) δ 1.37 (2H, 
s, 2×CH), 1.49 (4H, s, 4×CH), 2.42 (4H, s, 4×CH), 2.63 (2H, s, 2×CH), 3.69  (8H, s, 4×CH2), 
4.00 (2H, s, 2×CH), 6.50–6.52 (1H, m, ArH), 6.69–6.71 (2H, m, 2×ArH), 6.87–6.88 (1H, m, 
ArH), 7.12–7.18 (2H, m, 2×ArH), 7.26–7.28  (2H, m, 2×ArH), 8.35 and 8.54 (each 1H, brs, 
exchangeable, 2×NH). Anal. (C24H32Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(3-(2-morpholinoethoxy)phenyl)urea (131ae’). 
A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and triphosgene 
(1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (6 mL) was added 
dropwise and reaction mixture was stirred at -10 oC for 30 min then 3-(2-morpholinoethoxy)- 
benzenamine  (130ae’, 1.55 g, 6 mmol) in CHCl3 (25 mL) containing TEA (3 mL) was added 
dropwise and the  reaction mixture was stirred at room temperature for 16 h. After 
completion of reaction, the reaction mixture was washed with water (350 mL) and brine (350 
mL). The Organic layer was dried over anhy.Na2SO4 and filtered. The filtrate was evaporated 
to dryness under vacuo. The residue was purified by column chromatography using 
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CH2Cl2:MeOH(100:5) as an eluent. The fraction containing main products were combined 
and evaporated to dryness. The white solid residue was triturated with hexane and filtered to 
give 131ae’, yield: 0.948 g (31%); mp 168–169 oC; 1H NMR (DMSO-d6) δ 2.45–2.48 (4H, 
m, 4×CH), 2.68 (2H, t, J = 6.0 Hz, CH2), 3.58 (4H, t, J = 4.8 Hz, 2×CH2), 3.66–3.72 (8H, m, 
4×CH2), 4.04 (2H, t, J = 6.0 Hz, CH2),  6.51–6.54 (1H, m, ArH), 6.70 (2H, d, J = 9.2 Hz, 
2×ArH), 6.87 (1H, d, J = 8.0 Hz, ArH), 7.13 (1H, t, J = 8.0 Hz, ArH), 7.19 (1H, s, ArH), 7.27 
(2H, d, J = 9.2 Hz, 2×ArH), 8.31 and 8.50 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C23H30Cl2N4O3.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-4-(3-(2-(dimethylamino)ethoxy)phenyl)urea 
(131ba’). A suspension of aniline N-mustard HCl salt (107, 1.683 g, 5.4 mmol) and 
triphosgene (0.623 g, 4.2 mmol) in dry CHCl3 (50 mL) was cooled to -10 oC.  TEA (3 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 4-(2-
(dimethylamino)ethoxy)benzenamine (130ba’, 0.65 g, 3 mmol) in CHCl3 (25 mL) containing 
TEA (3 mL) was added dropwise and the reaction mixture was stirred at room temperature 
for 16 h. After completion of reaction, the reaction mixture was washed with water (150 mL) 
and brine (150 mL). The Organic layer was dried over anhy.Na2SO4 and filtered. The filtrate 
was evaporated to dryness under vacuo. The residue was purified by column chromatography 
using CH2Cl2:MeOH (100:7) as an eluent. The fraction containing main products were 
combined and evaporated to dryness. The white solid residue was triturated with hexane and 
filtered to give 131ba’, yield: 0.864 g (60%); mp 203–205 oC; 1H NMR (DMSO-d6) δ 2.83 
(6H, s, 2×NMe), 3.46–3.47 (2H, m, 2×CH), 3.69 (8H, s, 4×CH2), 4.30 (2H, t, J = 4.9 Hz, 
CH2), 6.72 (2H, d, J = 8.3 Hz, 2×ArH), 6.92 (2H, d, J = 8.8 Hz, 2×ArH), 7.28 (2H, d, J = 8.5 
Hz, 2×ArH), 7.38 (2H, d, J = 8.8 Hz, 2×ArH), 8.84 and 9.01 (each 1H, brs, exchangeable, 
2×NH). Anal. (C21H28Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-4-(3-(3-(dimethylamino)propoxy)phenyl)urea 
(131bb’). A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and 
Triphosgene (1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 4-(3-
(dimethylamino)propoxy)benzene-mine (130bb’, 1.384 g, 6 mmol) in CHCl3 (25 mL) 
containing TEA (3 mL) was added dropwise and the  reaction mixture was stirred at room 
temperature for 16 h. After completion of reaction, the reaction mixture was washed with 
 120
water (350 mL) and brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and 
filtered. The filtrate was evaporated to dryness under vacuo. The residue was purified by 
column chromatography using CH2Cl2:MeOH (100:5) as an eluent. The fraction containing 
main products were combined and evaporated to dryness. The white solid residue was 
triturated with hexane and filtered to give 131bb’, yield: 1.70 g (58%); mp 178–180 oC; 1H 
NMR (DMSO-d6) δ 2.07–2.14 (2H, m, 2×CH), 2.78 (6H, s, 2×NMe), 3.17–3.22 (2H, m, 
2×CH), 3.65–3.72 (8H, m, 4×CH2), 3.99 (2H, t, J = 6.0 Hz, CH2), 6.69 (2H, d, J = 8.9 Hz, 
2×ArH), 6.86 (2H, d, J = 9.0 Hz, 2×ArH), 7.26 (2H, d, J = 8.8 Hz, 2×ArH), 7.35 (2H, d, J = 
9.0 Hz, 2×ArH), 8.62 and 8.64 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C22H30Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-4-(3-(2-(pyrrolidin-1-yl)ethoxy)phenyl)urea 
(131bc’). A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and 
triphosgene (1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 4-(2-
(pyrrolidin-1-yl)ethoxy)benzenamine (130bc’, 1.456 g, 6 mmol) in CHCl3 (25 mL) 
containing TEA (3 mL) was added dropwise and the  reaction mixture was stirred at room 
temperature for 16 h. After completion of reaction, the reaction mixture was washed with 
water (350 mL) and brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and 
filtered. The filtrate was evaporated to dryness under vacuo. The residue was purified by 
column chromatography using CH2Cl2:MeOH (100:6) as an eluent. The fraction containing 
main products were combined and evaporated to dryness. The white solid residue was 
triturated with hexane and filtered to give 131bc’, yield: 1.56 g (52%); mp 205–207 oC; 1H 
NMR (DMSO-d6) δ 1.87–1.90 (2H, m, 2×CH), 2.00 (2H, brs, 2×CH), 3.07–3.10 (2H, m, 
2×CH), 3.53–3.58 (4H, m, 4×CH), 3.65–3.72 (8H, m, 4×CH2), 4.28 (2H, t, J = 4.9 Hz, CH2), 
6.69 (2H, d, J = 8.9 Hz, 2×ArH), 6.93 (2H, d, J = 8.9 Hz, 2×ArH), 7.27 (2H, d, J = 8.8 Hz, 
2×ArH), 7.38 (2H, d, J = 8.8 Hz, 2×ArH), 8.70 and 8.87 (each 1H, brs, exchangeable, 
2×NH). Anal. (C23H30Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-4-(3-(2-(piperidin-1-yl)ethoxy)phenyl)urea 
(131bd’). A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and 
triphosgene (1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) 
was added dropwise and reaction mixture was stirred at -10 oC for 30 min then 4-(2-
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(piperidin-1-yl)ethoxy)benzenamine (130bd’, 1.54 g, 6 mmol) in CHCl3 (25 mL) containing 
TEA (3 mL) was added dropwise and the  reaction mixture was stirred at room temperature 
for 16 h. After completion of reaction, the reaction mixture was washed with water (350 mL) 
and brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and filtered. The filtrate 
was evaporated to dryness under vacuo. The residue was purified by column chromatography 
using CH2Cl2:MeOH (100:7) as an eluent. The fraction containing main products were 
combined and evaporated to dryness. The white solid residue was triturated with hexane and 
filtered to give 130bd’, yield: 1.73 g (56%); mp 211–212 oC; 1H NMR (DMSO-d6) δ 1.37–
1.39 (1H, m, CH), 1.67–1.70 (1H, m, CH), 1.79 (4H, brs, 4×CH), 2.98 (2H, brs, 2×CH), 
3.43–3.50 (4H, m, 4×CH), 3.67–3.72 (8H, m, 4×CH2), 4.34 (2H, t, J = 4.9 Hz, CH2), 6.69 
(2H, d, J = 8.9 Hz, 2×ArH), 6.92 (2H, d, J = 8.9 Hz, 2×ArH), 7.27 (2H, d, J = 8.9 Hz, 
2×ArH), 7.38 (2H, d, J = 8.9 Hz, 2×ArH), 8.72 and 8.89 (each 1H, brs, exchangeable, 
2×NH). Anal. (C24H32Cl2N4O2.HCl) C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-4-(3-(2-morpholinoethoxy)phenyl)urea (131be’). 
A suspension of aniline N-mustard HCl salt (107, 3.366 g, 10.8 mmol) and triphosgene 
(1.246 g, 4.2 mmol) in dry CHCl3 (100 mL) was cooled to -10 oC.  TEA (5 mL) was added 
dropwise and reaction mixture was stirred at -10 oC for 30 min then 4-(2-
morpholinoethoxy)benzenamine (130be’, 1.55 g, 6 mmol) in CHCl3 (25 mL) containing TEA 
(3 mL) was added dropwise and the  reaction mixture was stirred at room temperature for 16 
h. After completion of reaction, the reaction mixture was washed with water (350 mL) and 
brine (350 mL). The Organic layer was dried over anhy.Na2SO4 and filtered. The filtrate was 
evaporated to dryness under vacuo. The residue was purified by column chromatography 
using CH2Cl2:MeOH (100:5) as an eluent. The fraction containing main products were 
combined and evaporated to dryness. The white solid residue was triturated with hexane and 
filtered to give 131be’, yield: 1.33 g (43%); mp 210–212 oC; 1H NMR (DMSO-d6) δ 3.20 
(2H, brs, 2×CH), 3.47–3.52 (4H, m, 4×CH), 3.65–3.71 (8H, m, 4×CH2), 3.78–3.84 (2H, m, 
2×CH), 3.95–3.98 (2H, m, 2×CH), 4.36 (2H, t, J = 4.8 Hz, CH2), 6.69 (2H, d, J = 9.0 Hz, 
2×ArH), 6.93 (2H, d, J = 8.9 Hz, 2×ArH), 7.27 (2H, d, J = 8.9 Hz, 2×ArH), 7.38 (2H, d, J = 
9.0 Hz, 2×ArH), 8.67 and 8.84 (each 1H, brs, exchangeable, 2×NH). Anal. 
(C23H30Cl2N4O3.HCl) C, H, N. 
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Biological Experiments 
 
Cytotoxicity Assays. The cytotoxic effects of the newly synthesized compounds were 
determined in T-cell acute lymphocytic leukemia (CCRF-CEM) and their resistant subcell 
lines (CCRF-CEM/Taxol and CCRF-CEM/VBL) by the XTT assay92 and human solid tumor 
cells (i.e. breast carcinoma MX-1 and colon carcinoma HCT-116) the SRB assay93 in a 72 h 
incubation using a microplate spectrophotometer as described previously.94 After the addition 
of phenazine methosulfate-XTT solution, incubated  at 37 oC for 6 h and absorbance at 450 
and 630 nm was detected on a microplate reader (EL 340). IC50 values were determined from 
dose-effect relationship at six or seven concentrations of each drug by using the CompuSyn 
software by Chou and Martin95 based on the median-effect principle and plot.96,97  
 
In vivo studies. Athymic nude mice bearing the nu/nu gene were used for human breast 
tumor MX-1 and human colon HCT-116 xenografts. Outbred Swiss-background mice were 
obtained from the National Cancer Institute (Frederick, MD). Male mice 8 weeks old or older 
weighing 22 g or more were used for most experiments. Drug was administrated via the tail 
vein by iv injection. Tumor volumes were assessed by measuring length × width × height (or 
width) using caliper. Vehicle used was 50 μL DMSO and 40 μL Tween 80 in 160 μL saline. 
The maximal tolerate dose of the tested compound was determined and applied for the in 
vivo therapeutic efficacy assay. All animal studies were conducted in accordance with the 
guidelines of the National Institutes of Health Guide for the Care and Use of Animals and the 
protocol approved by the Memorial Sloan-Kettering Cancer Center’s Institutional Animal 
Care and Use Committee. 
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Table 11. Elemental analysis of newly prepared N-mustard derivatives. 
 
C, H, N Analysis 
Anal.Calcd. Found Compd Molecular Formula MW 
C% H% N% C% H% N% 
124a C20H23Cl2N3O3 424.32 56.61  5.56 9.90 56.71 5.58 9.95 
124b C20H23Cl2N3O3 424.32 56.61  5.56 9.90 56.68 5.65 10.01 
125a C18H19Cl2N3O3 396.27 54.56  4.83 10.60 54.59 4.86 10.70 
125b C18H19Cl2N3O3 396.27 54.56  4.83 10.60 54.67 4.85 10.73 
126aa’ C22H29Cl2N5O2.HCl 502.86 52.55 6.01 13.93 52.82 6.04 13.98 
126ab’ C23H31Cl2N5O2.HCl 516.89 53.44  6.24 13.55 53.48 6.27 13.60 
126ac’ C24H31Cl2N5O2.HCl 528.90 54.50  6.10 13.24 54.60 6.13 13.28 
126ad’ C25H33Cl2N5O2.HCl 542.93 55.31  6.31 12.90 55.33 6.35 12.97 
126ae’ C24H31Cl2N5O3.HCl 544.90 52.90  5.92 12.85 52.95 5.93 12.86 
126af’ C28H37Cl2N5O2.HCl 582.99 57.69  6.57 12.01 57.92 6.63 12.03 
126ba’ C22H29Cl2N5O2.HCl 502.86 52.55 6.01 13.93 52.69 6.05 14.01 
126bb’ C23H31Cl2N5O2.HCl 516.89 53.44  6.24 13.55 53.70 6.28 13.75 
126bc’ C24H31Cl2N5O2.HCl 528.90 54.50  6.10 13.24 54.85 6.20 13.35 
126bd’ C25H33Cl2N5O2.HCl 542.93 55.31  6.31 12.90 55.43 6.33 12.92 
126be’ C24H31Cl2N5O3.HCl 544.90 52.90  5.92 12.85 52.99 5.98 12.89 
126bf’ C28H37Cl2N5O2.HCl 582.99 57.69  6.57 12.01 57.89 6.60 12.08 
131aa’ C21H28Cl2N4O2.HCl 475.84 53.01  6.14 11.77 53.03 6.24 11.89 
131ab’ C22H30Cl2N4O2.HCl 489.87 53.94  6.38 11.44 54.03 6.44 11.56 
131ac’ C23H30Cl2N4O2.HCl 501.88 55.04  6.23 11.16 55.20 6.25 11.22 
131ad’ C24H32Cl2N4O2.HCl 515.90 55.87  6.45 10.86 56.00 6.49 10.98 
131ae’ C23H30Cl2N4O3.HCl 517.88 53.34  6.03 10.82 53.51 6.10 10.93 
131ba’ C21H28Cl2N4O2.HCl 475.84 53.01  6.14 11.77 53.08 6.16 11.93 
131bb’ C22H30Cl2N4O2.HCl 489.87 53.94  6.38 11.44 53.98 6.40 11.49 
131bc’ C23H30Cl2N4O2.HCl 501.88 55.04  6.23 11.16 55.23 6.33 11.32 
131bd’ C24H32Cl2N4O2.HCl 515.90 55.87  6.45 10.86 55.91 6.54 10.88 
131be’ C23H30Cl2N4O3.HCl 517.88 53.34  6.03 10.82 53.44 6.04 10.90 
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4.5 1H NMR spectrum for compound 124a and 126aa’. 
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1H NMR spectrum for compound 126ae’ and 124b. 
 
 
 126
1H NMR spectrum for compound 126bb’ and 126bd’. 
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1H NMR spectrum for compound 129aa’ and 129ae’. 
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1H NMR spectrum for compound 130ab’ and 130ac’. 
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1H NMR spectrum for compound 129bb’ and 129bd’.  
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1H NMR spectrum for compound 130bb’ and 130bc’. 
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1H NMR spectrum for compound 131ac’ and 131ae’. 
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1H NMR spectrum for compound 131bc’ and 131be’. 
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CHAPTER 5 
 
Synthesis and Antitumor Activity of 5,10-Dihydro-pyrrolo[1,2-b]- 
isoquinoline Derivatives 
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5.1 Chemistry 
 
 
Synthetic route for bis(hydroxymethyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl 
derivatives (136a-d) and their bis(methylcarbamate) derivatives (137a-d) is shown in 
Scheme 8. Treatment of commercially available D,L-phenylalanine (132) with formaldehyde 
and con.HCl afforded 3-carboxy-1,2,3,4-tetrahydroisoquinoline (133),111 which was acylated 
by using acetic anhydride or various benzoyl chloride in 2N NaOH to give amide derivatives 
of 3-carboxy-1,2,3,4-tetrahydroisoquinolines (134a-d).112 The cycloaddition reaction of 
134a-d with dimethyl acetylenedicarboxylate (DMAD) in acetic anhydride at 60–70 oC 
yielded 5,10-dihydro-pyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid dimethyl esters (135a-
d).84 The diester 135a-d was reduced to bis-alcohol 136a-d by treating with LiAlH4 in a 
mixture of ether/CH2Cl2 at room temperature. The diol 136a-d was then reacted with methyl 
isocyanate in presence of TEA to furnish the desired bis(carbamate)-5,10-dihydro-
pyrrolo[1,2-b]isoquinoline-1-yl derivatives (137a-d) in good yield (Table 12).  
 
Scheme 8. Synthetic route for the 5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl derivatives. 
 
a: R = CH3
b: R = 4'-OMe-Ph
c: R = 4'-Cl-Ph
d: R = 3',4'di-F-Ph
132 133 134a-d 135a-d
NH2
COOH
NH
COOH
N
COOH
R
O N
COOEt
COOEt
R
N
CH2OH
CH2OH
R
N
CH2OCONHCH3
CH2OCONHCH3
R
i ii iii
iv
v
136a-d137a-d  
 
Reaction conditions: (i) 37% Formalin/Con.HCl, reflux; (ii) acid chloride, 2N NaOH/ 
acetone, room temperature; (iii) DMAD/AC2O, 60-70 oC; (iv) LiAlH4/CH2Cl2/EtO2, 10-15 
oC; (v) MeNCO/CH2Cl2/TEA, room temperature. 
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Scheme 9. Reaction mechanism of 1,3-dipolar cycloaddition reaction of 135a-d 
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The reaction mechanism of cycloaddition reaction of 134a-d with DMAD is depicted in 
Scheme 9. Reaction of amides 134a-d with dimethyl acetylenedicarboxylate (DMAD) in 
presence of acetic anhydride form mesoionic oxazolone intermediates 138a-d. 1,3-dipolar 
addition113 of 138a-d give 139a-d which spontaneously eliminate CO2 to give diester     
135a-d. 
All of the synthesized compounds were characeterized by using 1H NMR and Elemental 
analysis. For compounds 136a-d and 137a-d the characteristic peak for methylenedioxy (i.e., 
CH2OH) appeared at the ragne of 3.3-4.7 δ ppm. The 1H NMR signals for the carbamate 
residue appeared at 2.51-2.57 δ ppm. The elemental analysis of the newly synthesized 
derivatives was within ±0.4% range of the calculated C, H, N data.        
 
5.2 Biological Results and Discussion 
 
5.2.1 In vitro cytotoxicity. Table 13 shows the antiproliferative activities of the newly 
synthesized bis(hydroxymethyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinoline derivatives (136a-
d) and their bis(methylcarbamate) derivatives (137a-d)  against human lymphoblastic 
leukemia (CCRF-CEM) and its drug-resistant sublines (CCRF-CEM/Taxol and CCRF-
CEM/VBL) cell growth in vitro. It demonstrated that the newly synthesized conjugates 
possess significant cytotoxicity with IC50 in submicro molar range. The structure-activity 
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relationship (SAR) study showed that, in general, bis(methylcarbamate) derivatives (137a-d) 
were more potent than the corresponding bis(hydroxymethyl) derivatives (136a-d) except for 
diol 136a, which stand out as the most potent of the series having IC50 value of 0.081 μM 
against CCRF-CEM cell growth. In the series of bis(hydroxymethyl) derivatives bearing 
phenyl moiety at C-3 position (137b-d), compound having electron donating substituent (i.e, 
4’-OMe (136b)) was more cytotoxic than those bearing electron-withdrawing substituents 
(i.e., 4’-Cl (136c) or 3’,4’-di-F (136d)). Similarly, in the series of bis(methylcarbamates) 
derivatives, 4’-OMeC6H4 derivative (137b) appeared to be more active than corresponding 
4’-ClC6H4 (137c) or 3’,4’-diF C6H3 (137d) compounds. Comparison of the cytotoxicity of 
compounds having C-3 substituents, either as Me (136a, 137a) or substituted phenyl moiety 
(136b-d or 137b-d) revealed that the former were more active than the later . 
 
Table 12. Analytical data and yields of bis(hydroxymethyl)-5,10-dihydro-pyrrolo[1,2-   
b]isoquinolin-1-yl derivatives (136a-d) and their bis(methylcarbamate) derivatives  (137a-d). 
N
OR2
OR2
R1  
 
Compd R1 R2 Yield (%) Mp(oC) Analysis  
136a Me H 76 99-101 C, H, N  
136b 4’-OMeC6H4 H 68 174-176 
C, H, N 
 
136c 4’-ClC6H4 H 61 170-171 
C, H, N 
 
136d 3’4’-diFC6H3 H 67 145-146 
C, H, N 
 
137a Me CONHMe 44 174-176 C, H, N  
137b 4’-OMeC6H4 CONHMe 87 182-184 
C, H, N 
 
137c 4’-ClC6H4 CONHMe 77 190-192 
C, H, N 
 
137d 3’4’-diFC6H3 CONHMe 82 194-196 
C, H, N 
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The antiproliferative activity of new 5,10-dihydro-pyrrolo[1,2-b]isoquinoline derivatives 
(136a-d and 137a-d) against MX-1 and HCT-116 solid tumor cell growth was also studied 
(Table 13). The SAR is described as follows. In general, bis(methylcarbamate) derivatives 
(137a-d) were as potent as or more potent than the corresponding bis(hydroxymethyl) 
derivatives (136a-d).  Bis(hydroxymethyl) derivative 136a, was also most active against 
MX-1 cell line with IC50 values of 0.656 μM while bis(methylcarbamate) derivative 137c 
was most potent against HCT-116 cell growth with  IC50 values of 0.0358 μM. The 
cytotoxicity of bis(hydroxymethyl) derivatives (136a-d) against MX-1 cell growth showed 
that the 4’-OMeC6H4 derivative (136b) were about 2-3 fold more active than corresponding 
4’-ClC6H4 (136c) or 3’,4’-diF C6H3 (136d) compounds. Similar results were obtained for 
compounds 136a-d against HCT-116 cells. In contrast, bis(methylcarbamate) compounds 
(137a-d) bearing  4’-ClC6H4 (137c) or 3’,4’-diFC6H3 (137d) substituents at C-3 position 
were more cytotoxic than corresponding 4’-OMeC6H4 (137b) or Me (137a) substituted 
derivatives.   
 
5.2.2 In vivo study. On the basis of potent cytotoxicity in vitro, compounds 136a was 
selected for the evaluation of antitumor therapeutic efficacy in animal model. Figure 33 
shows the therapeutic effects of 136a, in nude mice bearing mammary MX-1 xenografts. 
Total tumor remission was achieved at maximal tolerated dose 30 mg/kg, QD×2 (Fig. 33A) 
with low toxicity (Fig. 33B). Compound 136a was also evaluated for its therapeutic effect 
against human ovarian adenocarcinoma xenograft (SK-OV-3) in nude mice (Figure 34). It 
demonstrated that 136a induced significant tumor inhibitaion (70%) at the dose of 20 mg/kg, 
QD×4 (i.v. injection) in comparision to control (Fig. 34A). At maximal tolerated doses 
treatment, about 0-15% body weight changes was found (Fig. 33B and 34B) in mice which 
recovered after cession of the treatment. Thus it indicated that 136a have relatively low 
toxicity to the host. 
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Table 13. Cytotoxicity of newly synthesized bis(hydroxymethyl)-5,10-dihydro-pyrrolo[1,2-   
b]isoquinolin-1-yl derivatives (136a-d) and their bis(methylcarbamate) derivatives (137a-d)  
against human lymphoblastic leukemia (CCRF-CEM) and its drug-resistant sublines (CCRF-
CEM/Taxol and CCRF-CEM/VBL) and solid tumors (MX-1 and HCT-116) cell growth in 
vitro.a 
 
aCell growth inhibition was measured by the XTT92 assay for leukemic cells and the SRB assay93 for solid 
tumor cells after 72 h incubation using a microplate spectrophotometer as described in experimental section. 
IC50 values were determined in duplicate or triplicate from dose–effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin based on the median-effect 
principle and plot and serial deletion analysis.94-97 Ranges given for taxol and vinblastine were mean ± SE (n = 
4). 
bCCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 330-fold resistant to 
Taxol, and 680-fold resistant to Vinblastine, respectively, when comparing with the IC50 of the parent cell line. 
cNumbers in the brackets are fold of cross-resistant determined by comparison with the corresponding IC50 of 
the parent cell line. 
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Figure 33.  The therapeutic effects of 136a in nude mice bearing MX-1 xenograft (i.v. 
injection, n = 3). Fig. 33A for average tumor size changes; Fig. 33B for average body weight 
changes.  
33A 
 
 
33B 
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Figure 34.  The therapeutic effects of 136a in nude mice bearing ovarian adenocarcinoma 
xenograft, SK-OV-3 (i.v. injection, n = 3). Fig. 34A for average tumor size changes; Fig. 
34B for average body weight changes. 
 
34A 
 
34B 
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5.3 Conclusion 
 
A series of bifunctional DNA alkylating agents, 5,10-dihydro-pyrrolo[1,2-b]isoquinoline 
derivatives were designed and synthesized for antitumor studies. The newly prepared 
derivatives showed significant cytotoxicity against CCRF-CEM, MX-1 and HCT-116 cell 
growths. It also demonstrated that these agents have little or no cross-resistance to either 
taxol or vinblastin and thus they are effective against multiple drug resistant tumors. It was 
also found that, compound 136a, possessed potent antitumor therapeutic efficacy against 
human mammary xenograft (MX-1) and human ovarian adenocarcinoma xenograft (SK-OV-
3) in animal model. Thus 136a is a potential candidate for preclinical studies. 
 
5.4 Experimental Section 
 
Melting points were determined on a Fargo melting point apparatus and are uncorrected.  
Column chromatography was carried out on silica gel G60 (70-230 mesh and 230-400 mesh). 
Thin-layer chromatography was performed on silica gel G60 F254 with short-wavelength UV 
light for visualization. Elemental analysis was done on a Heraeus CHN-O Rapid instrument. 
1H NMR spectra were recorded on 400 MHz spectrometers. The chemical shifts were 
reported in ppm (δ) relative to TMS.  
 
1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid hydrochloride (133).111 A mixture of 
D,L-phenylalanine (132, 50 g, 3.03 mol), con. HCl (325 mL) and 37 % formalin (110 mL) 
was heated to a gentle reflux with vigorous stirring. After 30 min, another portion of formalin 
(50 mL) and con. HCl (110 mL) was added. The reaction mixture was further stirred and 
heated for 4 h and cooled to room temperature. The white solid separated out was filtered and 
washed with methanol (30 mL) to give 133, yield: 64.09 g (98.%); mp > 280 °C;1H NMR 
(DMSO-d6) δ 3.10−3.20 (1H, m, -CH), 3.27– 3.35 (1H, m, -CH), 4.26–4.33 (2H, m, -CH), 
4.38–4.41 (1H, m, -CH), 7.20 –7.35 (4H, m, 4×ArH), 9.89 (1H, brs, exchangeable -NH); 
10.06 (1H, brs, exchangeable -OH); m/z 177.0 (M+H)+.  
2-Acetyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134a).112 1,2,3,4-Tetrahydro-
isoquinoline-3-carboxylic acid hydrochloride (133, 10.0 g, 46.8 mmol) was added into a 
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solution of acetone (75 mL) and 2NNaOH (100 mL) portion wise. Acetyl chloride (7.38 g, 94 
mmol) in acetone (50 mL) and 2NNaOH were added simultaneously at room temperature. 
The pH of the reaction mixture was maintained greater than 10 during addition. The reaction 
mixture was stirred at room temperature for 1 h.  The acetone was evaporated in vacuo and 
the remaining solution was made acidic with 3NHCl. The white solid separated out was 
filtered and dried to give 134a, yield: 7.89 g (77%); mp 178−180 °C; 1H NMR (DMSO-d6) δ 
2.15 (3H, s, Me), 2.95−3.27 (2H, m, -CH), 4.21– 4.65 (1H, m, -CH), 4.66–4.87 (1H, m, -
CH), 4.92–5.23 (1H, m, -CH), 7.00 –7.51 (4H, m, 4×ArH), 12.70 (1H, brs, exchangeable -
OH); m/z 219.0 (M+H)+.  
2-(4-Methoxybenzoyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134b). 1,2,3,4-
Tetrahydro-isoquinoline-3-carboxylic acid hydrochloride (133, 10.0 g, 46.8 mmol) was 
added into a solution of acetone (75 mL) and 2NNaOH (50 mL) portion wise. 4-
Methoxybenzyoyl chloride (9.38 g, 55 mmol) in acetone (50 mL) and 2NNaOH solutions 
were added simultaneously slowly at room temperature. The pH of the reaction mixture was 
maintained greater than 10 during addition. The reaction mixture was stirred at room 
temperature for 2 h. The acetone was evaporated in vacuo and the remaining solution was 
made acidic with 3N HCl. The solid separated out was filtered and washed several times with 
water and dried to give 134b, yield: 10.38 g (72%); mp 178−180 °C; 1H NMR (DMSO-d6) δ  
3.10−3.14 (2H, m, -CH2), 3.85 (3H, s, OMe), 4.50–4.70 (2H, m, -CH2), 5.10–5.51 (1H, m, -
CH), 6.89–6.95 (3H, m, 3×ArH), 7.05–7.30 (3H, m, 3×ArH), 7.31–7.60 (2H, m, 2×ArH); m/z 
311.0 (M+H)+ Anal. (C18H17NO4·0.2 H2O) C, H, N. 
2-(4-Chlorobenzoyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134c). 1,2,3,4-
Tetrahydro-isoquinoline-3-carboxylic acid hydrochloride (133, 10.0 g, 46.8 mmol) was 
added into a solution of acetone (75 mL) and 2NNaOH (75 mL) portion wise. 4-
Chlorobenzoyl chloride (8.75 g, 50 mmol) in acetone (50 mL) and 2NNaOH were added 
simultaneously slowly at room temperature. The pH of the reaction mixture was maintained 
greater than 10 during addition. The reaction mixture was stirred at room temperature for 1 h. 
The acetone was evaporated in vacuo and the remaining solution was made acidic with 
3NHCl. The solid separated out was filtered and washed several times with water and dried 
to give 134c, yield: 13.80 g, (93%); mp 77−79 °C; 1H NMR (DMSO-d6) δ  2.87−2.95 (1H, 
m, -CH), 3.29 (1H, d, J = 15.8 Hz, -CH), 4.12 (1H, d, J = 5.6 Hz, -CH), 4.49 (1H, d, J = 17.4 
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Hz, -CH), 5.02 (1H, d, J = 17.4 Hz, -CH), 7.01–7.17 (4H, m, 4×ArH), 7.40–7.58 (5H, m, 
5×ArH); m/z 315.00 (M+H)+; Anal. (C17H14ClNO3·5.1H2O) C, H, N.   
2-(3,4-Difluorobenzoyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134d). 
1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid hydrochloride (133, 10.0 g, 46.8 mmol) 
was added into a solution of acetone (75 mL) and 2NNaOH (50 mL) portion wise. 3,4-
Diflourbenzoyl chloride (10.23 g, 58 mmol) in acetone (50 mL) and 2NNaOH solution were 
added simultaneously slowly at room temperature. The pH of the reaction mixture was 
maintained greater than 10 during addition. The reaction mixture was stirred at room 
temperature for 1 h. The acetone was evaporated in vacuo and the remaining solution was 
made acidic with 3N HCl. The solid separated out was filtered and washed several times with 
water and dried to give 134d, yield: 14.67 g (98%); mp 89−91 °C; 1H NMR (DMSO-d6) δ  
2.89−2.99 (1H, m, -CH), 3.31 (1H, d, J = 15.7 Hz, -CH), 4.48 (1H, m, -CH), 4.48 (1H, d, J = 
17.6 Hz, -CH), 5.02 (1H, d, J = 17.6 Hz, -CH), 7.07–7.15 (5H, m, 5×ArH), 7.42–7.58 (2H, 
m, 2×ArH); m/z 317.00 (M+H)+; Anal. (C17H13F2NO3) C, H, N. 
3-Methyl-5,10-dihydro-pyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid dimethyl ester 
(135a). Dimethyl acetylenedicarboxylate (2.84 g, 20 mmol) was added into a mixture of 2-
acetyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134a, 3.00 g, 13.6 mmol) in acetic 
anhydride (25 mL), and the reaction mixture was heated at 65−70 oC for 1.5 h. The reaction 
mixture was then cooled to room temperature and evaporated to dryness under reduce 
pressure. The oily residue was crystallized from methanol to give 135a, yield: 3.29 g (80%); 
mp 152−154 °C; 1H NMR(DMSO-d6) δ 2.40 (3H, s, Me), 3.70 (3H, s, COOMe), 3.72 (3H, s, 
COOMe), 4.18 (2H, s, -CH2), 5.06 (2H, s, -CH2), 7.21–7.32 (2H, m, 2×ArH), 7.35–7.39 (2H, 
m, 2×ArH); m/z 299.0 (M+H)+; Anal. (C17H17NO4) C, H, N. 
3-(4-Methoxyphenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid 
dimethyl ester (135b).  Dimethyl acetylenedicarboxylate (4.26 g, 30 mmol) was added into a 
solution of 2-(4-methoxybenzoyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134b, 
6.22 g, 20 mmol) in acetic anhydride (50 mL), and the reaction mixture was heated at 60−70 
oC for 3.5 h. The reaction mixture was then cooled to room temperature and evaporated to 
dryness under vacuo. The residue was crystallized from ethanol to give 135b, yield: 7.38 g 
(94%); mp 155−158 °C; 1H NMR(DMSO-d6) δ 3.70 (3H, s, OMe), 3.86 (3H, s, COOMe), 
3.89 (3H, s, COOMe), 4.41 (2H, s, -CH2), 4.86 (2H, s, -CH2), 7.01(2H, d, J = 5.7 Hz, 
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2×ArH), 7.11 (1H, d, J = 12.3 Hz, ArH), 7.23 (1H, t, J = 5.0 Hz, ArH), 7.31 (1H, t, J = 4.9 
Hz, ArH), 7.37 (3H, d,  J = 5.6 Hz, 3×ArH); m/z 391.0 (M+H)+; Anal. (C23H21NO5·0.1H2O) 
C, H, N. 
3-(4-Chlorophenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid 
dimethyl ester (135c). Dimethyl acetylenedicarboxylate (4.55 g, 32 mmol) was added in to a 
solution of 2-(4-chloro-benzoyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134c, 
9.47 g, 30 mmol) in acetic anhydride (60 mL) and the reaction mixture was heated at 60–70 
oC for 15 min. The reaction mixture was then cooled to room temperature and evaporated to 
dryness under vacuo. The residue was crystallized from ethanol to give 135c, yield: 10.41 g 
(88%); mp 164−166 °C; 1H NMR(DMSO-d6) δ 3.60 (3H, s, COOMe), 3.76 (3H, s, COOMe), 
4.32 (2H, s, -CH2), 4.98 (2H, s, -CH2), 7.20–7.26 (1H, m, ArH), 7.27–7.33 (2H, m, 2×ArH), 
7.39–7.43 (1H, m, ArH), 7.48 (2H, d, J = 8.5 Hz, 2×ArH), 7.57 (2H, d, J = 8.5 Hz, 2×ArH); 
m/z 395.00 (M+H)+; Anal. (C22H18ClNO4·4H2O) C, H, N.    
3-(3,4-Difluorophenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid 
dimethyl ester (135d). Dimethyl acetylenedicarboxylate (7.39 g, 52 mmol) was added into a 
solution of 2-(3, 4-difluorobenzoyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (134d, 
11.10 g, 35 mmol) in acetic anhydride (70 mL) and the reaction mixture was heated at 60−70 
oC for 15 min. The reaction mixture was then cooled to room temperature and evaporated to 
dryness under vacuo. The oily residue was crystallized from ethanol to give 135d, yield: 
10.97 g (79%); mp 142−144 °C; 1H NMR(DMSO-d6) δ 3.61 (3H, s, COOMe), 3.77 (3H, s, 
COOMe), 4.31 (2H, s, -CH2), 5.00 (2H, s, -CH2), 7.21–7.27 (1H, m, ArH), 7.29–7.35 (3H, m, 
3×ArH), 7.37–7.43 (1H, m, ArH), 7.50–7.65 (2H, m, 2×ArH); m/z 397.00 (M+H)+; Anal. 
(C22H17F2NO4) C, H, N.    
[2-Hydroxymethyl-3-methyl-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-methanol 
(136a). A solution of the 3-methyl-5,10-dihydro-pyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic 
acid dimethyl ester (135a, 2.39 g, 8 mmol) in anhydrous dichloromethane (20 mL) was 
added dropwise into a stirred suspension of lithium aluminum hydride (0.69 g, 18.4 mmol) in 
anhydrous diethyl ether (30 mL) at 10−15 oC. The reaction mixture was further stirred for 2 h 
at room temperature after the addition was completed. The reaction mixture was cooled to 0 
oC and excess hydride was destroyed by the sequential addition of water (1.2 mL), 15% 
aqueous NaOH (1.2 mL), and water (3.6 mL) at 0 °C. The mixture was filtered and the white 
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solid residue was washed with hot THF (300 mL). The combine filtrate and washings were 
evaporated to dryness in vacuo. The residue was crystallized from 
dichloromethane/diethylether to give 136a, yield: 1.47 g (76%); mp 99−101 oC; 1H NMR 
(DMSO-d6) δ 2.22 (3H, s, Me), 3.96 (2H, s, -CH2), 4.32–4.35 (3H, m, -CH2OH), 4.36–4.41 
(3H, m, -CH2OH), 4.93 (3H, s, Me), 7.22–7.26 (2H, m, 2×ArH), 7.28–7.38 (2H, m, 2×ArH); 
m/z  243.0 (M+H)+; Anal. (C15H17NO2·0.1H2O) C, H, N. 
[2-Hydroxymethyl-3-(4-methoxyphenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-
methanol (136b). A solution of the 3-(4-methoxy-phenyl)-5,10-dihydro-pyrrolo[1,2-
b]isoquinoline-1,2-dicarboxylic acid dimethyl ester (135b, 3.0 g, 7.6 mmol) in anhydrous 
dichloromethane (20 mL) was added dropwise to a stirred suspension of lithium aluminum 
hydride (0.66 g, 23 mmol) in anhydrous diethyl ether (30 mL) at 10-15 oC. The reaction 
mixture was further stirred for 2 h at room temperature after the addition was completed. The 
mixture was then cooled to 0 oC and excess hydride was destroyed by the sequential addition 
of water (1.2 mL), 15% aqueous NaOH (1.2 mL), and water (3.6 mL) at 0 °C. The reaction 
mixture was filtered and the solid residue was washed with hot THF (300 mL). The combine 
filtrate and washing were evaporated to dryness in vacuo. The residue was crystallized from 
dichloromethane/ether to give 136b, yield: 1.78 g (68%); mp 174–176 oC; 1H NMR (DMSO-
d6) δ 3.82 (3H, s, OMe), 4.04 (2H, s, -CH2), 4.26 (2H, d, J = 5.0 Hz, -CH2), 4.40–4.56 (4H, 
m, -CH2, 2×OH), 4.93 (2H, s, -CH2), 7.05 (2H, d, J = 8.4 Hz, 2×ArH), 7.16–7.22 (1H, m, 
ArH), 7.23–7.29 (2H, m, 2×ArH); m/z 451.9 (M+H)+; Anal. (C21H21NO3·0.2 H2O) C, H, N. 
[2-hydroxymethyl-3-(4-chlorophenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-
methanol (136c). A solution of the 3-(4-chlorophenyl)-5,10-dihydro-pyrrolo[1,2-
b]isoquinoline-1,2-dicarboxylic acid dimethyl ester (135c, 5.93 g, 15 mmol) in anhydrous 
dichloromethane (120 mL) was added dropwise into a stirred suspension of lithium 
aluminum hydride (1.31 g, 34.5 mmol) in anhydrous diethyl ether (50 mL) at 10−15 oC. The 
reaction mixture was further stirred for 2 h at room temperature after the addition was 
completed. The reaction mixture was cooled to 0 oC and excess hydride was destroyed by the 
sequential addition of water (2.0 mL), 15% aqueous NaOH (2.0 mL), and water (6.0 mL). 
The mixture was filtered and the solid residue was washed with hot THF (300 mL). The 
combine filtrate and washings were evaporated to dryness under vacuo. The residue was 
crystallized from dichloromethane/ether to give 136c, yield: 3.12 g (61%); mp 170−171 oC; 
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1H NMR (DMSO-d6) δ 4.06 (2H, s, -CH2), 4.28 (2H, d, J = 5.0 Hz, -CH2), 4.50 (2H, d, J = 
5.1 Hz, -CH2), 4.55 (1H, t, J = 4.5 Hz, exchangeable -OH), 4.57 (1H, t, J = 5.1 Hz, 
exchangeable -OH), 4.98 (2H, s, -CH2), 7.18–7.20 (1H, m, ArH), 7.25–7.30 (2H, m, 2×ArH), 
7.36–7.40 (1H, m, ArH), 7.49 (2H, d, J = 8.5 Hz, 2×ArH), 7.54 (2H, d, J = 8.5 Hz, 2×ArH); 
m/z 339.82 (M+H)+; Anal. (C20H18ClNO2) C, H, N.  
[2-hydroxymethyl-3-(3,4-difluoro-phenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-
methanol (136d). A solution of the 3-(3,4-difluorophenyl)-5,10-dihydro-pyrrolo[1,2-
b]isoquinoline-1,2-dicarboxylic acid dimethyl ester (135d, 7.94 g, 20 mmol) in anhydrous 
dichloromethane (180 mL) was added dropwise to a stirred suspension of lithium aluminum 
hydride (1.75 g, 46 mmol) in anhydrous diethyl ether (50 mL) at 10–15 oC. The reaction 
mixture was further stirred for 2 h at room temperature after the addition was completed. The 
reaction mixture was then cooled to 0 oC and excess hydride was destroyed by the sequential 
addition of water (2.5 mL), 15% aqueous NaOH (2.5 mL), and water (9.0 mL). The reaction 
mixture was filtered and the solid residue was washed with hot THF (300 mL). The combine 
filtrate and washing were evaporated to dryness under vacuo. The residue was crystallized 
from dichloromethane/ether to give 136d, yield: 4.57 g (67%); mp 145–146 oC; 1H NMR 
(DMSO-d6) δ 4.06 (2H, s, -CH2), 4.28 (2H, d, J = 5.2 Hz, -CH2), 4.50 (2H, d, J = 5.1 Hz, -
CH2), 4.55 (1H, t, J = 4.5 Hz, exchangeable -OH), 4.62 (1H, t, J = 5.1 Hz, exchangeable -
OH), 5.02 (2H, s, -CH2), 7.17–7.22 (1H, m, ArH), 7.24–7.35 (3H, m, 3×ArH), 7.34–7.36 
(1H, m, ArH), 7.50–7.58 (2H, m, 2×ArH); m/z 341.00 (M+H)+; Anal. (C20H17F2NO2·0.3H2O) 
C, H, N.  
Methyl carbamic acid 3-methyl-1-methylcarbamoyloxymethyl-5,10-dihydro-
pyrrolo[1,2-b]isoquinolin-1-ylmethyl ester (137a). A solution of (2-hydroxymethyl-3-
methyl-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl)methanol (136a, 0.80 g, 3.2 mmol) in 
anhydrous dichloromethane (8 mL) was treated with triethylamine (1.01 g, 10 mmol) 
followed by methylisocyanate (1.14 g, 20 mmol). The reaction mixture was stirred at ambient 
temperature for 16 h under an argon atmosphere and then it was evaporated to dryness in 
vacuo. The residue was crystallized from dichloromethane/hexane to give 137a, yield: 0.53 g 
(44%); mp 174−176 °C; 1H NMR (DMSO-d6) 2.23 (3H, s, Me), 2.51–2.56 (6H, m, 2×Me), 
3.99 (2H, s, -CH2), 4.88 (2H, s, -CH2), 4.92 (2H, s, -CH2), 4.95 (2H, s, -CH2), 6.74 (2H, brs, 
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exchangeable 2×NH), 7.21–7.32 (2H, m, 2×ArH), 7.34–7.38 (2H, m, 2×ArH); m/z 356.1 
(M+H)+; Anal. (C19H23N3O4) C, H, N. 
Methyl carbamic acid 3-(4-methoxyphenyl)-2-methylcarbamoyloxymethyl-5,10-
dihydro-pyrrolo[1,2-b]isoquinolin-1-ylmethyl ester (137b). A solution of [2-
hydroxymethyl-3-(4-methoxyphenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-methanol 
(136b, 1.00 g, 2.9 mmol) in anhydrous dichloromethane (10 mL) was treated with 
triethylamine (1.45 g, 14 mmol) followed by methylisocyanate (1.65 g, 29 mmol). The 
reaction mixture was stirred at room temperature for 6 h and then evaporated to dryness in 
vacuo. The residue was crystallized from dichloromethane/hexane to give 137b, yield: 1.17 g 
(87%); mp 182−184 °C; 1H NMR (DMSO-d6) 2.48–2.59 (6H, m, 2×Me), 3.85 (3H, s, Me), 
4.08 (2H, s, -CH2), 4.78 (2H, s, -CH2), 4.93 (2H, s, -CH2), 5.01 (2H, s, -CH2), 6.81 (2H, brs, 
exchangeable 2×NH), 7.06 (2H, d, J = 8.6 Hz, 2×ArH), 7.17–7.23 (1H, m, ArH), 7.24–7.30 
(2H, m, 2×ArH), 7.32–7.40 (3H, m, 3×ArH); m/z 311.00 (M+H)+; Anal. (C25H27N3O5) C, H, 
N.  
Methyl carbamic acid 3-(3,4-difluorophenyl)-2-methylcarbamoyloxymethyl-5,10-
dihydro-pyrrolo[1,2-b]isoquinolin-1-lmethyl ester (137c). A solution of [2-
hydroxymethyl-3-(3,4-difluorophenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-
methanol (136c, 1.0 g, 2.9 mmol) in anhydrous dichloromethane (10 mL) was treated with 
triethylamine (1.08 g, 10.7 mmol) followed by methylisocyanate (0.855 g, 15 mmol). The 
reaction mixture was stirred at room temperature for 3 h and evaporated to dryness under 
vacuo. The residue was crystallized from MeOH/ether to give 137c, yield: 1.02 g (77%); mp 
190−192 °C; 1H NMR (DMSO-d6) 2.52–2.56 (6H, m, 2×Me), 4.09 (2H, s, -CH2), 4.81 (2H, 
s, -CH2), 4.99 (2H, s, -CH2), 5.03 (2H, s, -CH2), 6.83 (2H, brs, exchangeable 2×NH), 7.18–
7.23 (1H, m, ArH), 7.25–7.31 (3H, m, 3×ArH), 7.36–7.40 (1H, m, ArH), 7.52–7.61 (2H, m, 
2×ArH); m/z 454.00 (M+H)+; Anal. (C24H23F2N3O4) C, H, N.  
Methyl carbamic acid 3-(4-chlorophenyl)-2-methylcarbamoyloxymethyl-5,10-dihydro-
pyrrolo[1,2-b]isoquinolin-1-ylmethyl ester (137d). A solution of [2-hydroxymethyl-3-(4-
chlorophenyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl]-methanol (1.02 g, 3.0 mmol) in 
anhydrous dichloromethane (15 mL) was treated with triethylamine (1.45 g, 14.3 mmol) 
followed by methylisocyanate (0.856 g, 15 mmol). The reaction mixture was stirred at room 
temperature for 6 h and evaporated to dryness under reduce pressure. The residue was 
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crystallized from methanol/ether to give 137d, yield: 1.11 g (82%); mp 194−196 °C; 1H 
NMR (DMSO-d6) 2.52–2.56 (6H, m, 2×Me), 4.09 (2H, s, -CH2), 4.80 (2H, s, -CH2), 4.97 
(2H, s, -CH2), 5.03 (2H, s, -CH2), 6.81 (2H, brs, exchangeable 2×NH), 7.17–7.23 (1H, m, 
ArH), 7.24–7.30 (2H, m, 2×ArH), 7.36–7.40 (1H, m, ArH), 7.46 (2H, d, J = 8.2 Hz, 2×ArH), 
7.56 (2H, d, J = 8.2 Hz, 2×ArH); m/z 453.93(M+H)+; Anal. (C24H24ClN3O4) C, H, N.  
 
Biological Experiments 
 
Cytotoxicity Assays. The effects of the compounds on cell growth were determined in T-cell 
acute lymphocytic leukemia CCRF-CEM) and their resistant subcell lines (CCRF-
CEM/Taxol and CCRF-CEM/VBL) by the XTT assay92 and human solid tumor cells (i.e. 
breast carcinoma MX-1 and colon carcinoma HCT-116) the SRB assay93 in a 72 h incubation 
using a microplate spectrophotometer as described previously.94 After the addition of 
phenazine methosulfate-XTT solution at 37 oC for 6 h, absorbance at 450 and 630 nm was 
detected on a microplate reader (EL 340; Bio-Tek Instruments Inc., Winooski, VT).  IC50 
values were determined from dose-effect relationship at six or seven concentrations of each 
drug by using the CompuSyn software by Chou and Martin95 based on the median-effect 
principle and plot.96,97 Ranges given for taxol and vinblastine were mean ± SE (n = 4). 
 
In vivo studies. Athymic nude mice bearing the nu/nu gene were used for human breast 
tumor MX-1 and human glioma U87 MG xenograft. Outbred Swiss-background mice were 
obtained from the National Cancer Institute (Frederick, MD). Male mice 8 weeks old or older 
weighing 22 g or more were used for most experiments. Drug was administrated via the tail 
vein by i.v. injection.  Tumor volumes were assessed by measuring length × width × height 
(or width) by using caliper.  Vehicle used was 50 μL DMSO and 40 μL Tween 80 in 160 μL 
saline. The maximal tolerate dose of the tested compound was determined and applied for the 
in vivo therapeutic efficacy assay. All animal studies were conducted in accordance with the 
guidelines of the National Institutes of Health Guide for the Care and Use of Animals and the 
protocol approved by the Memorial Sloan-Kettering Cancer Center’s Institutional Animal 
Care and Use Committee. 
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Table 3.  Elemental analysis of compound 134-137. 
 
C,H,N  Analysis 
Anal. Calcd. Found  Compd. M.F. MW 
C% H% N% C% H% N% 
134b C18H17NO4·0.2H2O 314.94 68.64 5.57 4.44 68.63 5.62 4.27 
134c  C17H14ClNO3·5.1H2O 407.64 50.09 4.72 3.43 49.98 5.12 3.27 
134d  C17H13F2NO3 317.29 64.35 4.13 4.41 64.31 4.09 4.35 
135a  C17H17NO4 299.33 68.22 5.72 4.68 68.29 5.77 4.67 
135b C23H21NO5·0.1H2O 393.23 70.25 5.43 3.56 70.15 5.44 3.49 
135c  C22H18ClNO4·4H2O 467.91 56.47 4.73 2.99 56.66 4.81 2.51 
135d  C22H17F2NO4 397.38 66.50 4.31 3.52 66.48 4.26 3.47 
136a C15H17NO2·0.1H2O 245.11 73.50 7.07 5.71 73.42 6.97 5.71 
136b  C21H21NO3·0.2H2O 339.01 74.40 6.36 4.13 74.41 6.30 4.13 
136c  C20H18ClNO2 339.82 70.69 5.34 4.12 70.42 5.37 4.05 
136d  C20H17F2NO2·0.3H2O 346.76 69.27 5.03 4.03 69.66 5.01 3.63 
137a  C19H23N3O4 357.41 63.85 6.49 11.76 63.37 6.57 11.64 
137b  C25H27N3O5 449.51 66.80 6.05 9.35 66.72 6.15 9.24 
137c  C24H24ClN3O4 453.93 63.50 5.33 9.26 63.33 5.35 9.20 
137d  C24H23F2N3O4 455.47 63.29 5.09 9.23 63.00 5.12 9.16 
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5.5 1H NMR spectrum for compound for compound 134a and 135a. 
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1H NMR spectrum for compound 136a and 137a. 
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1H NMR spectrum for compound 134b and 135b. 
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1H NMR spectrum for compound 136b and 137b.  
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SUMMARY 
 
Historically, the DNA-alkylating agents have played an important role in the development of 
cancer chemotherapy. Though several DNA-alkylating agents such as chlorambucil, 
melphalan, mitomycin C, cisplatin are currently in clinical use, the potential utility of these 
agents is restricted due to a number of pharmacological deficiencies resulting from the high 
chemical reactivity of these agents. Directing the alkylating pharmacophore to the defined 
geometric sites of DNA would greatly enhance the therapeutic utility of these classes of 
drugs. Recently, Su et al. have reported a series of alkyl N-mustards-9-anilinoacridines 
conjugates via a O-alkyl spacer. Among these agents, BO-0742 exhibited potent therapeutic 
efficacy against human breast and ovarian tumor xenografts in vivo.  However, this agent is 
chemically unstable and has short half-life (t1/2 < 25 min) in rat.  
To search for more stable and potent DNA-directed alkylating agents endowed with potent 
antitumor activity, several new phenyl N-mustard-9-anilinoacridine conjugates linked via 
urea, carbamate or carbonate linkers were synthesized for antitumor studies. These 
conjugates exhibited a broad spectrum of antitumor activity. Among these derivatives, 109d 
(BO-1051) and 119a (BO-1062) possessed potent therapeutic efficacy against human breast 
MX-1, human colon HCT-116 and human glioma xenografts in animal model. These agents 
are capable of inducing marked dose dependent level of DNA interstrand cross-linking and 
found to be more stable than BO-0742 in i.v. injection vehicle and in rat plasma. Compound 
109d (BO-1051) also effectively suppressed human glioma U87 MG xenografts. For MX-1 
xenograft, total tumor remission was achieved with only one cycle of treatment and no tumor 
relapse was found over 129 days in mice treated with compound 126a (BO-1062). It was 
found that these agents have little or no cross-reistance to either taxol or vinblastin and thus 
they are effective against multiple drug resistant tumors. Additionally, a series of water 
soluble N-mustard derivatives was prepared for antitumor studies in which the phenyl N-
mustard pharmacophore was linked with the water solublizing counterparts via a urea linker. 
The preliminary results demonstrated that compound 126aa’ (BO-1055) exhibited significant 
cytotoxicity against CCRF-CEM, MX-1 and HCT-116 cell growths and potent therapeutic 
efficacy in animal nude mice bearing MX-1 xenograft. BO-1055 induced complete tumor 
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remission at the maximal doses 30 mg/kg in nude mice bearing human breast tumor (MX-1) 
xenograft. Moreover, a series of novel DNA bifunctional alkylating agents, 
bis(hydroxymethyl)-5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl and their bis (methylcarba- 
mate) derivatives comprised of linear tricyclic ring system was designed and synthesized for 
antitumor evaluation. These agents also exhibited significant antiproliferative activity against 
CCRF-CEM, MX-1 and HCT-116 cell growths with low cross-resistance. The in vivo 
antitumor activity of these agents revealed that compound 136a (BO-1107) have potent 
therapeutic efficacy against MX-1 xenografts in nude mice. BO-1107 also exhibited 
significant tumor inhibitory effect against ovarian adenocarcinoma xenografts (SK-OV-3) 
with low toxicity.   
In conclusion, the current reseach efforts have yielded several novel DNA-alkylating agents 
endowed with potent antitumor activity. From these studies, compounds BO-1051, BO-1062, 
BO-1055 and BO-1107 identified as potential led candidates for preclinical developments.  
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